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Luciferins are a class of light emitting small molecule substrates. These molecules are oxidised to 
produce visible light in a reaction catalysed by the luciferase enzymes. The combination of this 
luminescent reaction coupled with charge-coupled device (CCD) cameras, has produced revolutionary 
technologies that enable measurements of mammalian gene expression in cells, as well as protein-
protein interactions, biochemical labelling, and small molecule flux, to name a few. Of all the luciferin 
molecules, D-luciferin is the most widely researched. D-Luciferin is the light emitting molecule isolated 
from the American firefly Photinus pyralis (Ppy). Synthetic D-luciferin has become increasingly 
valuable since its incorporation into a growing number of commercially available assay kits where the 
molecule is used as a sensitive reporter both in vitro and in vivo.   
This thesis focuses on improved methods of preparing synthetic D-luciferin and related C6-analogues, 
as well as exploring the bioluminescent properties of a novel C6-thio analogue of D-luciferin. The novel 
analogue was targeted to provide an alternative or complementary substrate for bioluminescence 
imaging, that would allow for bioluminescence to be applied in systems where traditional D-luciferin 
application was limited.  
In the first part of the thesis, D-luciferin and a C6-amino analogue of D-luciferin, D-aminoluciferin, 
were prepared and evaluated for the luciferase catalysed bioluminescent reaction. Both D-luciferin 
and D-aminoluciferin were prepared from para-substituted anilines, with overall yields ranging 
between 8 and 20 %. The poor overall yield was attributed to a low yielding C-S coupling reaction, that 
was common in both luciferin syntheses. Thus, modifications to the synthetic routes were 
subsequently explored, based on disadvantages and limitations that became apparent during initial 
luciferin preparation, these included among others; low yields and reliance on classical transition 
metal catalysed reactions. To address the synthetic shortcomings of the previous routes, a more 
efficient and scalable method for synthesising C6-substituted 2-cyanobenzothiazoles was developed. 
The C6-substituted 2-cyanobenzothiazoles were identified as key intermediates to the bioluminescent 
substrates. The new methodology employed easily prepared and inexpensive ortho-brominated 
anilines as starting materials. These anilines were subsequently converted to thioanilides and 
thereafter cyclised using base-mediated intra-molecular cyclisation reactions to generate the desired 
C6-substituted 2-cyanobenzothiazoles, resulting in improved overall yields for both D-luciferin and 
D-aminoluciferin (50-85 %). It was further demonstrated that these reactions, unlike their palladium-





The second part of the thesis focuses on the preparation and bioluminescent evaluation of a novel C6-
thio analogue of D-luciferin. Initial attempts at forming the C6-thio analogue, D-thioluciferin, were 
met with various challenges, including undesired S-oxidation and S-protecting group instability. 
Eventually a synthetic route based on a thiol-protecting group strategy proved successful. The method 
allowed for the preparation of pure D-thioluciferin over six steps (34 % yield) using an unconventional 
thioacrylate S-protecting group. The new luminogenic substrate displayed a lower Km (0.1 µM relative 
to the 8 µM of D-luciferin) and a more red-shifted maximum emission (λmax 600 nm compared to the 
557 nm of D-luciferin), but with a much lower luminescent output relative to D-luciferin. The 
homodisulfide and sulfide of D-thioluciferin were also evaluated for their ability to produce light in 
the luciferase catalysed reaction. Both substrates were found to emit much more weakly relative to 
the free thiol, with the sulfide producing a non-statistically significant signal barely different from the 
background emission, while the disulfide produced a bioluminescence emission that was under 25 % 
of D-thioluciferin in emission intensity.  
The thiol handle of D-luciferin and its bioluminescence properties were then explored for potential 
glutathione reductase (GSR) monitoring. The technology was based on an increase in bioluminescence 
emission resulting from disulfide reduction. A mixed disulfide of D-thioluciferin and the low molecular 
weight thiol glutathione (GSH) was prepared, where the disulfide functionality resulted in a weaker 
bioluminescent signal relative to free D-thioluciferin. Then, when the disulfide was reduced by GSR, a 
detectable bioluminescent signal in the presence of luciferase was produced. The D-Thioluciferin GSH 
hetero-disulfide was demonstrated to be a good substrate for GSR (Km of 0.89 mM relative to 0.51 mM 
for GSSG) and, further to that, the hetero-disulfide was demonstrated to have successfully coupled its 
resulting luminescence signal to disulfide reduction, upon treatment with luciferase at increasing 
concentrations of GSR in a physiological buffer.  In these examples, increased luminescence was 
observed at increasing concentrations of GSR and the data obtained was found to be comparable to 
commonly used colorimetric GSR assays, where induced changes in GSR activity were observed as 













BET Back-electron transfer  
Bs Broad singlet (NMR) 
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Introduction to Bioluminescence 
Abstract 
Imaging technologies have been developed and refined to advance our understanding of biological 
processes by revealing cellular and molecular features of biology and disease, in real-time. One rapid 
and increasingly accessible technology for in vivo analysis employs internally generated light emitted 
from photobiological reactions. Luminous substrates, luciferins, are catalysed by enzymes, luciferases, 
and utilised for various imaging applications. The combination of this luminescent reaction with 
charge-coupled device (CCD) cameras has allowed for sensitive in vivo measurements of mammalian 
gene expression in cells, protein-protein interactions, biochemical labelling, and small molecule flux, 
to name a few. This chapter serves to introduce the subject of bioluminescence and its exploitation in 

















Introduction to Bioluminescence 
Luminescence  
Luminescence is the emission of light that does not directly depend on the temperature of the emitting 
substance and it is therefore considered the opposite of incandescence. For centuries luminescence 
has fascinated mankind and over many years this phenomenon has been noted in different forms and 
settings. From the extraordinary Northern Lights (Aurora Borealis) to the humble dim glow of the 
railroad worm (Phengodidae). Of course, many theories arose to explain these phenomena. The 
glowing tide (also known as sea light) for example, was at first attributed to the ignition of sea salt 
(Papin, 1647) or the rubbing together of salt molecules that gave off flint like sparks (Oartesius, 1648). 
It was the German physicist Eilhard Wiedmann, among others, who helped make the connection 
between the different forms of light emitting phenomena and coined the term luminescence to 
collectively describe them. He theorised that all light emitted from materials which did not require 
heating and did not evolve heat were being emitted by a similar mechanism, which in turn was also 
dissimilar from the evolution of light from incandescent bodies, such as burning wood or molten iron. 
Eilhard Wiedmann went on to further categorise the distinct types of luminescence (Figure 1.1). He 
studied the phenomena and generalised luminescence into two main groups; Photoluminescence and 
Chemiluminescence.  
 
Figure 1.1. Luminescence as defined by Eilhard Wiedmann1 
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Both types of luminescence occur when a substance releases energy in the form of visible light. In the 
case of photoluminescence, the energy released is derived from the absorption of energy in the form 
of UV or visible light, which is then re-emitted as light of a longer wavelength. The light 
absorbing/emitting component of a substance is called its luminophore.  Photoluminescence is further 
divided into fluorescence and phosphorescence. Fluorescence occurs when visible light is absorbed to 
raise the emitting material’s fluorophore (molecular component/compound responsible for 
fluorescence) to a higher state of energy, and light then gets rapidly re-emitted when the material 
returns to its ground state (i.e. its energy state before the absorption of light). The light emitted is 
usually longer in wavelength relative to the light absorbed. Fluorescence is widely observed in the 
natural world, and many organisms are highly fluorescent. Phosphorescence is closely related to 
fluorescence, but unlike fluorescence, the energy absorbed is not immediately re-emitted. This results 
in phosphorescence having a much slower re-emission time scale that is associated with "forbidden" 
energy state transitions in quantum mechanics. Phosphorescence is less common in nature, there are 
however many everyday examples of phosphorescent materials, such as glow-in-the dark paints and 
glow sticks. These materials are characterised by their ability to ‘store’ light. Chemiluminescence is 
arguably the most interesting branch of luminescence. It is the evolution of light as a result of a 
chemical reaction (Scheme 1.1) and therefore, can be produced in complete darkness. The generation 
of light in its absence is a truly fascinating phenomenon, however, the light generated is by no means 
produced ex nihilio. 
 
Scheme 1.1. General reaction for chemiluminescence 
For chemiluminescence to be observed two or more substances must react to afford a high energy 
intermediate that relaxes to the ground state with the emission of visible light. One very famous 
example of a chemiluminescent reaction is that of luminol with blood.  Forensic investigators 
commonly use luminol to detect trace amounts of blood at crime scenes, as it reacts with the iron in 
haemoglobin. Chemiluminescence is also observed widely in nature, where it is termed 
bioluminescence or ‘living light’. 
Bioluminescence remains one of Nature’s most admired showcases. It is indeed a splendid display of 
her mastery over chemistry and has inspired many human endeavours.  
 
  Chapter 1: Introduction to Bioluminescence 
4 
 
Bioluminescence - living light 
 "…a world without a sun and without fire would by no means be a dark world" 
LIVING LIGHT, E. N. HARVEY 
When a chemical reaction results in the emission of light, it is termed chemiluminescent and when a 
chemiluminescent reaction is derived from a biological source, it is termed bioluminescent. 
Bioluminescence is therefore the chemical production of light by living organisms and is widely 
distributed among animal groups, particularly marine organisms. The biochemical reaction involves 
an enzyme and a small molecule substrate and, unlike photoluminescence, can be achieved in total 
darkness. The substrates used by luminous organisms for the light emitting reaction are collectively, 
and rather appropriately referred to as luciferins, derived from the Latin word Lucifer which means 
light bearing/bearer.2 Luciferins are considered a class of structurally diverse small molecules that are 
oxidised in the presence of highly specific enzymes to produce light.3 Figure 1.2 shows the structures 
of selected luciferins. These compounds are naturally produced by many different organisms and 
examples of such organisms include; the firefly Photinus pyralis (Ppy), the jelly fish Aequorea victoria, 
and glow worm larvae Lampyris noctiluca, to name a few.4-7 
 
Figure 1.2. Bioluminescent organisms and their corresponding luciferins 
Luciferin producing organisms make use of this biochemical reaction to produce light of different 
colours and intensities, often seen as spectacular bioluminescent displays. Indeed, bioluminescence 
has many wondrous applications in nature.  Certain insects, such as the fire fly Photinus pyralis, may 
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use the light emitted from its tail for courtship signals.8 Where distinct flashes of light in different 
patterns are used by the insects to indicate their locality and availability, thus it acts as a form of 
communication.8-9 Jellyfish make use of the light emitting reaction to startle and deter potential 
predators,5 and many other organisms have evolved to use this particular chemoenzymatic reaction 
in different and interesting ways. While many different organisms make use of the reaction they do 
not necessarily make use of the same luciferin. In fact, it has been proposed that there is genetic 
homology between different organisms using the same luciferin and that sufficiently structurally 
unique luciferin systems have evolved separately (albeit for the same purpose) and therefore, the 
evolution of bioluminescence is non-linear.10-11  
The enzymes that catalyse the bioluminescent reaction are collectively referred to as luciferases. The 
observed green/yellow light emitted from the tail of the firefly Ppy, is due to the reaction of  
D-luciferin, with the enzyme luciferase in the presence of ATP, O2 and magnesium ion.12 In the 
crustacean Cypridina hilgendorfii bioluminescence is due to the reaction of a tryptamine derivative, 
cypridina luciferin, with its corresponding luciferin. The luciferin in freshwater snails, Latia neritodes, 
is latia luciferin and that in the sea pansy, Renilla reniformis, is coelenterazine. Dinoflagellate luciferin 
is a chlorophyll derivative and is found in some dinoflagellates, which are responsible for the observed 
night-time glowing of waves. Selected bioluminescent organisms and the wavelength at which the 
light emission is observed for specific luciferin/luciferase pairs are summarised in Table 1.1 below. 
Table 1.1. Selected luciferin-utilising bioluminescent species and their corresponding luciferases 
Luminous species Luciferase Luciferin λmax (nm) 




molecular weights in the 
range of 76 000 + 4000 
a reduced riboflavin 
phosphate (FMNH2) 
and a corresponding 
long chain aldehyde 
465/475 
Photinus pyralis Firefly luciferase, Family 
lampyridae 
D-luciferin  560 
Luciola mingrelica   D-luciferin 570 
Luciola lateralis   D-luciferin 552 
Luciola cruciata  LcLuc1 554 
Luciola cruciata  LcLuc2 543 
Luciola italica  D-luciferin 566/614 
Hotaria unmunsana   D-luciferin - 
Hotaria tsushimana   D-luciferin - 
Hotaria parvula   D-luciferin 568 
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Lampyris noctiluca   D-luciferin 550 
Lampyris turkestanicus   D-luciferin - 
Nyctophyla caucasica   D-luciferin - 
Pyrocoelia rufa  D-luciferin - 
Pyrocoelia miyako  D-luciferin 550 
Diaphanes pectinealis  D-luciferin - 
Cratomorphus distinctus   D-luciferin 550 
Photuris pennsylvanica   D-luciferin - 
Amydetes vivianii  D-luciferin 538 
Microlampis sp.  D-luciferin 569 
Pyrearnus termitilluminans Click beetle luciferase, 
family Elateridae  
D-luciferin 537 
Pyrophorus plagiophthalamus   D-luciferin 540 
Pyrophorus mellifluus  D-luciferin 549 
Pyrophorus angustus  D-luciferin 566 
Fulgeochizus bruchi  D-luciferin 540 
Photophorus jansoni  D-luciferin 559 




Phrixothrix hirtus  D-luciferin 630 
Phrixothrix vivianii  D-luciferin 542 
Oplophorus gracilinostris Coelenterazine utilising 
luciferase   
Coelenterazine  454 
Renilla reniformis  Coelenterazine 480 
R. muelleri  Coelenterazine 485/479 
Gaussia princeps  Coelenterazine 473 
Metridia longa  Coelenterazine 480 
M. pacifica  Coelenterazine 485 
Cypridina (Vargula hilgendorfii)  Cypridina luciferase  Cypridina luciferin  465 
Cypridina noctiluca   Cypridina luciferin  465 
Periphylla peryphilla   Cypridina luciferin   
Benthosema pterotum  Cypridina luciferin  475 
Gonyaulax polyedra, Pyrocystis lunula,   
Noctiluca scintillians 
Dinoflagellate luciferase  Dinoflagellate 
luciferin  
475 
Latia neritoides Latia luciferase  Latia luciferin  536 
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It is clear from the above table that the wavelength of the light emitted is highly dependent on the 
luciferin/luciferase pair (570 – 465 nm). Substantial research has gone into the various 
luciferin/luciferase systems, culminating in a wealth of research that has spanned decades from all 
scientific domains. The result of this has been that many of these bioluminescent systems have been 
explored within and outside of a biological setting to both probe our understanding of the mechanism 
and to also search for potential applications. Currently, there are approximately nine unique 
luciferin/luciferase systems that account for all known bioluminescence. The underlying mechanism 
of how light is emitted in these various systems have been well studied and it is accepted that light is 
emitted by the same mechanism in all instances.  
Mechanism of Bioluminescence  
Although the biological purpose of luminescence varies from species to species, the chemical 
mechanism for the generation of the electronically excited-state, responsible for the emission of light, 
appears to be common to all known bioluminescent organisms. Typically, the generation of light from 
a chemiluminescent reaction involves the formation of an electronically excited state product, which 
decays to the ground state while emitting light of a specific wavelength corresponding to the 
difference in energies between the excited and ground states. Figure 1.3 shows a general pathway for 
the generation of light from a chemical reaction. Important to note is that a reaction that occurs with 
enough energy to generate an electronically excited state molecule may generate light through the 
decay of the said molecule, or through the transfer of energy to an acceptor molecule or moiety (this 
may be achieved inter- or intramolecularly) which in turn would also decay with emission of light.  
 
     
Figure 1.3. a) Proposed mechanism for chemiluminescence and b) its corresponding energy diagram 
 
a) b) 
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In most cases, bioluminescence is a result of the breakdown of a high energy cyclic peroxide molecule 
(dioxetane or dioxetenone) to an excited species, in the form of a decarboxylated or deoxygenated 
molecule, which relaxes to the ground-state with the expulsion of a photon. There are a number of 
publications which describe the chemical mechanism for the formation of electronically excited-state 
molecules. The proposed mechanism involves the luciferase mediated synthesis of a luciferin peroxy 
adduct and subsequent chemically-initiated electron exchange luminescence (CIEEL) or charge 
transfer induced luminescence (CTIL).14-15 In the former case, an electron from either a heteroatom or 
aromatic pi-system is donated into the anti-bonding orbital of the peroxy O-O bond (π,σ*) resulting in 
a weakening of the bonding O-O molecular orbital and subsequent cleavage to afford  the alpha-alkoxy 
acid radical anion. The generation of the electronic singlet excited state via the donation of one 
electron from the electron rich reservoir is shown (Scheme 1.2).  
 
Scheme 1.2. CIEEL mechanism demonstrating the electron transfer process 
The mechanism (initially proposed Gary B. Schuster and co-workers in 1977) relates the chemi-
excitation to the electron transfer process and proposes that the energy for chemiluminescence 
results from intramolecular electron transfer in the decarboxylated product. Advances in quantum 
mechanical modelling have, however, called for a shift away from the CIEEL mechanism to the 
computationally supported CTIL mechanism.15 The cyclic peroxy molecules and related dioxetanones 
have been investigated in great detail in a number of synthetic and mechanistic studies and the 
observation that the thermal reactions of these high-energy compounds lead to the formation of 
electronically excited-state carbonyl compounds is taken as strong circumstantial evidence for the 
involvement of similar intermediates in bioluminescence. In addition, it has also been observed that 
the thermal reaction of simply substituted dioxetanes and dioxetanones give rise to the non-
luminescent triplet excited state of the carbonyl compound. On the other hand, the luminescent 
singlet excited-state was observed (at almost 100 %) for dioxetanones substituted with activated 
aromatic hydrocarbons. It was thus hypothesised that the aromatic group acted as an electron donor 
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were both proposed to account for the role of an electron donating group in the formation of the 
luminescent singlet-excited state. Both mechanisms start with a partial charge transfer from the 
electron donating fragment to the chemiluminophore dioxetanone moiety. In the step-wise CIEEL 
mechanism, a radical anion pair is formed through a single electron transfer (SET) followed by a back 
electron transfer (BET). In the CTIL, the fragmentation of the C-C and O-O bonds are concerted with 
the back charge transfer process. The CIEEL mechanism has met challenges concerning its potential 
for unwanted reactions involving radicals.15 
 
Scheme 1.3. CTIL mechanism demonstrating charge transfer mechanism 
Both these mechanisms have contributed significantly to our understanding of how the 
bioluminescent reaction works, as well as in the development of new, non-natural and often improved 
bioluminescent substrates for applications in bioluminescent imaging (BLI). These mechanisms have 
also proved useful in rationalising the effects of different electron reservoirs on the wavelength of 
emission and how this can be exploited to design luciferins that emit at a specific wavelength. It also 
informs on what kind of derivatives can be made from natural luciferins by allowing for the 
identification of molecular components crucial for the light emitting reaction and components that 
are less so.  All of this affects how bioluminescent systems are modified for new applications. One 
such application is bioluminescence imaging (BLI) which concerns the repurposing of natural 
bioluminescent systems to image biological analytes or processes.  
Bioluminescence imaging has also evolved to observe biological processes as they are happening in 
real-time, and there is an increasing number of cellular assays based on various bioluminescent 
technologies where a reporter molecule, whose activity can be measured and imaged, is employed to 
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Applications of Bioluminescence  
Two major breakthroughs marked the start of the era of bioluminescence technologies. The first was 
the first total synthesis of a luciferin and the second was the determination of the nucleotide sequence 
of the Ppy luciferase gene. Together, these two events ushered in the era of applied bioluminescence 
and research concerning the applications of Nature’s bioluminescence grew exponentially. Non-
luminescent organisms were transfected to express luciferase and new luciferins were engineered to 
supplement and/or provide alternatives to conventional imaging modalities.  
To gauge the importance of these developments we need only look at the list of Nobel Prizes awarded 
in Chemistry, where the most recent Nobel Prize (2017) was awarded to Richard Hendersen, Joachim 
Frank, Jacques Dubochet for their contribution to molecular imaging.27-28 The prize was also awarded 
to Eric Betzig, Stefan W. Hell and William E. Moerner (2014) for their contribution to molecular imaging 
through fluorescence microscopy.29 There are a number of imaging modalities that constitute 
molecular imaging, including; magnetic resonance imaging (MRI), near infra-red imaging, single 
photon emission tomography (SET), positron photon emission tomography (PET) and optical imaging. 
The term optical imaging relates to the use of bioluminescence, fluorescence and 
absorption/reflectance as applied to molecular imaging. Optical imaging has been used extensively in 
science and medicine and its applications are steadily growing. One of the benefits of optical imaging 
relative to other molecular imaging techniques is its comparatively benign nature. Generally, optical 
imaging and the imaging agents used are not harmful in a biological sense. Bioluminescence imaging 
in particular is extraordinarily biocompatible, which is expected given its origin.   
Bioluminescence imaging (BLI) is the use of bioluminescent reactions for optical imaging. BLI makes 
use of the light emitting luciferase/luciferin interaction to monitor cellular and bio-molecular 
processes. How this works is that luciferase can be genetically engineered into organisms which 
formerly lacked the gene for the enzyme (can also be introduced ex vivo). Then, when the appropriate 
substrates and cofactors are introduced, emission of visible light at variable wavelengths can be 
detected by charge-coupled device (CCD) cameras. Information may then be obtained by coupling the 
emission of light to specific biological events. In conventional in vivo experiment strategies, temporal 
information about biological processes is often obtained through repeated, time stacked animal 
sacrifice. With BLI however, information can be obtained continuously over the duration of the event 
of interest. Many BLI systems have been developed to address the challenges faced in the broader 
field of molecular imaging.  
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These include; i) the development of reporter systems and probes that are able to reveal cellular and 
molecular processes over a designated time period, ii) the development of probes that are sufficiently 
sensitive to small changes in cell function and distribution over time, and iii) probes that do not 
significantly alter/ interfere with the biological process of interest.  Many BL systems have since been 
developed based on the above-mentioned points and cover a wide area of applications. 
in vivo BLI is now considered a cornerstone technology for preclinical molecular imaging. It is generally 
coupled to a specific biological process through enzyme-substrate interactions that become biological 
indicators that can be studied non-invasively in living animals. Different substrates exhibit different 
kinetic properties and different intracellular accumulation profiles due to differences in their 
molecular structure, which in turn influence their bio-distribution in animals. The most widely used 
applications of BLI includes its use in the study of gene expression, gene delivery, cell viability, cell 
physiology, in vivo cell trafficking, tumour burden, and protein-protein interactions.30 
Bioluminescence imaging vs fluorescence imaging  
Imaging techniques routinely used in clinical studies include: magnetic resonance imaging (MRI scan), 
radionuclide imaging (e.g. Gallium scan), ultrasound imaging (sonogram) and computed tomography 
(CAT scan).31 In contrast to these techniques, optical imaging has been found to be very useful in terms 
of research and development. Thus far, its utility has been limited to studying small animals and plants. 
However, optical imaging remains the more cost-effective, and rapid technique, and can be easily 
applied to the study of various processes at a cellular level. 
There are two major classes of optical imaging, Bioluminescence imaging (BLI) and Fluorescence 
imaging (FLI). FLI requires an external light source to excite a fluorophore and enable luminescence 
(fluorophores are chemical compounds or scaffolds which absorb and reemit electromagnetic 
radiation, most often in the form of visible light). In FLI, a fluorescent probe containing a fluorophore 
is introduced into a subject and an external light source is used to excite the probe resulting in 
luminescence. Fluorescent tagging is a practical example of this technology. Fluorescent probes can 
be tethered to drug like molecules and then, using FLI, one can determine the locality of the drugs in 
the organism, and even within cells. Similarly, the simultaneous use of two different fluorescent tags 
can allow for the determination of protein-protein, protein-DNA, and/or protein-substrate 
interactions. Despite its many applications and continued use, there are limitations associated with 
FLI. The limitations of FLI include auto-fluorescence (self-induced fluorescence) which arises from 
endogenous molecules in mammalian tissue. Auto-fluorescence occurs when endogenous molecules 
interfere with target resolution by scattering and absorbing light at the same wavelengths as the 
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exogenous fluorophores. For example, haemoglobin whose signals have to be distinguished from 
administered exogenous molecules.32-34 However, studies are being done on the selection of 
appropriate wavelengths for the external light source to minimise background noise. 
As previously discussed, bioluminescence imaging involves the production of light as a result of a 
biochemical reaction. BLI uses enzyme/substrate systems such as the Ppy luciferase/D-luciferin 
interaction to emit light. Unlike FLI, BLI is independent of external light sources required to induce 
luminescence. In addition, the enzyme luciferase has to be genetically engineered into non-luciferase 
expressing organisms in order for BLI to be used. Bioluminescence imaging (BLI) is gaining preference 
over FLI due to the opaque nature of mammalian tissue as well as the presence of endogenous 
fluorophores which may undesirably fluoresce upon excitation and interfere with FLI.33 Luciferase 
based BLI was found to be more sensitive than green fluorescent protein (GFP) imaging. An example 
is reported where luciferase expressing tumours were detected as early as 1 day after tumour-cell 
inoculation, whereas GFP expressing tumours were only detectable after 7 days.35 Limitations to the 
BLI technique include rapid depletion of the luciferin upon administration for diagnostic purposes. 
Thus, there is a need for a cheap and industrially sustainable synthetic route toward luciferins or 
cheaper analogues thereof.  
Scope of this study    
Of all known luciferins, D-luciferin, the molecule responsible for the emission of light from the tail of 
the American firefly Ppy (figure 1.4), is by far the most widely researched luciferin for its applications 
in bioluminescence imaging. 
 
Figure 1.4. Bioluminescence of the American firefly (Ppy) and the structures of the enzyme, Ppy luciferase, and 
substrate, D-luciferin, responsible for the bioluminescent reaction. 
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Broadly, the aim of this study was to investigate the synthetic preparation of D-luciferin and its 
analogues and, further to that, to explore how the bioluminescent molecule could be exploited in 
terms of bioluminescent assay development. D-Luciferin was chosen as the luciferin of interest 
because of its growing use in the development of luciferin-based assays.  
The synthetic preparation of D-luciferin was of particular interest since its cost and synthesis were 
well-known limiting factors to its practical applications. When this project was first proposed, the cost 
of D-luciferin was approximately R 8 000 for 10 mg (Sigma-Aldrich, March 2014). It was therefore of 
interest to explore and evaluate the synthetic routes that were available at the time and, thereafter, 
to propose and develop more efficient routes to the sought-after D-luciferin molecule.  
Having an efficient and reliable procedure for luciferin preparation was necessary since further 
studies, involving the design and synthesis of D-luciferin derivatives, were also envisioned. It was 
therefore an early goal of this study to develop synthetic routes that would ensure rapid access to the 
required bioluminescent material.  
It has been four years since the projects inception and the cost of D-luciferin has since been reduced 
to less than half of its initial price. The decrease in cost is largely due to the development of improved 
luciferin analogues as well the development of cheaper and more efficient synthetic sequences. This 
project aimed to contribute to these developments by producing a more efficient synthesis of 
D-luciferin and by introducing new luciferin analogues with improved properties.  
Currently, there are a number of commercially available D-luciferin based BLI technologies and this 
study focused on further adding to the existing BLI arsenal, by developing BL alternatives to existing 
technologies. Of course, most of these BL technologies were based on Ppy D-luciferin whose synthesis 
is described subsequently (Chapter 2). 
Structure of the thesis  
The thesis has been divided into unique but related chapters, each with its own abstract, introduction 
and discussion. Each chapter has its own defined aim which highlights the focus of the research for 
that specific chapter.  
This first chapter serves as an introduction to luminescence and bioluminescence, while subsequent 
chapters (Chapters 2-3) deal with the synthetic preparation of D-luciferin and its analogues, as well as 
their reported applications. These chapters also highlight the limitations of existing synthetic 
sequences and employed methodologies, so as to emphasise the relevance of research relating to 
improvements on the synthesis of D-luciferin and its derivatives. Accordingly, the following chapter 
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(Chapter 4) then deals with the study of novel and improved syntheses and synthetic methods. The 
study then shifts focus from the synthesis of the luciferin scaffold, to the preparation of a new luciferin 
derivative using the methods highlighted in the preceding chapter. The subsequent chapter 
(Chapter 5) covers the synthesis of a new derivative and extensively explores its bioluminescent 
properties. The remaining chapters (Chapters 6-7) focus on the potential applications of the new 
derivative, with an emphasis on applications where the new derivative offers greater utility than its 
predecessors.   
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Synthesis and Evaluation of D-Luciferin Bioluminescence 
Abstract 
D-Luciferin, the light emitting molecule isolated from the American firefly Photinus pyralis (Ppy), was 
synthesised from commercially available p-anisidine with an overall yield of 12 %. Modifications to the 
synthetic route were subsequently explored, based on disadvantages and limitations that became 
apparent during the synthesis, these included among others; low yields and reliance on classical 
transition metal catalysed reactions. The optimised method unfortunately did not provide the target 
compound in an improved manner. An improved synthesis was, of course, of interest in the 
development of cost effective imaging modalities. Instead, both the employed and modified methods 
remain generally low yielding but do offer other opportunities for improvement which are explored 
in subsequent Chapters. This Chapter details the synthesis of D-luciferin based on reported synthetic 





















Synthesis and Evaluation of D-Luciferin Bioluminescence 
D-Luciferin: An Introduction 
 
Scheme 2.1. Luciferase-catalysed light emitting reaction of D-luciferin  
D-Luciferin is the molecule responsible for the emission of light from the tail of the American firefly, 
Photinus pyralis (Ppy). Currently, it is the most widely researched luciferin for its applications in 
bioluminescence imaging and its exploitation forms the main focus of this study. As shown in scheme 
2.1, D-luciferin reacts with oxygen to produce light in a decarboxylative oxidation reaction catalysed 
by the enzyme luciferase (luc). Part of D-luciferin’s appeal concerns its broad emission spectrum, 
which contains a significant near-IR component (over 650 nm), ideal for imaging in biological systems.  
D-Luciferin was first isolated in 1957, and a total synthesis to confirm its proposed structure followed 
shortly thereafter.1 Structurally, it is a relatively simple heterocyclic molecule comprising of a C6’-
hydroxybenzothiazole C2-linked dihydroxythiazole carboxylic acid. There is however, a degree of 
synthetic complexity resulting from the stereogenic centre at C4 of the 4,5-dihydrothiazole ring. 
Natural D-luciferin is found in an almost enantiopure form, where only one enantiomer is bioactive 
and naturally synthesised.2 In fact, it has been found that the enantiomer L-luciferin, whilst not 
effective for the light emitting reaction, is a potent competitive inhibitor of luminescence for both 
natural and commercially available mutant luciferases.1-2 Consequently, any proposed synthesis must 
account for the necessary stereoselectivity to achieve the desired stereochemistry at C4. 
Biosynthesis of D-luciferin   
The biosynthesis of D-luciferin has yet to be fully elucidated. It is generally accepted that D-luciferin is 
synthesised from 6-hydroxy-2-cyanobenzothiazole and the amino acid L-cysteine (L-Cys). Studies 
involving the treatment of Ppy luc expressing cells with 6-hydroxy-2-cyanobenzothiazole showed that 
the exogenous precursor was used, in vivo, to produce D-luciferin.3 However, it is well established that 
the reaction of 6-hydroxy-2-cyanobenzothiazole and natural L-Cys produces L-luciferin, and not the 
bioactive D-isomer. Since D-Cys is not produced in any eukaryotes, the biosynthesis for D-luciferin may 
involve a stereoisomeric bio-inversion. There are studies which support the possible conversion of 
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L-Cys via L-luciferin into D-luciferin, suggesting that the biosynthesis is enzymatically regulated by the 
isomerisation of L-luciferin.3-4 Other studies suggest that D-luciferin may in fact be synthesised from 
achiral oxyluciferin (formed from the decarboxylation of L-luciferin).  A recent publication by Oba et al 
demonstrated that the biosynthesis involved the condensation of p-benzoquinone and two L-Cys 
molecules. Oba et al employed isotope-labelled compounds that were injected into the adult lantern 
of live Japanese firefly Luciola lateralis to confirm their incorporation in the biosynthetic pathway.5 
There are a number of studies that make similar suggestions through similar experiments, however, 
until the associated biosynthetic enzymes are isolated the biosynthesis remains uncertain.   
D-Luciferin bioluminescence 
Imaging techniques have become widely used diagnostic tools in chemical and medicinal research. 
The luciferase/luciferin system has been successfully applied in bio imaging, in which cells containing 
the luciferase enzyme can be visualized when supplied with free D-luciferin.11 Research involving 
D-luciferin bioluminescence and the applications thereof is ongoing and an impressive foundation has 
already been laid by the many pioneers of the BLI field.6-8 The mechanism by which luciferase catalyses 
the emission of light is shown in scheme 2.2, where luciferase binds its substrate, D-luciferin, and 
catalyses the emission of yellow-green or red light in a decarboxylation reaction in the presence of 
ATP, Mg2+ and oxygen.2, 9  
 
Scheme 2.2. Proposed mechanism for the luciferase-catalysed emission of light 
-hv -hv 
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The first step of the luciferase bioluminescence reaction is the luciferase catalysed conversion of 
luciferin to luciferyl adenosine monophosphate (luciferin-AMP). The thiazolane ring is then reacted 
with oxygen to form the dioxyethanone/dioxetanone complex, and subsequent decarboxylation 
results in excited oxyluciferin species. When the excited complex returns to its electronic ground state, 
energy is released in the form of visible light. Depending on the difference in energy between the 
ground state and excited state, light of different wavelengths may be emitted. It has been established 
that the decarboxylation is responsible for the chemi-excitation of the molecule and mechanism for 
decarboxylation proceeds via the previously described CTIL or CIEEL mechanisms. Interestingly, 
luciferase is capable of emitting both red and yellow-green light depending on the pH of the media in 
which the reaction takes place. However, the underlying mechanism affecting the wavelength of the 
emitted light has yet to be fully understood. It has been proposed that the different wavelengths of 
light emitted is due to keto-enol tautomerism of oxyluciferin in the excited state, as shown in the 
above scheme. Keto-enol tautomers are isomeric forms which are related by the transfer of an α-
proton and the shifting of bonding electrons. Da Silva et al proposed that the keto and enol form of 
oxyluciferin have different energies in their excited states and thus emit light of different wavelengths 
upon returning to their respective ground states.10 Other studies have also supported the idea that 
oxyluciferin is produced in a singlet excited state, and that relaxation to its corresponding ground state 
results in the emission of light.11 Computational and experimental studies further support that the 
degree of chemi-excitation determines the degree of bioluminescence and that the angle between 
the dihydrothiazole and benzothiazole may also influence the excitation energy.12 Both chemi-
excitation and luciferin conformation are of course regulated/mediated by the enzyme luciferase. 
Firefly Luciferase 
Firefly luciferase Ppy luc is a 62 kDa protein found in the light-emitting organ within the abdomen of 
the firefly.  Ppy luc was first characterised via crystal structure analysis by Conti et al in 1996.13 
Structurally, the protein is folded into two compact domains. The large N-terminal domain consists of 
a β-barrel and two β-sheets and the sheets are flanked by α-helices. The C-terminal portion of the 
molecule forms a distinct domain, which is separated from the N-terminal domain by a wide cleft. The 
structure of the enzyme is shown in figure 2.1 below. 
Functionally, the 62 kDa molecular weight enzyme is considered to be an oxygenase and it is well 
established that all known bioluminescent reactions require oxygen.14 However, while all known 
luciferases isolated from varying species all make use of an oxidation reaction, it is important to note 
that these reactions involve a variety of different cofactors and often structurally unrelated substrates. 
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Figure 2.1. Ribbon representations of the firefly luciferase molecule shown in two orthogonal views. The three 
subdomains of the large N-terminal domain are shown in blue (β-sheet A), purple (β-sheet B) and green (β-
barrel) and the small C-terminal domain is shown in yellow. Disordered loops are drawn in violet.13 
In terms of its amino acid sequence, Ppy luc shows extensive sequence homology with a number of 
enzymes that utilize ATP in adenylation reactions, including acyl-CoA ligases15 and various other 
enzymes involved in the synthesis of linear and cyclic polypeptides found in fungi and bacteria.16 
With regards to the light emitting reaction that Ppy luc catalyses, the quantum yield (which is the 
percentage of the observed photons emitted relative to the expected maximum) is the highest of all 
known bioluminescent reactions.17 The Ppy luc catalysed reaction does however display unusual 
kinetics, in that firefly luciferase has a relatively slow turn-over.18 After an initial flash of light, the 
luminescence rapidly decreases to a low level of emission, due to product inhibition of the enzyme.  
D-Luciferin/luciferase burst kinetics 
When the enzyme luciferase is injected into a solution containing D-luciferin, there is a burst of light 
within the first few seconds, followed by a rapid decay and then sustained levels of light emission.18 
This emission profile is termed burst kinetics and is characteristic of Luciferase-catalysed reactions. 
The initial burst and subsequent decay in light emission is due to product inhibition where products 
formed from the light emitting reaction, specifically oxyluciferin and luciferin-AMP also inhibit the 
enzyme (oxyluciferin Ki = 0.50 + 0.03 µM, Luciferin-AMP Ki = 3.8 + 0.7 nM).11, 19 Nakatsu et al reports 
that the enzyme is forced into a closed conformation through non-competitive inhibition that was 
shown to be relieved upon the addition of CoA, which reacts with luciferin-AMP to form luciferin-CoA, 
a less potent inhibitor.20 
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Figure 2.2 shows how a rapid injection of luciferase to D-luciferin produces a burst of light followed 
by a decay caused by product inhibition. The addition of CoA at 60 s relieves some product inhibition, 
resulting in a second burst and a decrease in the subsequent decay (Figure adapted from Fraga, 2008). 
 
Figure 2.2. Burst kinetics profile of Ppy luc injected into a D-luciferin solution (Fraga, 2008) 
The burst kinetics profile of D-luciferin/ luciferase has had significant effect on the practical use of the 
system in bioluminescence assays. Since the emission of light varies largely in the first minute, most 
assays that have been developed require that readings be taken one-minute post enzyme addition to 
substrate. In this way, error related to burst kinetics is minimised.    
D-Luciferin gene reporter assay principle   
Possibly the most famous application of D-luciferin/luciferase in science and biology relate to its use 
as a reporter in the evaluation of gene expression. There are a number of luciferin-based assay kits 
commercially available, most of which are directly used in gene reporter assays. These assays measure 
luciferase activity via treatment with D-luciferin, or a salt thereof (Scheme 3.2).  
 
 
Scheme 2.3. Luciferase-fused gene activity measured through luciferase activity 
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Genetic reporters are used to study gene expression and related cellular events. They are widely used 
in cellular and molecular biology as well as clinical pharmacology. Typically, a reporter gene (luc) is 
cloned with a DNA sequence of interest into an expression vector that is then transferred into cells. 
Following transfer, the cells are assayed for the presence of the reporter by measuring resultant 
enzyme activity. In the case of D-luciferin, the enzyme activity is related to light output. As a gene 
reporter system, the D-luciferin/luciferase has been found to be more sensitive (anywhere from 10 to 
1000-fold) than fluorescent reporters making ideal for the study of complex biological systems. These 
Luciferase-based genetic reporter assays provide sensitive methods for assaying gene expression, 
enabling the accurate quantification of small changes in transcription resulting from subtle changes in 
biology. One of the most common applications of reporter genes is the analysis of a cloned mutated 
promoter sequence. This is done by measuring the effects of mutations and deletions in the promoter 
region through the coupling of the promoter to a reporter gene.21 
An example of the use of a luc reporter assay is given below. How this works is that luciferase is 
genetically engineered into cells which formerly lacked the gene for the enzyme. Cloning the 
regulatory region of a gene-of-interest upstream of the luciferase gene then allows for the measure 
of the protein transcription/expression using a luminometer. Since the gene of interest is fused to the 
luciferase reporter gene, the luciferase activity can be directly correlated with the expression of that 
particular gene. Of course, the appropriate substrates and cofactors are also needed in vivo for the 
emission of visible light which can be detected by charge-coupled device (CCD) cameras. 
 
Figure 2.3. Example of a luciferase reporter vector 
As described, the luciferin-luciferase reaction requires ATP, Mg2+, and oxygen for bioluminescence and 
the degree of luminescence is directly correlated to the most limiting of the reactants in the light 
emitting reaction. This has allowed for the assays to be developed whereby all of the reactants, save 
one, ATP for example, are introduced in excess to a particular system. Any observable luminescence 
is then attributed to ATP in the system. Apart from the many luciferase based assays, there have also 
been a number of assays that have been developed by modifying the luciferase substrate, D-luciferin. 
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D-Luciferin assays based on modified substrates   
It was discovered quite early in the history of D-Luciferin bioluminescence research that chemical 
modifications to its core structure significantly altered its luminescent activity. White et al discovered 
that moving the hydroxyl from the C6’ position to either C5’ or C7’ resulted in the loss of luminescent 
activity. White further demonstrated that alkylation and acylation of the C6-hydroxyl also resulted in 
the loss of luciferin activity. This very important experiment formed the basis of many D-luciferin 
based assays, some of which are commercially available today.  
The foundation of D-luciferin assays follows an ON/OFF logic, where D-luciferin is modified at the C6-
hydroxyl, turning off luminescent activity. The modification is cleverly designed to be removed by 
specific agents which, through the removal process, liberates free D-luciferin. The light emitted by the 
D-luciferin can then be related to the removal process and the associated removal agents. Scheme 2.4 
illustrates this process.  
 
Scheme 2.4. Mechanism of action of modified luciferin assays 
D-Luciferin conjugated to a phenylboronic acid (PCL-1) has been used to image tumor cells. The idea 
here was that the luciferin-boronic acid conjugate, when reacted with hydrogen peroxide, would 
release free D-luciferin which can be detected by a luminometer, as shown in figure 2.4. Since tumor 
cells have increased concentrations of peroxides, the degree of luminescence due to D-luciferin would 
be higher in these cells relative to non-tumor cells.18 PCL-1 has since been patented and is currently 
used in medical- and biochemical research to monitor tumor growth and regression. 
 
Figure 2.4. The luciferase-PCL-1 assay used for imaging tumor cells 
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The use of luciferase for optical molecular imaging, as a tag to track grafted cells, as a transgenic 
marker, to monitor gene expression, to assess protein stability, to sense bioactive small molecules, 
and to image drug delivery mechanisms have also been documented.11, 14, 19 It is evident that this 
particular chemoenzymatic reaction and its application to imaging has become an area of great 
interest. Thus, luciferin has become a popular synthetic target as ease of access to this particular 
compound would contribute significantly to the development of rapid, cost effective imaging 
techniques. 
 
Scheme 2.5. Bioluminescence detection of O3 by a D-luciferin based probe 
A D-luciferin homoallylic ether was reported as a highly selective and sensitive bioluminescent probe 
that emitted light in the presence of ozone but not other ROS.22 The probe is a modified D-luciferin 
where the activity is turned off through alkylation of the C6 hydroxyl with a butenyl chain containing 
a terminal alkene. The terminal alkene reacts with ozone to produce a 1,2,3-trioxolane that further 
undergoes a retro [3+2] cycloaddition eliminating acrolein and D-luciferin. The generated luciferin is 
then oxidised to oxyluciferin with the emission of light. In this way D-luciferin was used to measure 
concentrations of ozone in environmental and biological samples.22  
Various modified D-luciferin esters have been prepared, as seen in figure 2.5. These esters were found 
to be bioluminescent inactive and were used to measure specific esterase activity.23 Phosphate esters 
were produced similarly where the C6-hydroxyl was phosphorylated resulting in the loss of 
bioluminescent activity. The hydroxyl was liberated upon alkaline phosphatase (ALP) mediated 
dephosphorylation and the resultant luminescence measured. The luminescence was then related to 
ALP activity.24 D-Luciferin carbonate derivatives have also been reported.25 The D-luciferin carbonate 
derivative was prepared by covalently tethering D-luciferin to a transporter molecule that would then 
transport the conjugate across the cell membrane after which the linker would be reduced by 
glutathione (GSH), liberating free luciferin. In this way, luminescence can be used to evaluate cellular 
uptake of the D-luciferin conjugate. 




Figure 2.5. Structures of D-luciferin ester, carbonate and phosphate derivatives 
There are many other examples of D-luciferin probes, each uniquely modified for a specific function. 
Most of the latter are synthesised from commercially obtained D-luciferin. There are numerous 
publications that describe the use of D-luciferin to produce luciferin-based probes,26-28 there are 
however much less publications that concern the synthesis of D-luciferin itself.   
Review on the syntheses of D-luciferin  
Structurally, there are two key components to D-luciferin; the benzothiazole ring and the 
dihydrothiazole carboxylic acid moiety. As previously mentioned, C4 of the dihydrothiazole ring is a 
stereogenic centre and, as such, due consideration should be given to its configuration. The first total 
synthesis of D-luciferin was achieved by White et al in the early 60’s. Inspired by what was known of 
the biosynthesis of D-luciferin at the time, White et al made use of L-Cys to form the dihydrothiazole 
carboxylic acid ring. He then discovered that L-Cys afforded the undesired enantiomer, L-luciferin. 
Subsequent reactions using non-naturally occurring D-Cys afforded the correct stereoisomer. In some 
cases, the White synthetic route is still followed for commercial preparation of D-luciferin.  
The White synthesis uses p-anisidine 2.1 as a starting material.1 The thiazoline component of the 
benzothiazole ring is then formed using ethyl oxalate. The reaction of p-anisidine with ethyl oxalate 
forms the amide ester 2.2. Thionation and hydrolysis then gives the thio-acid 2.4, which subsequently 
undergoes an oxidative cyclisation which results in the key benzothiazole intermediate 2.5. Several 
functional group transformations are then employed to form 2-cyano-6-hydroxybenzothiazole which 
is then reacted with D-Cys to form D-luciferin, in an almost quantitative reaction.   




Scheme 2.6. Reagents and conditions:  i) ethyl oxalate / 180 0C / 5 min, 87 %, ii) P2S2 / ∆ / 40 min, 60 %, iii) NaOH 
/ 0 0C / HCl, 99 %, iv) K3[Fe(CN)6] / NaOH / 0 0C / 11 h, 61 %, v) CH2N2 / 0 0C / 15 min, 89 %, vi) NH3 / MeOH / ∆ / 
30 min, 62 %, vii) POCl3 / MeOH / rt / 30 min, 64 %, viii) PyHCl / 200 0C / 1 h, 90 %, ix) D-Cys / H2O:MeOH (1:1) / 
rt / 30 min, 9 % overall yield  
The White et al synthetic approach (Scheme 2.6) has an overall yield of 9 % over 9 steps, arguably 
making the synthesis of D-luciferin costly and wasteful. Thus, commercially relevant, alternate 
approaches to D-luciferin are still under investigation. Uninterestingly, most attempts at improving on 
the synthesis of D-luciferin retained the same general strategy as that developed by White and co-
workers. Wherein the benzothiazole is formed first, followed by C6 and C2 functionalisation, 
generating a nitrile functionality, to which D-Cys is added. In fact, most of the subsequent syntheses 
of luciferin differ only in their construction of the 2-cyanobenzothiazole nucleus. One of the lower 
yielding steps in the commercial synthesis of D-luciferin is the benzothiazole forming cyclisation. 
Seto et al developed an alternate synthetic route (Scheme 2.7), which forms the benzothiazole 2.7 
from the thioamide 2.12 to generate the benzothiazole directly. Dehydration then yields the 
cyanobenzothiazole 2.8, a key intermediate for luciferin synthesis.29 
 








Scheme 2.7. Reagents and conditions:  i) KOH(aq) / H2S, ii) ClCH2CO2H, iii) p-anisidine / MeOH(aq), 29 % 
iv) K3[Fe(CN)6] / NaOH, 65 %, v) POCl3 / ∆, 63 % and 12 % overall 
The Meroni synthesis also identified the 2-cyano-6-hydroxybenzothiazole as a key intermediate for 
the synthesis of D-Luciferin. However, unlike most luciferin synthesis that incorporate p-anisidine, the 
Meroni reaction sequence instead makes use of commercially available 1,4-benzoquinone 2.13. The 
benzoquinone was reacted with L-cysteine ethyl ester to afford a quinone thiophenol adduct 2.14, 
which was then subjected to an oxidative-cyclization reaction to afford 2-carbethoxy-6-
hydroxybenzothiazole 2.15.  
 
Scheme 2.8. Reagents and conditions: i) L-Cysteine ethyl ester hydrochloride / MeOH:H2O (1:1) / rt / 1 h, ii) 
K3(FeCN)6 / NaOH / EtOH / rt / 1 h, iii) 1 M HCl / EtOH / rt / 24 h, 32 % overall yield 
Subsequent C2-functional group conversion afforded the nitrile with an overall yield of 32 %. The latter 
is one of the highest yields when compared with previously reported procedures that ranged between 
6-29 %. Furthermore, by starting with benzoquinone to construct the benzothiazole, Meroni was able 
to directly form the C6-hydroxyl, as opposed to the p-anisidine utilising syntheses which instead form 
the methyl ether (2-cyano-6-methoxybenzothiazole) that requires demethylation. Meroni was 
however, unable to convert the C2-ester to the nitrile without protecting the C6 hydroxyl group. An 
arguably more versatile synthon for D-luciferin synthesis was developed by Hrobàrik et al, in the form 
of a 2-cyano-6-iodobenzothiazole ring. The iodo derivative allows for versatile functionalisation at the 
C6 position of any synthesised luciferin. Giving access to a myriad of C6 substituted Luciferin 
analogues. Moreover, the iodo functionality allows for cross coupling reactions for forming luciferin-
small molecule conjugates, of relevance in various assays. Thus, in a recent study toward the synthesis 
of triphenylamine-based chromophores involving benzothiazole-based systems,34 a shorter route to 
2.9 2.10 2.11 
2.12 
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the benzothiazole scaffold was achieved compared to the relatively longer commercial preparation. 
In this study, p-iodoaniline 2.16 was used as the starting material. p-Iodoaniline was acetylated to 
form an iodoanilide 2.17 and subsequent thionation formed a thioamide 2.18, which underwent 
cyclisation to afford the benzothiazole intermediate, 6-iodo-2-methyl-benzothiazole 2.19. Oxidation 
of the methyl group at C2 afforded the aldehyde, 6-iodobenzothiazole-2-carbaldehyde 2.20. Hrobàrik 
et al were able to successfully prepare a 2-cyanobenzothiazole-6-carboxaldehyde in relatively good 
yield (25 %), however, it was not further transformed into the 2-cyanobenzothiazole 2.21 and was 
therefore not used in the context of luciferin preparation. Despite this, it is still worth noting the 
synthesis for its potential use in luciferin analogue construction.  
Scheme 2.9. Reagents and conditions:  i) Ac2O / Py, 97 %, ii) Lawessons reagent / toluene, 68 %, iii) K3[Fe(CN)6] 
/ NaOH, 59 %, iv) SeO2 / dioxane / ∆, 25 % overall yield  
C6 Functionalisation has been used to prepare luciferin conjugates (such as PCL-1) which, upon 
exposure to certain reactants or reaction conditions, release luciferin. In this way, the release of 
bioluminescent luciferin can be coupled to varying biochemical processes and, through the degree of 
bioluminescence, these processes can be measured. The Hrobàrik et al route was particularly 
attractive because part of the aims of this research project was to couple the release of luciferin to 
varying biochemical processes through 6’-modification, which one could easily envisage through a 2-
cyano-6-iodobenzothiazole.  
Proposed Synthesis of D-Luciferin  
Based on the previous syntheses of D-luciferin28, the 2-cyanobenzothiazole core was identified as a 
key intermediate in the synthesis of D-luciferin and related compounds. In most cases, the 2-
cyanobenzothiazole core was prepared from the cyclisation and functionalisation of an acetamide. 
However, it can also be directly prepared from the cyclisation of an already functionalised 
cyanothioformanilide (Route A, Scheme 2.10).30 Such highly functionalised anilides are not easy to 
prepare because of their greater reactivity and reports on their synthesis are limited.  A rather 
interesting approach for their preparation has been reported by Reese et al, where the thioanilide was 
2.16 2.17 2.18 
2.19 
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accessed from the fragmentation of a dithiazolimine prepared from the condensation of Appel’s salt 
and aniline.31 Recently, the Appel’s salt approach has been singled out as the premier methodology 
for preparing cyanothioformanilides from substituted anilines.32 Other synthetic approaches are 
notably longer and some include relatively toxic cyanide reagents. The reported synthesis of the 2-
cyanobenzothiazole core and D-luciferin in this study initially followed route B (Scheme 2.10), the 
Appel’s salt approach, adapted from Prescher et al in their recent synthesis of D-luciferin. Prescher et 
al impressively used Appel’s salt to form a dithiazolimine that was subsequently fragmented to afford 
the cyanoformanilide. The cyanoformanilide was then cyclised using a C-S intra-molecular coupling to 
afford the 2-cyanobenzothiazole (84 %) and thereafter D-luciferin. To date, the Prescher et al synthesis 
(route B) clearly towers far above all its predecessors. 
 
Scheme 2.10. Synthetic routes toward C6-substituted 2-cyanobenzothiazoles; route A involves formation of the 
benzothiazole first followed by subsequent C2 functional group transformations, while route B installs desired 
functionality pre-cyclisation 
Aims and Objectives 
The aim of this work was to explore and evaluate various reported synthetic routes to D-luciferin in 
terms of overall yield and accessibility and to then synthesise D-luciferin by choosing an appropriate 
route based on that evaluation. Thereafter, the aim was to investigate whether any improvements 
could be made to the chosen reported synthetic procedure, since it would help in both securing access 
to a ready supply of D-luciferin and possibly lead to the development of a unique and improved 
synthetic route. A further aim involved effectively evaluating the luminescence of the synthesised 
material by reacting the synthesised luciferin with the enzyme luciferase in the presence of ATP, Mg2+, 
and O2 and recording the resultant luminescence 
The specific objectives were thus:  
Route A 
Route B 
R1 = OH / NH2 / I / Br 





Imine formation  
Cyclisation  
N-acylation/ acetylation  
fragmentation  
R1 = OMe / H 
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i) The synthesis and characterisation of D-luciferin using spectroscopic and analytical 
characterisation techniques, including; NMR, MS, IR and melting point analyses. 
ii) The bioluminescent evaluation of the synthesised D-luciferin using purified luciferase 
bioluminescence assays where the luciferase was expressed and purified from E. coli. 
iii) The identification of key limiting steps in the synthetic sequence used, where an 
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Synthesis and Bioluminescent Evaluation of D-Luciferin   
One of the more recent and most efficient routes to D-luciferin was reported by McCutcheon, Prescher 
and co-workers.32-33 As discussed, their synthesis was aimed at forming the nitrile functionality prior 
to cyclisation. This was done using dithiazolimine fragmentation, a reaction that was refined by Thierry 
Besson and Charles W. Reese (both well known for their work in field of heteroaromatic synthesis).30-
31, 34-35 The methodology used to form the dithiazolimine was actually first reported by Rolf Appel (of 
the Appel reaction) where he reacted various substituted anilines with 2,3-dithiazole chloride (later 
known as Appel’s salt).36 After extensive evaluation and deliberation, this route was chosen as a 
starting point for the synthesis of D-luciferin.  
Prescher et al Synthesis of D-Luciferin 
 
Scheme 2.11. Reagents and conditions: i) S2Cl2 / DCM / rt / 24 h, ii) Appel’s salt 2.25 / DCM / pyr / rt / 3 h,  
iii) DBU / DCM / 5 oC / 30 min, iv) PdCl2 / CuI / TBAB / DMF:DMSO (1:1) / 110 oC / 3 h, v) PyHCl / DMF / 150 oC / 
1 h, vi) D-cys / K2CO3 / MeOH:H2O / 20 min 
The detailed synthetic route used by Prescher et al is outlined in scheme 2.11. The synthesis of 
D-luciferin was achieved from the condensation of 4,5-dichloro-1,2,3-dithiazolium chloride (Appel’s 
salt) 2.25 with p-anisidine 2.1, generating an N-arylimino-1,2,3-dithiazole 2.22, which then further 
underwent DBU mediated dithiazole fragmentation to afford the corresponding cyanothioformanilide 
2.23. A copper iodide/palladium chloride catalysed C-S cross-coupling reaction was then used to form 
the benzothiazole 2.8 from the thioacetamide precursor. Subsequent O-alkyl deprotection generated 
6-hydroxy-2-cyanobenzothiazole and D-Cys addition on the nitrile functionality of 2.9 generated the 
carboxy-thiazoline ring of D-luciferin with the correct stereochemistry required for luminescent 
activity.  
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To start the synthesis, warrants the preparation of Appel’s salt. This was done following literature 
methods as seen below. Appel’s salt 2.25 was prepared from the addition of sulfur monochloride to a 
solution of chloroacetonitrile in anhydrous DCM at room temperature (Scheme 2.12). 
 
Scheme 2.12. Reagents and conditions: i) S2Cl2 / DCM / rt / 18 h 
The solution was swirled a few times and left to stand for 24 h under an inert nitrogen atmosphere. 
The resulting green-brown crystals were filtered under vacuum and washed copiously with DCM. The 
crystals were then dried under vacuum and stored at room temperature. Appel’s salt was found to be 
extremely hygroscopic. The formation of Appel’s salt was confirmed only by mass spectrometry and 
its melting point, since it is a known compound with a well-documented poor solubility profile. The 
proposed mechanism of the formation of Appel’s salt is not well understood. However, varying 
mechanisms of the salt’s formation have been previously proposed. Although, there is very little 
evidence to support any one particular mechanism. It is generally accepted that the reaction proceeds 
via the addition of S2Cl2 to the cyano group, followed by cyclisation and ionisation.  With the Appel’s 
salt formed, the dithiazolimine was then prepared for subsequent fragmentation.  
p-Anisidine 2.1 was reacted with a slight excess of previously prepared Appel’s salt in DCM at room 
temperature, to generate an imine 2.22. The mechanism involves a nucleophilic substitution at the 
carbon centre of the thionium (also referred to as sulfenium) functionality, in which the chlorine at 
position C5 on the dithiazoline ring is replaced by the amine nitrogen of p-anisidine, as shown in 
scheme 2.13. 
 
Scheme 2.13. Reagents and conditions: i) Appel’s salt 2.25 / DCM / Py / 3 h 
The reaction was monitored by thin layer chromatography, which revealed complete consumption of 
p-anisidine 2.1 after one hour. The reaction then required that two equivalents of pyridine be added; 
one to abstract the thioamide proton and the other to quench the resulting HCl, as shown in 








Scheme 2.14. Proposed mechanism for the formation of an N-arylimino-1,2,3-dithiazole 
The N-aryliminodithiazole 2.22 was isolated and purified by chromatography in relatively good yield 
(>70 %). The 1H-NMR spectrum of 2.22 (Figure 2.5) showed a distinct downfield shift in the aromatic 
proton signals relative to the starting material, from 6.70-6.78 ppm to 6.98-7.27 ppm. The downfield 
shift in aromatic proton resonances is reasoned to be the result of a decrease in electron density 
within the aromatic ring due to the conversion of the heavily donating amine group, to the lesser 
electron donating imine functionality. Additionally, the 1H-NMR spectrum of 2.22 did not display the 
amine resonance previously observed in the starting material, further supporting the formation of an 
imine. A slight downfield shift in the O-methyl singlet from 3.75 to 3.85 ppm was also observed. This 
again was reasoned to be the result of electron density being siphoned from the benzene ring in the 
imine product by the newly formed dithiazole ring to which it is linked. The 13C-NMR spectrum (Figure 
2.6) displayed the expected total of 7 signals, further confirming the formation of 2.22. The 13C-NMR 
spectrum revealed resonances at 147.8 and 156.9 ppm confirming the presence of the dithiazole ring. 
The melting point of the product was found to be 111-112 0C, corresponding to the recorded literature 








Figure 2.5. 1H-NMR spectrum of dithiazolimine 2.22 in CDCl3 
 
Figure 2.6. 13C-NMR spectrum of dithiazolimine 2.22 in DMSO 
A sharp melting point along with 1H-NMR and 13C-NMR spectral data indicated that the product 2.22 











Scheme 2.15. Reagents and conditions: i) DBU / DCM / 5 oC / 30 min 
Base-mediated fragmentation of 2.22 was used to prepare the cyanothioformanilide 2.23 required for 
the benzothiazole synthesis. 1,8-Diazobicyclo[5.4.0]undec-7-ene (DBU) was slowly added to a stirred 
solution of imine 2.22 in DCM at 5 oC, over a period of 30 min. After the addition, TLC analysis of the 
solution showed the complete conversion of the non-polar imine, to multiple products, observed as 
several relatively more polar spots, very similar in Rf (0.5 in 30% EtOAc). The reaction mixture was 
allowed to warm to room temperature, and the solvent reduced in vacuo. The crude product was 
purified on a silica gel column, eluting with EtOAc:Hexane (50:50) to afford thioacetamide 2.23 as a 
red-brown solid in good yield (66 %). The mechanism by which fragmentation occurs has previously 
been proposed and is shown in scheme 2.16. 
 
Scheme 2.16. Proposed mechanism of dithiazoline fragmentation 
The mechanism involves nucleophilic attack by the DBU 2.22a amidine nitrogen at the dithiazole S2 
ring sulfur and subsequent ring opening to afford the disulfide 2.22b. A second equivalent of DBU then 
abstracts HCl from the reaction mixture, followed by a nucleophilic attack by a third equivalent of DBU 
which cleaves the disulfide bond to give the cyanothioformanilide 2.23 and the neutral sulfane 2.22c. 
The sulfane was not isolated from the reaction mixture and thus could not be used to reinforce the 
proposed mechanistic rationale. However, the need for three equivalents of DBU was confirmed, since 
the use of less than three equivalents resulted in incomplete conversion of the starting dithiazolimine. 
The 1H-NMR spectrum of the fragmented product, figure 2.7, shows a significant change in the 
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The 1H-NMR spectrum of 2.23 displayed three distinct aromatic signals instead of the doublet of 
doublets expected of a 1,4-disubstituted benzene ring. These signals integrate for the expected total 
of four protons. The appearance of the aromatic resonances was reasoned to be due to cis/trans-
isomers or, more likely, a form of keto-enol tautomerism in the product. This suggests that 2.23 has 
two interconverting isomeric forms which exist in equilibrium. The chemical equilibrium between the 
isomeric thione and thioenol (or iminothiol) forms of 2.23 involves the transfer of the thioamide 
proton and shifting of the bonding electrons. The proton ortho to the methoxy group appears to be 
less affected by the tautomerism and, as such, a distinct signal integrating for its two protons are 
observed, assigned in figure 2.7 as H-3. In contrast, the protons ortho to the tautomerising thioanilide 
moiety are significantly affected resulting in separate signals for protons in the thione and thioenol 
forms. Both signals are observed as doublets, with J = 11.9 Hz, as a result of their coupling to proton 
H-3. Interestingly, proton H-3 is observed as an apparent triplet (J = 11.9 Hz) reasoned to be as a result 
of its coupling to proton H-2 and H-2’.  The ratio of signals H-2 and H-2’ indicated that compound 2.23 
favours one form more than the other. Two broad singlets integrating for one proton collectively were 
also observed at 9.54 and 9.79 ppm with the more acidic proton assigned to the thioanilide proton H-
1’ and the less acidic as H-1 respectively, and were based on predicted pKa calculations. Similarly, 
these protons are distinct signals representative of the thione and thioenol isomers and the ratio of 
the two signals correspond to that previously calculated from H-2 and H-2’. 
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Further supporting that approximately 60 % of the thioanilide is in the iminothiol form by 1H-NMR 
spectroscopy. This tautomerism is very important in terms of reactivity, as the iminothiol form is 
required for cyclisation. Cyclisation of the thioamide intermediate 2.23 to the corresponding 
benzothiazole 2.8 was achieved via a C-S intramolecular cross coupling reaction shown in scheme 2.17. 
 
Scheme 2.17. Reagents and conditions: i) PdCl2 / CuI / TBAB / DMF:DMSO (1:1) / 110 oC / 3h 
The thioamide 2.23 was dissolved in a solution of DMF and DMSO, to which copper iodide, palladium 
chloride, and tetrabutyl ammoniumbromide (TBAB) were added. The reaction was then heated at 
110 oC for 3 h under N2. TLC analysis of the reaction revealed the conversion of the starting material 
to multiple products, observed as a myriad of non-polar spots, where the spot that was most intense 
in appearance (Rf 0.9 and 0.95 in 10% EtOAc) was thought to be the major product from the cyclisation 
reaction. After completion of the reaction, the crude mixture was diluted with EtOAc and washed with 
brine, ammonium chloride and water to remove the metal salts. However, TLC analysis of the organic 
layer revealed the persistence of trace amounts of highly polar impurities, possibly derived from metal 
adducts. After the aqueous wash, the organic layer was concentrated and purified on a silica column, 
eluting with hexanes to afford the 6-methoxy-2-cyanobenzothiazole product as a pale-yellow solid in 
a poor yield of 13 %. The proposed mechanism for benzothiazole cyclisation involves the directed 
insertion of the palladium catalyst into a C-H bond ortho to the anilide moiety. It is believed that the 
anilide functionality facilitates insertion of the metal into the C-H bond, which might explain why 
insertion occurs at only the proton ortho to the anilide. It is noted that TBAB acts as a ligand as well 
as a base via the bromide ion. TBAB facilities formation of the thioenolate form which is subsequently 
stabilised by the copper(I) catalyst. Subsequent oxidative addition and transmetalation results in the 
formation of a six membered metallocycle which undergoes reductive elimination of Pd(0), thus 
affording the benzothiazole ring, as shown in scheme 2.18. 
2.23 2.8 




Scheme 2.18. Proposed mechanism for the C-S oxidative coupling reaction 
The cyclisation reaction was based on a previously reported literature method with a yield of 87 %, 
but despite its reported efficacy, the reaction consistently afforded the product in poor yield (~10 %). 
This forced deviations from the method where increased catalyst loading and alternate Pd(II) catalysts 
where used, namely; Pd(OH)2, Pd(dppf)2, and Pd(OAc)2. In all instances the product recovery remained 
low, with little to no improvement, as shown in table 2.1. 
Table 2.1. Attempted optimisations for C-S cyclisation reaction  
Catalyst  Catalyst loading, mol eq. Co-catalyst  Co-catalyst loading, mol eq. Yield, %  
PdCl2 0.1 CuI 0.5 13 
PdCl2 0.2 CuI 0.5 10 
PdCl2 0.5 CuI 0.5 12 
PdCl2 1 CuI 0.5 16 
PdCl2 0.1 CuI 0 - 
PdCl2 0.1 CuI 1 <10 
Pd(OH)2 0.1 CuI 0.5 <10 
Pd(OH)2 0.5 CuI 0.5 <10 
Pd(OAc)2 0.1 CuI 0.5 - 
Pd(OAc)2 0.5 CuI 0.5 - 
Pd(dppf)2 0.1 CuI 0.5 - 
*Based on average isolated yields 
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The 1H-NMR spectrum of the isolated benzothiazole product displayed a singlet at 3.93 ppm 
integrating for 3 protons due to the C6-methoxy group as well the three aromatic resonances expected 
of a C6-substituted benzothiazole ring system, integrating for one proton each. The 1H-NMR spectrum 
of the benzothiazole product is shown in figure 2.8.  
 
Figure 2.8. 1H-NMR spectrum of 2-cyano-6-methoxybenzothiazole 2.8 in DMSO 
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The 1H-spectrum of the benzothiazole scaffold showed 3 distinct aromatic signals. The observed 
coupling constants of individual signals were used to determine their locality. The most obvious 
assignment was that of H-4, which appeared as a doublet (J = 2.4 Hz) due to long range coupling with 
H-3. Normally, long range couplings are less than 1 Hz, however, such long-range couplings become 
more significant when dealing with aromatic compounds. Interactions of C-H bonds with pi electrons 
of aromatic rings along the coupling pathway resulted in an increase in the magnitude of the long-
range coupling. This can be seen in figure 2.8, where the resonance at 7.90 ppm (H-4) displays a small 
coupling of 2.4 Hz, despite having no vicinal protons to couple to. This long-range coupling constant 
of J = 2.4 Hz, is also observed in H-2. Thus, signal H-2 appears as a doublet of doublets integrating for 
1 proton due to its 3J coupling to H-3 and its 4J coupling to H-4. The 13C-NMR spectrum of 2.8 displayed 
the expected total of 9 resonances and its IR spectrum revealed a sharp absorption band at 2200 cm-1, 
further supporting the presence of the nitrile functionality. The melting point of 2.8 was found to be 
in the range of 123-130 oC, which was in close agreement with the recorded literature value of 129-
131 oC. The broad melting point and elemental analysis data of compound 2.8 suggested possible 
traces of impurities. However, since the reaction was low yielding and the crude material had already 
been subjected to column chromatography, it was decided that the trace impurities would be dealt 
with in the next synthetic purification step. O-Methyl deprotection was used to prepare 4-hydroxy-2-
cyanobenzothiazole. The O-alkyl precursor was heated at 110 oC with pyridinium hydrochloride 
(PyHCl) in DMF for 1 h. TLC analysis of the reaction showed the conversion of the non-polar starting 
material to a single, more polar product (Rf 0.3 in 30% EtOAc). After completion of the reaction, as 
evidenced by TLC analysis, the mixture was diluted with EtOAc, washed with brine and the organic 
layer concentrated and purified using silica column chromatography to afford 2.9. Most obvious in the 
analysis of the 1H-NMR spectrum of 2.9 is the absence of the O-methyl singlet previously observed in 
the starting material. All other 1H-NMR signals were conserved in the transformation. 
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A noticeable upfield shift in the aromatic proton resonances of the deprotected product relative to 
the starting material was also observed. The shift upfield concerns the greater electron donating effect 
of the hydroxyl group, relative to the methoxy precursor (It is well known that the hydroxyl group is a 
more strongly electron donating substituent than the methoxy group). The IR spectrum of 2.9 
indicated that the nitrile functionality was conserved in the transformation and the melting point of 
the product was in close agreement with that of the recorded literature value (206-207 oC, lit. 205-
207 oC). 
 
Scheme 2.19. Reagents and conditions: i) D-Cys / K2CO3 / MeOH:H2O / 20 min / rt 
The final step was the synthesis of D-luciferin 2.10, which comprises of a benzothiazole C2-linked 
thiazoline ring. The thiazole ring has a carboxyl group at the C4 position and, notably, the carbon 
bearing the carboxyl group is a stereogenic centre with defined stereochemistry. The activity of 
D-luciferin is highly dependent on the configuration at the C4 position, meaning only one of the two 
enantiomers are biologically active. To generate a thiazole ring with the correct stereochemistry, 4-
hydroxy-2-cyanobenzothiazole was reacted with enantiomerically pure D-Cys (99 % ee) in the 
presence potassium carbonate. The mechanism involves nucleophilic addition of the thiolate of D-Cys 
on the carbon of the nitrile group to generate an imine. A second attack by the free amine of D-Cys on 
the same carbon, now bearing an imino functionality, followed by elimination of ammonia generates 
the thiazoline ring (Scheme 2.20).  
 
Scheme 2.20. Proposed mechanism for formation of D-Luciferin 
 
2.9 2.10 
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An acidic work up protonates the carboxylate moiety to afford D-luciferin. The described cysteine 
coupling was achieved by adding potassium carbonate to a stirring solution of D-Cys and benzothiazole 
in a water/methanol mixture under an inert nitrogen atmosphere. TLC analysis of the reaction 
revealed conversion of the starting material to a new product, seen as the formation of a new, more 
polar spot (Rf 0.3 in 5 % MeOH). In cases where incomplete conversion of the starting material was 
observed, an acid-base extraction was employed to selectively isolate 2.10. The theory behind this 
technique is that the potassium salt of 2.10, formed from the base mediated D-Cys addition, is ionic 
and thus water soluble. Undesired neutral compounds, such as unreacted 2.8, are extracted from the 
aqueous layer using diethyl ether. The aqueous layer is then acidified to form a neutral compound, 
which is then extracted into an organic solvent such as EtOAc, rendering the acid > 95 % pure (based 
on 1H-NMR spectroscopy and LCMS). The acidification was done at 0 oC to limit decarboxylation and 
racemisation, well known reactions undergone by 2.10 reported in both basic and acidic media. The 
acid form of 2.10 was isolated as a pale-yellow solid in excellent yield (86 %), and was unstable at 
room temperature. Such instability was revealed by TLC where the polar acid converted to a much 
less polar product, believed to be due to decarboxylation which is favoured entropically by increasing 
temperatures. Therefore compound 2.10 was maintained at low temperatures at all times. 
Figure 2.11. 1H-NMR spectrum of D-luciferin 2.10 in MeOD, with trace amounts of EtOAc 
The 1H-NMR spectrum of D-luciferin showed all the expected proton signals, formerly reported for the 
isolated natural product. The spectrum (Figure 2.11) displays three distinct signals in the aromatic 
region (7-8 ppm) integrating for one proton each. These resonances were assigned to the aromatic 
protons (H-1,2,3). What appeared to be a well-defined triplet at 5.40 ppm, integrating for one proton, 
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was assigned the proton alpha to the carboxyl group (H-5). The triplet was found to be highly 
deshielded, most likely due to the electron withdrawing effects of the geminal carboxyl group. This 
particular resonance is very interesting because of D-luciferin’s chiral character. This chirality 
differentiates the H-4 protons by their environment and potential. Consequently, a doublet of 
doublets is expected instead of the observed triplet for proton H-5. A possible reason for the apparent 
triplet may be due to the carboxythiazoline ring interconverting between two different puckered 
conformations and that the observed coupling constants are an average over these conformations. 
Another possible explanation could be that the triplet H-5 is in fact two overlapping doublets. If the 
signal H-5 is indeed a triplet, then each H-4 coupling will have a 9 Hz coupling constant, which can be 
seen from the 1H-NMR spectrum. 
It is evident from the 1H-NMR spectrum that H-4 has two distinct coupling partners. The coupling 
constants were found to be 9.0 Hz, and 3.0 Hz. The smaller coupling constant is due to the vicinal 
coupling of H-4 to H-5. The larger coupling constant is due to the geminal coupling between the two 
H-4 protons. This further indicated that the two protons are magnetically non-equivalent and are thus 
said to be diastereotopic. Diastereotopicity confirmed the presence of a stereogenic element and by 
extension that it is optically active. However, the 1H-NMR data of course gave no indication of the 
optical purity of D-luciferin, since the enantiomers are equivalent by 1H- and 13C-NMR experiments. 
For this reason, the optical rotation of D-luciferin was determined.  
The [α]20
𝐷
 was found was found to be in good agreement with that recorded for enantiomerically pure 
D-luciferin ([α]20
𝐷 obs.
 = -290, [α]20
𝐷 lit.
 = -340, DMF, c = 1), which indicated only a small degree of 
racemisation (85 % optical purity, 92.5 % D-luciferin, 7.5 % L-luciferin). The formation of D-luciferin 
was further confirmed by 13C-NMR spectroscopy (vide infra), and melting point analysis, all of which 
were in good agreement with the data on the previously isolated natural product. The 13C-NMR 
spectrum displayed the correct number of carbon resonances. 




Figure 2.12. 13C-NMR spectrum of D-luciferin 2.10 in MeOD 
The purity of the material was further assessed using elemental analysis and LCMS, both of which 
supported that analytically pure D-luciferin had been produced and with the synthesis of D-luciferin 
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Modifications to Prescher et al Synthesis of D-luciferin  
The step that was found to be most limiting in the Prescher sequence was the C-S coupling reaction, 
despite it having been reportedly high yielding (86 %).32 The lower yielding step was therefore further 
investigated. 
 
Scheme 2.21. Reagents and conditions: a) PdCl2 / CuI / TBAB / NMP:DMSO (1:1) / 120 oC / 2 h b) PdCl2 (0.1 eq)/ 
CuI (0.5 eq)/ TBAB / DMF:DMSO (1:1) / 110 oC / 3h 
The cyclisation reaction was originally developed by Inamoto et al who reported a Pd-catalysed, CuI 
co-catalysed C-S cross coupling reaction in 1:1 mixture of DMSO and an appropriate co-solvent.37 The 
addition of TBAB reportedly enhanced the transformation as lower yields were observed in its absence 
and NMP was found to be the best co-solvent. The reaction was originally done exclusively with aryl 
and amine substituents as shown in scheme 2.21. Prescher et al then used the same reaction on the 
cyano precursor 2.23 to afford the 2-cyano-6-methoxybenzothiazole 2.8 with the following changes 
to the cyclisation reaction; DMF was used as a co-solvent instead of NMP, the reaction was heated to 
110 oC instead of 120 oC. These changes were not at all explained in any of their publications and 
afforded consistently low yields under the described conditions. Thus, warranting the use of the 
original, optimised reaction conditions (described by Inamoto et al) in an attempt to improve the yield 
and, perhaps, better understand why Prescher et al decided to make those particular changes to the 
Inamoto method.  
The cyclisation reaction starting from 2.23 was therefore repeated using NMP as the co-solvent 
instead of DMF and the reaction was repeated at 110, 120 and 150 oC. From these reactions it was 
found that there was a negligible difference between the use of NMP and DMF as both reactions 
afforded similar average isolated yields with identical TLC profiles. There was however a slight increase 
in the average yield for the reactions done at 150 oC relative to those done at 110/120 oC (from 10-
13 % to 25 %). Furthermore, it was also found that relatively consistent yields were afforded for the 
same reaction up to 600 mg starting scale, but reduced isolated yields were observed when cyclising 
gram quantities (1 and 2 g reactions afforded 8 and 10 % of the cyclised product, respectively).  
2.23 2.8 
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Since both the reaction conditions used by Inamoto et al and Prescher et al afforded equally low yields, 
it was not possible to determine why Prescher et al made use of DMF instead of NMP or carried out 
the reaction at reduced temperatures. What was also quite interesting was that Prescher et al 
continued to work on improving their reportedly high yielding coupling reaction, suggesting that they 
too were perhaps aware of its limitations in the context of 2-cyanobenzothiazole syntheses. Another 
possible explanation for the low yields could be the absence of an effective oxidant that could more 
effectively regenerate the catalysts. Both the Prescher and Inamoto methods report that the reactions 
were carried out under dry and inert conditions. These conditions could in fact have been retarding 
catalyst regeneration. Unfortunately the reaction was not attempted with any oxidant additive to 
confirm this theory, however, it should be noted that Prescher et al later moved away from the limiting 
C-S coupling method.   
Prescher et al Improved and Scalable Synthesis of D-luciferin  
McCutcheon and Prescher et al subsequently developed an improved synthesis that bypassed the 
need for a C-S Pd-catalysed coupling reaction claiming that it improved the overall sequence since it 
improved both overall yield and scalability.33 The improved reaction sequence is shown in 
scheme 2.22.  
 
Scheme 2.22. Reagents and conditions: i) Appel’s salt / Sulfolane / 40 oC / 3 h, ii) 180 oC / 20 min, iii) PyHCl 
(10 eq) / 180 oC / 1 h, (2.4: 21 %, 2.5: 51 %) 
The reaction involved forming a dithiazolimine from the condensation of p-anisidine and Appel’s salt 
followed by dithiazolimine thermolysis and electrocyclisation to afford the cyclised benzothiazole.33, 
38 This publication encouraged a move away from the metal mediated C-S coupling methodology and 
to further explore dithiazolimine electrocyclisation, discussed in Chapter 4 in the context of the 
development of a unique and improved general luciferin synthetic sequence. Ultimately, efforts 
toward optimising the Pd and Cu catalysed reaction were abandoned and focus was instead shifted to 
developing novel modes of 2-cyanobenzothiazole cyclisation and to the bioluminescent evaluation of 
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Bioluminescent Evaluation of D-Luciferin  
In general, the bioluminescence properties of luciferin substrates are evaluated by either purified 
luciferase bioluminescence assays or by using luciferase expressing mutant cell lines. In the case of 
the purified luciferase assay, if the synthesised material is indeed luminescent, then it will produce a 
detectible luminescent output when treated with luciferase. This is usually done by dissolving the 
substrate in a neutral buffer, containing all the elements required for the light emitting reaction, such 
as Mg2+ and ATP. The enzyme (usually also dissolved in a stabilising buffer) then gets added to the 
substrate and the resulting luminescence is recorded using a luminometer. In the case of luciferase 
expressing cell lines, luminescence is measured similarly, with the only difference being that buffers 
containing magnesium and ATP are not required since they are already present in the cells. The 
D-luciferin that was prepared was evaluated in two ways, the first involved using a purified luciferase 
bioluminescence assay and the second involved using luciferase expressing tobacco plants.  
Purified enzyme assay: The synthesised D-luciferin was reacted with luciferase and the resultant 
luminescence measured using a Luminoskan Ascent luminescence plate reader. The luciferase enzyme 
was prepared as a 10 nM solution in enzyme buffer where luciferase lyophilised powder was dissolved 
in previously prepared luciferase enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 
0.8 mg/mL BSA). Luminescence assays were initiated by adding 30 μL of luciferase in luciferase enzyme 
buffer to 60 μL of 0.1 µM or 3.56 µM D-luciferin in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM 
EDTA, 8 mM MgSO4, and 4 mM ATP) in a white 96-well plate. The RLU were then determined 1 min 














































    




























Figure 2.12. a) Graph of D-luciferin bioluminescence and b) Luminescence over time demonstrating Burst 
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For the standard evaluation of luminescence, figure 2.12 graph (a), two control readings were 
recorded. Control 1 contained 90 µL of 10 nM the enzyme luciferase in enzyme buffer, control 2 
contained 90 µL of 0.1 µM D-luciferin in substrate buffer. In both instances, no significant 
luminescence was observed. Only when both the enzyme and substrate were present, was 
luminescence observed. When 30 µL of the 10 nM enzyme was injected into 60 µL of 0.1 µM D-luciferin 
an output of 480 RLU was observed after 1 min. A threefold increase in luminescence was observed 
when the concentration of D-luciferin was increased to 3.65 µM. Graph (b) showed the luminescence 
profile of D-luciferin over time. It is evident from the graph that there was a spike in luminescence in 
the first minute, which then decayed to produce a steadier luminescent output over time. This is 
characteristic of the luciferase enzyme and, as previously discussed by Fraga et al, is caused by 
inhibition of the enzyme by by-products formed in the light emitting reaction.11 Graph (c) shows the 
burst kinetic profile of luciferase reported by Fraga et al for comparison purposes. 
Live imaging using luciferase expressing tobacco plants: The synthesised D-luciferin was further 
evaluated using transgenic luciferase expressing N. Tabacum plants.  The plants were transfected with 
a previously prepared luciferase coupled stress inducible promotor, XvSap1. Luciferase expression was 
then induced by subjecting mature N. Tabacum plants to a 6-day dehydration period, after which 
leaves were taken from plants for bioluminescence imaging.   
 
Figure 2.13. BL images of luciferase expressing N. Tabacum leaves treated with a 5 mM aqueous solution of 
a) D-luciferin potassium salt and b) D-luciferin free acid 
  
  
   
  
  
   
a) b) 
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Leaves were individually sprayed with equal amounts of 5 mM D-luciferin and D-luciferin potassium 
salt after which Luciferase activity was imaged with a 3D-luminometer at an exposure time of 300 s 
per leaf. Photon or count emission by luciferase expressing leaves were quantified using the Living 
Image software (Caliper, USA) and are shown in figure 2.13. Luminescence was recorded before and 
after the treatment with luciferin and was used to evaluate luciferase expression and by extension 
luc-coupled promotor activity. The fact that luminescence was observed provided evidence that 
XvSAP1 had been upregulated in response to dehydration, since negligible luc activity had been 
reported prior to dehydrating. As a control, non-luc expressing tobacco leaves were also treated with 
D-luciferin and as predicted, luminescence was not observed, figure 2.14.  
 
Figure 2.14. Non-luciferase expressing control 
 
Summary and Conclusions 
The synthesis of D-luciferin was achieved over 6 steps with a 23 % overall yield. All spectroscopic and 
analytical data were in good agreement with that previously reported for the natural product. The 
metal mediated cyclisation to form the benzothiazole was limiting and an alternative methodology for 
the formation of the benzothiazole from the thioanilide would be advantageous. In terms of its 
luminescence properties, D-luciferin was found to be luminescent active when treated with luciferase. 
The synthesised D-luciferin was evaluated alongside commercially sourced D-luciferin, as a positive 
control, where no significant difference in luminescent output was observed between commercial and 
synthetic luciferin, further supporting that D-luciferin had been successfully synthesised. In 
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Synthesis and Bioluminescent Evaluation of D-Aminoluciferin 
Abstract 
D-Aminoluciferin, a C6’-amino variant of D-luciferin, was identified to have more favourable 
luminescent properties relative to natural D-luciferin; in terms of it having a more red-shifted 
maximum wavelength of emission (λmax of 557 nm for D-luciferin and 594 nm for D-aminoluciferin 
using natural luciferase, Ppy luc) and in terms of luminescence half-life and binding affinity for the 
luciferase enzyme. The amino group also provides a unique handle for coupling D-aminoluciferin with 
other molecules of interest, particularly peptides, to form amides and carbamates of relevance in the 
development of probes based on amide and carbamate hydrolysis. This chapter concerns the 
preparation, characterisation and bioluminescent evaluation of D-aminoluciferin, which was prepared 























Synthesis and Bioluminescent Evaluation of D-Aminoluciferin 
D-Aminoluciferin: An Introduction 
Fluorogenic and chromogenic substrates are used commonly in analytical methods for determining 
enzyme activities. The substrates are cleaved, generally by a target enzyme, to release a detectible 
analyte. For example, such an analyte could be a bioluminescent active molecule that would luminesce 
upon release. In this way, the measured luminescence can be used to determine the analyte 
concentration and hence correlate to enzyme activity.1 D-Luciferin has been used extensively in this 
regard2-4 and, in an effort to diversify its bioluminescent applications, amino derivatives of D-luciferin 
were developed. D-Aminoluciferin was first prepared by Emile White and co-workers following on 
their successful synthesis of D-luciferin and some regio-isomers thereof (figure 3.1).5  
 
Figure 3.1. The structures of the first synthetic analogues of D-luciferin prepared by Emile White and 
William McElroy 
From these analogues, White and McElroy established that the C6’-hydroxyl of D-luciferin could be 
replaced with an amino group and still retain luminescent activity.5 They also reported that C6’-
aminoluciferin emits light at a longer wavelength (λmax of 594 nm, relative to 557 nm for D-luciferin) 
and that it has a 10-fold higher affinity for luciferase than natural D-luciferin.5-6 Additionally, it was 
demonstrated that light was not emitted when the amino group was acylated. Much like how 
D-luciferin loses its luminescent activity when the 6’-hydroxyl is removed, alkylated or acylated. 
Reportedly, this is not due to a lack of binding, in fact, these and many other modifications are well 
tolerated by the enzyme. Instead, the modifications prevent light emission by causing the light 
emitting reaction to generate a singlet excited state as opposed to the triplet excited state required 
for luminescence.7  
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The replacement of the C6’-hydroxyl of D-luciferin with the more strongly electron-donating amino 
group red shifts the spectral properties of the luciferin chromophore while maintaining affinity for the 
enzyme. The red-shifted emission is of course desirable for deep tissue imaging, but what has actually 
made D-aminoluciferin so popular is the added option of peptide chemistry at the terminal amino 
group.  
Bioluminescent properties of D-aminoluciferin and related analogues  
In nature there are approximately thirty different forms of BL systems, of which nine have been 
established to be unique. Each of the nine BL systems has its own limitations (reactivity, solubility, 
λmax, etc), which forms the rationale behind the need for new BL systems based on novel or existing 
luciferins and/or luciferases. For example, a D-luciferin-utilising BL system may be preferable to a 
coelenterazine BL system due to the lower cost and better bioavailability of the D-luciferin substrate. 
Unlike D-luciferin, coelenterazine cannot effectively overcome the blood brain barrier which may limit 
its applications accordingly. On the other hand, D-luciferin has a relatively low stability in solution and 
hence new luciferins are constantly being investigated. 
As previously detailed, all luciferins emit light by the same mechanism of oxidative decarboxylation 
that results in a high energy excited state intermediate that relaxes to the ground state with the 
emission of light (CTIL/CIEEL). The energy associated with the excited state is derived, in part, from 
the electron rich reservoir that is the benzothiazole moiety. In the case of D-aminoluciferin, the amine 
raises the energy of the electron rich benzothiazole resulting in a lower energy excited state and 
ultimately a smaller energy gap between the excited and ground state. This smaller energy gap is 
observed as a longer wavelength of emission as seen in figure 3.2. 
 
Figure 3.2. a) Bioluminescence emission spectra of Ppy luciferase treated with aminoluciferin at pH 6.0, pH 7.7 
and pH 8.55, and b) the fluorescence emission spectra of dehydroluciferin (A), 4'-hydroxyluciferin (B), D-luciferin 
(C), and aminoluciferin (D) in glycylglycine buffer at pH 8.0. The spectra are adapted from White et al and 
normalised to 1 at peak emission5 
a) b) 
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The spectral properties of various other substituted aminoluciferins were studied independently. It 
was demonstrated that mono- and di-substituted alkylaminoluciferins 3.2a-d as well as cyclo-
aminoluciferins 3.3a-b were all substrates for natural Ppy luc. All of the amino-derivatives, shown in 
figure 3.3, displayed greater affinity for luciferase than D-luciferin and D-aminoluciferin and a 
significant bathochromic shift in the BL maxima in the spectra of alkylaminoluciferins (in vitro) relative 
to D-luciferin and D-aminoluciferin was also observed. However, the total light output of the 
enzymatic reactions with the luciferin analogues were significantly reduced relative to D-luciferin. 
 
Figure 3.3. The structure of various substituted aminoluciferins 
Interestingly, tests with the mutant Ultra-Glo luciferase in P450-Glo buffer solution demonstrated 
increases of 5.7 and 4.7 times, respectively, in the luminescence intensity and the total light output 
for cycloluciferin 3.3a and N-methylcycloluciferin 3.3b.8 Unfortunately, the mutant Ultra-Glo luc is 
currently not available for transformation in living cells and hence cannot be used for in vivo imaging. 
The combination of an electron donating amino group and a polarisable selenium atom was used by 
Conley et al to expand the range of red-shifted D-luciferin analogues whose emission maxima are 
shown in figure 3.4. The selenazole 3.4 emits red light in vitro and in vivo (λmax 600 nm), thus it’s 
emission is easily distinguishable from the yellow green light of D-luciferin (λmax 550 nm) making it 
ideal for use in dual sensing applications.  
 
Figure 3.4. Bioluminescence emission spectra of D-luciferin, D-aminoluciferin (6’-NH2LH2) and various amino 
analogues demonstrating increasing λmax 
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Another interesting example of a 6’-amino derivative of D-luciferin was reported by Zhou et al, who 
prepared a series of N-cycloalkylated luciferins.9 Of these luciferins, CybLuc demonstrated a 20-fold 
increase in luminescence intensity relative to D-luciferin and D-aminoluciferin (Figure 3.5).   
 
Figure 3.5. Bioluminescence imaging of D-luciferin, D-aminoluciferin and CybLuc in a nude mouse brain that was 
implanted with ES-2-Fluc cells, to generate tumour xenografts. Structures and representative bioluminescence 
images after intraperitoneal injection of D-luciferin, D-aminoluciferin, and CybLuc (1 mM, 0.2 mL) over time are 
shown 
In the study by Zhou et al, it was not only demonstrated that CybLuc and related N-cycloalkyl luciferins 
were effective substrates for native Ppy luciferase, but also that CybLuc could be used for deep tissue 
imaging since it produced elevated bioluminescent signals in vivo when compared to the known 
luciferins. Moreover, CybLuc demonstrated a more red-shifted BL emission maxima (607 nm), similar 
to that of the previously reported amino-analogues, which again is of significance for tissue 
penetration in live animal imaging.  
While the effects of the different modifications on the emission intensity and BL maxima are 
interesting and can be exploited to various ends, it must be reiterated at this point that aminoluciferins 
are generally valued not for their BL wavelength of emission but rather for the unique chemical handle 
that the amine provides. 
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Applications of D-aminoluciferin and related analogues  
The amino functionality allows for the formation of amides. These amides are non-luminescent active 
until hydrolysed (either selectively or non-selectively) and luminescence allows for measuring the 
hydrolysis process (scheme 3.1). A number of technologies have been developed on this premise, 
some of which are highlighted here. 
 
Scheme 3.1. D-Aminoluciferin-peptide conjugates 
Specific peptidase activity can be monitored by coupling D-aminoluciferin to specific peptide 
sequences that are recognised by specific enzymes. An example of such a coupled conjugate is the 
commercially available Vivoglo® Caspase-3/7 substrate. This luciferin conjugate is recognised by the 
caspase enzymes which hydrolyses the conjugate to afford aminoluciferin, which further reacts in the 
presence of luciferase to emit light. In this way, the light output can be correlated to caspase activity 
and can therefore be used to image apoptotic cells (Scheme 3.2).10 The Promega caspase-3/7 assay 
has been used extensively in cancer biology research where caspase activity is of interest.  
 
Scheme 3.2.  Luciferin-linked caspase-3/7 assay 
In a study concerning the characterisation of apoptotic cells Z-DEVD-aminoluciferin, the substrate in 
the Promega caspase-3/7 assay, was cleaved by caspase-3 to liberate aminoluciferin, which then 
reacted with luciferase to generate a luminescent signal. In two oncology models (namely SKOV3-luc 
and MDA-MB-231-luc-LN, at 24, 48, and 72 h after treatment with docetaxel) cells were injected with 
Z-DEVD-aminoluciferin and the resultant bioluminescence was recorded. Significantly more light was 
detected in the docetaxel-treated group compared with the vehicle-treated group. This was expected 
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since docetaxel is a well-known inducer of apoptosis. Interestingly, significant differences between 
the docetaxel treated and untreated groups were detected as early as 24 h after treatment by 
bioluminescence imaging, whereas caliper measurements were unable to detect a difference for 4–5 
additional days. The results from this study are highlighted in figure 3.6, where increasing 
luminescence is observed upon increasing docetaxel concentration.11 
         
Figure 3.6. VivoGlo® modified aminoluciferin substrate for monitoring caspase-3/7 activity 
This report suggests that in vivo imaging of apoptosis using Z-DEVD-aminoluciferin could provide a 
sensitive and rapid method for early detection of drug efficacy, with potential applications in pre-
clinical therapeutic programs. Similarly, various other luciferin amides have been used as substrates 
for fatty acid amide hydrolase (FAAH). These luciferin amides reportedly enable highly sensitive and 
selective bioluminescent detection of FAAH activity in vitro and in vivo. The potency and tissue 
distribution of FAAH inhibitors can be imaged in live mice, and luciferin amides serve as exemplary 
reagents for greatly improved bioluminescence imaging in FAAH-expressing tissues such as the brain.12 
Other interesting analogues formed from nitroluciferin were demonstrated to be active substrates for 
specific reductase enzymes that reduced the nitro moiety to form luminescent active aminoluciferin.13 
In a study concerning the imaging of cell-cell contacts a nitroluciferin derivative, Luntr, was used to 
measure bacterial nitroreductase (NTR) activity in cells.13 Some of the results from this study are 










Figure 3.7. NTR-mediated reduction of Luntr produces a light-emitting luciferin; a) 1H-NMR spectra of Luntr 
combined with NTR and NADH in deuterated PBS, b) Luntr was incubated with NADH in the presence (+) or 
absence (-) of NTR for 0−90 min and a graph that demonstrates the fold induction in bioluminescent signal (from 
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There are many other examples of D-aminoluciferin based probes, most of which are recognised and 
hydrolysed by aminopeptidase to produce luminescence. Figure 3.8 shows the first examples of 
bioluminescent probes for imaging aminopeptidase activity in deep tissue and living cells.14 
 
Figure 3.8. Structures of aminoluciferin aminopeptidase probes 
All of the probes reviewed here and, for the most part, luciferin probes in general are designed to be 
substrates for enzymes that are of interest because of their dysregulation as a result of a diseased or 
abnormal state. For example, studies have shown that aminopeptidase is clearly dysregulated in 
numerous human malignancies, mainly solid tumours.15 Thus aminopeptidase has been identified as 
a potential biomarker for anticancer therapy.  
In the previously described reductase probe it was noted that the reductase activity is coupled to 
NADH/NAD+ status, which in turn is closely associated with redox imbalances related to oxidative 
stress. A non-specific or specific reductase probe is therefore of interest in monitoring oxidative stress 
which is significantly increased in diseased cells and disordered states. 
Similarly, the Promega Caspase-3/7 probe was designed to monitor changes in the enzyme activity of 
the Caspase enzymes whose up-regulation is linked to increased oxidative stress and an associated 
redox imbalance.  
It should now be apparent that the various probes are in fact also sensors for redox imbalance, 
although they are designed to monitor the affected downstream enzymes and analytes. Interestingly, 
an aminoluciferin probe that directly monitors changes in redox status has yet to be reported. Linking 
aminoluciferin luminescence, or even D-luciferin luminescence, to the direct measurement is 
therefore of interest. However, the functional groups (-OH, -NH2) that would be used to link luminesce 
offer very limited access to redox chemistry, which is more synonymous with the thiol 
functionality (-SH). In any case, exploration of aminoluciferin applications in such a way would require 
ready access to D-aminoluciferin which, because of its synthetic preparation, makes its use in synthetic 
probe development relatively costly.  
Although D-aminoluciferin clearly offers many advantageous over the D-luciferin parent, its cost is 
equally prohibitively expensive. The cost of course is associated with the synthetic routes used to 
prepare D-aminoluciferin, many of which have been noted as relatively low yielding. 
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Review on the synthesis of D-aminoluciferin  
The first synthetic route toward D-aminoluciferin differed significantly from that reported by White 
et al for D-luciferin. The synthesis involved the formation of 6-amino-2-cyanobenzothiazole 3.7 
(Scheme 3.3 a) from the substitution of a 2-chloro precursor 3.5 with cyanide. It is not explicitly stated 
why the D-luciferin synthetic sequence was not or could not be used to prepare D-aminoluciferin, but 
it can reasonably be assumed that it concerned the relatively more reactive C6-amine.  
 
Scheme 3.3. Synthesis of 6-amino-2-cyanobenzothiazole   
Most of the reported synthesis of 2-cyanobenzothiazoles make use of a C2-chloro intermediate which 
reacts in the presence of cyanide to afford the 2-cyanobenzothiazole (scheme 3.3 b). This reaction 
works particularly well with C6-nitrobenzothiazoles (Scheme 3.4), since the nitro functionality is able 
to better facilitate chloro substitution by stabilising the resultant Meisenheimer-like complex.  
 
Scheme 3.4. Proposed mechanism for C6-nitro mediated substitution of C2-chloro-6-nitrobenzothiazole by 
cyanide 
A US patent reported the preparation and applications of D-aminoluciferin, prepared via the 
regioselective nitration of an unsubstituted benzothiazole 3.8 and its subsequent conversion into an 










Scheme 3.5. Perkins et al synthesis of D-aminoluciferin 
The ester 3.10 was converted to an amide which then underwent dehydration to afford the C-2 nitrile. 
Thereafter, chemoselective reduction of the nitro group afforded the 6-amino-2-cyanobenzothiazole 
molecule 3.7, to which D-cysteine was added to generate D-aminoluciferin.16 Interestingly, at the time, 
there were no reports on the use of the Appel’s salt methodology in the context of an aminoluciferin 
synthesis. However, its use in the synthesis of D-nitroluciferin 3.14 was later demonstrated by 
Prescher et al, as shown in scheme 3.6 a. Prescher et al, who first used the Appel methodology to 
prepare D-luciferin later reported on the synthesis of a nitroluciferin 3.14 for imaging cell-cell contacts. 
The nitrobenzothiazole 3.13 was formed from the cyclisation of cyanoformanilide 3.12, which in turn 
was formed, in one-pot, from p-nitroaniline 3.11.13 Prescher et al also reportedly replaced the 
fragmenting base DBU, with the less nucleophilic sodium thiosulfate which resulted in an increased 
overall yield of 50 % for both D-luciferin and eventually D-aminoluciferin.17 
 
Scheme 3.6. Reagents and conditions: i) Appel’s salt/ (1:2) THF:CH3CN, ii) Na2S2O3 (3 eq) / H2O / rt / 3 h (80 %), 
iii) PdCl2 / CuI / TBAB / (1:1) )DMF:DMSO / 130 oC / 3 h (74 %),  iv) D-Cys / K2CO3 / CH3CN:H2O (2:1) / rt / 
2 h (100 %), v) NH2NH2.H2O / EtOH / rt / 12 h, vi) Appel’s salt / DCM / reflux / 12 h (62 %)  
A follow up publication then reported on a new scalable one-pot method which made use of the 
condensation of 1,2-aminothiophenol 3.15 (generated in situ from the iminolysis of 3.9) and Appel’s 
salt to form the 2-cyano-6-nitrobenzothiazole 3.13 directly, as shown in scheme 3.6 b.17  
It is worth noting that the metal-free scalable method developed by McCutcheon and Prescher et al 
for D-aminoluciferin (Scheme 3.6 b) was markedly different from the scalable procedure developed 
for D-luciferin (described in Chapter 2, shown in scheme 3.7).  
3.8 3.9 3.10 3.7 
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This was because the methodology that was used for D-luciferin synthesis mechanistically involved a 
thermolytic electrocyclisation reaction, which only produces the 2-cyanobenzothiazole when the C6-
substituent is electron donating in character.18-20 The same reaction could thus not be used to prepare 
2-cyano-6-nitrobenzothiazole 3.13.  
 
Scheme 3.7. Reagents and conditions: i) Appel’s salt / Sulfolane / 40 oC / 3 h, ii) 180 oC / 20 min, iii) PyHCl 
(10 eq) / 180 oC / 1 h, (3.16: 21 %, 3.17: 51 %) 
The toxicity of the cyanide routes and the limitations associated with Appel’s salt methodologies 
meant that there was indeed scope for an improved D-aminoluciferin synthesis and, perhaps, for the 
development of a more general, scalable route that would allow equally efficient access to both 
D-luciferin and D-aminoluciferin.    
With this in mind, it was decided to first evaluate the previously used D-luciferin synthetic route 
(described in Chapter 2) to also prepare D-aminoluciferin, since the same method was already 
reported in the preparation of D-nitroluciferin by Prescher et al.  
Aims and Objectives 
The aim was to synthesise D-aminoluciferin and, thereafter, to evaluate the bioluminescence of the 
synthesised material, whilst also investigating whether any improvements could be made to the 
reported synthetic procedure. 
The specific objectives were thus:  
i) The synthesis and characterisation of D-aminoluciferin using standard analytical and 
spectroscopic techniques, including; NMR, MS, IR and melting point analyses.  
ii) The bioluminescent evaluation of prepared D-aminoluciferin using purified luciferase 
enzyme assays. 
iii) The identification of key limiting steps in the synthetic sequence where an improvement 
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Synthesis and Bioluminescent Evaluation of D-Aminoluciferin  
Synthesis of D-aminoluciferin 
 
Scheme 3.8. Reagents and conditions: i) S2Cl2 / DCM / rt / 24 h, ii) Appel’s salt / DCM / Py / rt / 4 h, iii) DBU / 
DCM / 5 oC / 30 min, iv) PdCl2 / CuI / TBAB / DMF:DMSO (1:1) / 120 oC / 4 h, v) Zn / NH4Cl / MeOH / rt / 20 min, 
vi) D-Cys / K2CO3 / MeOH:H2O / 20 min 
D-Aminoluciferin was initially prepared similarly to D-luciferin whereby p-nitroaniline 3.11 was 
reacted with Appel’s salt 3.19 to afford a dithiazolimine 3.20, which further underwent base mediated 
fragmentation to yield the cyanoformanilide 3.12. The key difference in the synthesis of 
D-aminoluciferin and the nitroluciferin synthesis by Prescher et al was the use of DBU to fragment the 
dithiazolimine instead of sodium thiosulfate, all other reactions were performed as previously 
described. Intra-molecular cyclisation and subsequent chemoselective reduction afforded the 6-
amino-2-cyanobenzothiazole core 3.7 and, as before, D-Cys addition to the cyanobenzothiazole 
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Of note in the synthesis of D-aminoluciferin, was that the formation of the nitrodithiazolimine 3.20 
was much slower when compared to the methoxydithiazolimine formed from p-anisidine. The 
fragmentation reaction also differed significantly from what was observed in the D-luciferin synthesis, 
as the major product formed from this reaction was not the desired product 3.12, but possibly an 
intermediate DBU adduct (characterised by MS and 1H-NMR spectroscopy). The DBU adduct made 
isolation of the fragmented product challenging and prompted an investigation into alternative bases 
for fragmentation (detailed in chapter 5). Key signals were inspected for in the analysis of the NMR 
spectra of 3.20 and 3.12. The carbon resonances in the 13C-NMR spectrum of 3.20, observed at 145 
and 157 ppm, were diagnostic of successful dithiazolimine formation. In the subsequent 
fragmentation of the imine 3.20 to the cyanoformamide 3.12 (figure 3.9), a significant shift for C-6 
was observed in the product relative to the starting material (from 157 ppm to 114 ppm). This 
corresponded to the conversion of the sp2 imine carbon to the more shielded sp3 nitrile.  
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The palladium chloride/copper iodide intramolecular C-S cross-coupling reaction that afforded the 
nitrocyanobenzothiazole worked, as expected, with the nitrocyanoformamide substrate. However, 
the product was only formed upon increasing the amounts of palladium(II) and copper(I) added (from 
the reported 10 and 50 % to 20 and 100 %, respectively). The 1H-NMR spectrum of 3.13 (Figure 3.10) 
showed the expected three proton resonances and the 13C-NMR spectrum displayed the expected 
eight carbon signals, with a conspicuous signal at 112.5 ppm (C-8) due to the conserved nitrile moiety. 
 
 
Figure 3.10. 1H- and 13C-NMR spectra of 2-cyano-6-nitrobenzothiazole 3.13 in CDCl3 and DMSO, respectively 
Supplementary support for the formation of 3.12 was found in its mass spectrum which displayed a 
base peak that corresponded to the molecular weight of 3.13 (m/z 204.9715, corresponding to M+). 
The nitro group then had to be chemo-selectively reduced to the amine. To this end, two methods 
were used, the first of which made use of a solution of SnCl2 in HCl and EtOH. This reaction afforded 
the desired product, but in very low yield, presumably due to the hydrolysis of the nitrile functionality. 
The second method proved to be milder and more efficient, resulting in the isolation of the amine in 
high yield (>95 %). The second method involved stirring the nitrobenzothiazole in a mixture of Zn 
powder and NH4Cl in MeOH. The reaction also proved to be much faster, with complete consumption 
of the starting material within twenty minutes, as evidenced by TLC analysis.  Interestingly, the 1H-
NMR spectrum of the reduced product 3.7 (figure 3.11) displayed a second set of mirroring aromatic 
resonances (H-1’, H-2’, and H-3’), despite TLC analysis having suggested the isolation of one 
C-3 C-2 










 Chapter 3: Synthesis and Bioluminescent Evaluation of D-Aminoluciferin 
71 
 
supposedly pure product. These extra signals did not correspond to starting material, nor were they 
expected to since TLC analysis of the reaction had revealed total consumption of the starting material. 
 
Figure 3.11. 1H-NMR spectrum of 6-amino-2-cyanobenzothiazole 3.7 in DMSO 
The mass spectrum of the compound displayed a mass ion peak corresponding to the molecular 
weight of 6-amino-2-cyanobenzothiazole 3.7 (m/z 176.0115, corresponding to [M+H]) and LCMS 
studies also supported that the reaction had indeed gone to completion, since a single elution band 
(not corresponding to starting material) was observed. It was proposed that the doubling signals were 
perhaps due to the formation of an ammonium salt or as a result of incomplete reduction to the 
hydroxylamine. This was further reinforced when the elemental analysis was carried out, where 
differences in the calculated and experimental percentages were observed. The elemental analysis of 
3.7 was not in agreement with what was expected, and therefore indicated that compound 3.7 was 
not analytically pure. Despite the obvious doubling of signals observed in the 1H-NMR spectrum of the 
2-cyano-6-aminobenzothiazole, the material was used as is (although repeated washes with various 
bases were carried out in attempt to further purify 3.7) and reacted with one equivalent of both D-Cys 
and potassium carbonate to afford the D-aminoluciferin potassium salt. The 1H-NMR spectrum for the 
D-aminoluciferin potassium salt is shown in figure 3.12 and displays all the signals previously reported 
by White et al and, gratifyingly, did not display any doubling of aromatic resonances observed 















Figure 3.12. 1H-NMR spectra of D-aminoluciferin potassium salt and D-cysteine in D2O 
Unfortunately, unreacted D-Cys was also observed in the NMR spectrum and was reasoned to be the 
result of having formed the D-aminoluciferin D-Cys ammonium carboxylate salt. This was corrected 
by resuspending the material in NaHCO3 and extracting with EtOAc to afford pure D-aminoluciferin 
whose 1H-NMR spectrum is shown in figure 3.13.  
 
Figure 3.13. 1H-NMR spectrum of D-aminoluciferin 3.1 in DMSO 















Figure 3.14. HRMS trace of D-aminoluciferin 
Further support for the successful synthesis of D-aminoluciferin was provided by the 13C-NMR which 
displayed the expected 11 signals and the mass spectrum which displayed a mass ion at m/z 317.9768 
corresponding to [M+K] (calculated 317.9768). D-aminoluciferin was produced in an overall yield of 
20 % using the modified Prescher et al sequence utilised in the prior D-luciferin synthesis.   
Prescher et al Improved Syntheses; scalable but not general 
As previously stated, the low overall yield was largely as a result of the low yielding C-S coupling 
reaction. McCutcheon and Prescher et al have since developed an improved scalable one-pot method 
that does not make use of a Pd-catalysed C-S coupling reaction (discussed in Chapter 2).17 However, 
the reaction reportedly does not allow for the cyclisation of anilides containing electron withdrawing 
substituents and therefore could not be made use of as an alternative synthetic strategy for 
D-aminoluciferin synthesis.  
These findings suggest that the development of a more general route that negates the use of 
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Bioluminescent Evaluation of D-aminoluciferin  
The synthesised D-aminoluciferin was evaluated for bioluminescence using purified luciferase in the 
same manner that D-luciferin was evaluated in the preceding Chapter. 
The synthesised D-aminoluciferin was reacted with luciferase and the resultant luminescence 
measured. The results from the assay are highlighted in figure 3.15. 
 
 
Figure 3.15. Bioluminescence emission of D-luciferin and D-aminoluciferin. The RLU were determined 1 min 
post-enzyme addition and were recorded in triplicate and are represented as the mean ± SEM 
Control 1 contained only 90 μL of 10 nm luciferase in its enzyme buffer and control 2 contained 90 μL 
of 0.1 µM D-aminoluciferin in substrate buffer. In both instances the resultant luminescence recorded 
was negligible. However, a strong luminescent response was observed upon injecting 30 μL of 10 nm 
luciferase in luciferase enzyme buffer to 60 μL of 0.1 µM D-luciferin and 0.1 µM D-aminoluciferin. As 
expected the light emission intensity observed for the natural D-luciferin was found to be 5-fold higher 
relative to that of D-aminoluciferin and, as previously discussed, is not due to lower binding affinity, 
but rather as a result of the reaction’s lower light emitting efficiency.  
Since D-aminoluciferin had a reportedly longer wavelength of emission, it was also necessary to record 
its observed λmax to ensure that it corresponds to the λmax previously reported. This was done using a 
fluorimeter which records the emission wavelength of light emitted in the D-aminoluciferin/ luciferase 
reaction. Normally fluorimeters are used to measure fluorescence emission in response to excitation. 
However, in the case of bioluminescence emission spectra, the excitation slits required to irradiate a 
particular sample are sealed off, and the resultant luminescence is recorded in the absence of an 


















































) Control 1 – Luciferase only 
Control 2 – Aminoluciferin only  
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To record the emission spectrum, purified luciferase in enzyme buffer was rapidly injected into a 
cuvette containing D-aminoluciferin in substrate buffer to a final enzyme concentration of 100 nM and 
a final substrate concentration of 10 μM. The peak emission (measured from 200 to 800 nm) was 
recorded and the resultant bioluminescence emission spectrum of D-aminoluciferin, along with D-
luciferin for reference is shown in figure 3.16. Peak bioluminescence emission for D-aminoluciferin 
was observed at 595 nm while peak emission for D-luciferin at 550 nm. The observed λmax for both 
D-aminoluciferin and D-luciferin were found to be in good agreement with those previously reported 
and further confirms the successful preparation of the amino analogue. 

































Figure 3.16. Bioluminescence emission spectrum of D-luciferin and D-aminoluciferin in pH 7.4 Tris buffer 
Summary: D-luciferin and D-aminoluciferin, what next? 
The synthesis of D-aminoluciferin was achieved in six steps with a 20 % overall yield. Again, the metal 
mediated cyclisation to form the benzothiazole was limiting and an alternative methodology for 
forming the benzothiazole from the thioanilide would be advantageous. In terms of its luminescent 
properties, the synthesised D-aminoluciferin was found to be luminescent active when treated with 
luciferase and hence, pure D-aminoluciferin had been successfully prepared and was now primed for 
use as a luminescent standard.  
With both the 6’-hydroxy and 6’-amino luciferins in hand, focus was shifted to two main goals; the 
first being the potential preparation of a 6’-thio analogue of D-luciferin, of which there was surprisingly 
not a reported synthesis or bioluminescent data. The premise for this undertaking concerned the 
previously noted knowledge gap in directly linking luminescence and sulfur-related redox chemistry. 
Of course, there were other reasons for attempting to synthesise 6’-thio derivatives of D-luciferin, all 
of which are described in the relevant Chapters. 
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The second goal concerned the consistently low yielding C-S oxidative coupling employed in the 
D-luciferin and D-aminoluciferin syntheses. Prescher et al had already demonstrated that the overall 
D-luciferin synthesis could be improved using their latest scalable one-pot methodology, which 
avoided the use of the palladium mediated intramolecular C-S coupling oxidative coupling reaction. 
However, that methodology was exclusive to the D-luciferin synthesis and could not be used to 
construct D-aminoluciferin.  
After some deliberation, it was predicted that both the low yielding intramolecular C-S oxidative 
coupling and the Prescher et al scalable one-pot method could be improved, so that the low yielding 
C-S coupling would be higher yielding and that the Prescher et al scalable method could be applied to 
D-aminoluciferin synthesis. Moreover, it was predicted that both these improvements would be 
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Improved Syntheses of 2-Cyanobenzothiazoles 
Abstract 
Bioluminescence imaging with luciferase–luciferin pairs are popular methods of visualising biological 
processes in vivo. Unfortunately, most luciferins are difficult to access and remain prohibitively 
expensive for some imaging applications. The most cited methods of luciferin preparation were found 
to be generally low yielding and made use of relatively toxic reagents. This chapter concerns the 
development of scalable and efficient syntheses of C6-substituted 2-cyanobenzothiazoles, precursors 
to bioluminescent substrates. The proposed methodologies employ easily prepared and inexpensive 
ortho-brominated anilines as starting materials. These anilines are subsequently converted to 
thioanilides and thereafter cyclised using base-mediated intra-molecular cyclisation reactions to 
generate the desired 2-cyanobenzothiazoles. Additionally, it is demonstrated that the syntheses of 6-
substituted 2-cyanobenzothiazoles can be achieved in one-pot by the stepwise addition of reagents 
and in the absence of palladium and copper catalysts. It is further demonstrated that these reactions, 
unlike their metal-based equivalents, are more scalable, have better functional group tolerability and 


















Improved Syntheses of 2-Cyanobenzothiazoles 
Introduction 
One of the factors limiting the use of D-luciferin based imaging is associated with the cost of 
commercial D-luciferin. This has been attributed to the difficulty in synthesising the 2-
cyanobenzothiazole ring, which forms the D-luciferin core. Thus, an efficient, economical and 
convenient method for the construction of highly functionalised 2-cyanobenzothiazoles is of interest. 
Previously, the synthesis of D-luciferin involved a metal mediated C-S cross-coupling reaction to 
generate the benzothiazole motif. It was previously noted that the palladium, copper co-catalysed 
cross-coupling reaction was limiting and consistently afforded the benzothiazole in low yield. 
Furthermore, the metal mediated methodology did not allow for the preparation of C6-halogenated 
2-cyanobenzothiazoles and hence motivated an investigation into alternative cyclisation strategies.  
Limitations and Shortcomings of Existing Methodologies and Sequences  
The syntheses of benzothiazoles in the context of D-luciferin preparation has been limited to two 
general strategies highlighted in scheme 4.1. The original sequence used by White et al in the first 
synthesis of D-luciferin involved forming a C2-carboxybenzothiazole derivative from the oxidative 
cyclisation of a thioanilide. The oxidative cyclisation was metal mediated and generally produced the 
C2-carboxybenzothiazole in low yield and, in addition, the C6-carboxybenzothiazole had to be further 
chemically transformed to afford the desired 2-cyanobenzothiazole.1 A few different routes have been 
reported since but almost all of them make use of the same general strategy to generate a 2-
carboxybenzothiazole derivative that requires further modification to afford the 2-cyano 
functionality.2 Prescher et al improved on the original sequence by employing a methodology 
developed by Rolf Appel and refined by Reese et al.3 
 
Scheme 4.1. Previous syntheses of the 6-substituted 2-cyanobenzothiazole core 
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This method involved fragmenting N-aryldithiazolimines to afford cyanoformanilides which directly 
produced 2-cyanobenzothiazoles when cyclised. The cyclisation step however, is equally low yielding 
and makes use of palladium(II) and copper(I) catalysts. McCutcheon and Prescher et al then further 
refined that sequence and recently reported a condensed and improved methodology which 
completely negated the use of metal catalysts for the cyclisation, instead employing a thermolytic 
cleavage cyclisation reaction.4 In this way, they were able to report the successful synthesis of a 2-
cyanobenzothiazole from an aniline in two steps, with a 50 % overall yield of D-luciferin (one of the 
highest recorded to date). Similarly, the aim of this study was to move away from the low yielding C-S 
oxidative couplings and develop an improved and unique cyclisation strategy.  
Metal-mediated C-S bond formation  
Having confirmed from previous syntheses that the intramolecular C-S bond forming reaction was 
indeed limiting, potential improvements and alternative reactions were then investigated. The first 
option considered was to increase the reactivity of the carbon involved in the coupling reaction by 
substituting it with a bromine, since palladium insertion occurs more readily between the C-Br bond 
relative to the C-H equivalent, hence improving the overall reaction. This was already demonstrated 
in a report on the synthesis of 2-substituted-benzothiazoles by palladium-catalysed intramolecular 
cyclisation of o-bromo-phenylthioureas, where yields from various substituted anilides ranged 
between 68-100 % using a Pd2(dba)3/monophosphine catalytic system .5 This o-brominated reaction 
was reported to be an improvement on the unsubstituted  system, where palladium activation occurs 
on a less reactive C-H and yields ranged from 3-78 % while also strictly requiring a copper co-catalyst 
(Figure 4.1).6 The bromine allowed for a relatively milder cyclisation, occurring at 80 oC compared to 
the 120-150 oC in the unsubstituted case and reportedly allowed for copper(I) mediated cyclisation 
under reflux in DME, in the absence of palladium.7  
 
Figure 4.1. Palladium mediated intramolecular C-S cross-coupling reactions. 
What was also exciting was that the o-bromo intramolecular cyclisation was not previously used to 
construct 2-cyanobenzothiazoles and thus further prompted the investigation. However, the 
improved brominated method was still by nature an oxidative coupling and, therefore, meant that it 
probably was not scalable and that it still maintained a relatively prohibitive cost associated with the 
palladium catalysts and/or palladium/copper ligands. Accordingly, it was decided that other potential 
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modes of cyclisation would also be investigated, like the thermolytic electrocyclic cyclisation 
developed by Charles W. Reese and employed by McCutcheon et al in their scalable luciferin synthesis. 
Thermolytic cyclisation of N-aryliminodithiazoles for 2-cyanobenzothiazole synthesis    
When Prescher et al first synthesised D-luciferin starting from an N-aryliminodithiazole formed from 
Appel’s salt they opted to not use the reaction in its original form, instead employing a stepwise 
approach where the N-aryliminodithiazole was fragmented first, and then cyclised using an oxidative 
coupling reaction. The original transformation is shown in scheme 4.2 which involved heating the N-
aryliminodithiazole (neat or in solvent) to afford the corresponding 2-cyanobenzothiazole and 
cyanoimdoyl chloride.8-10 
 
Scheme 4.2. a) The use of a cyanoformanilide in an oxidative cross-coupling reaction employed by Prescher et al 
to prepare 2-cyanobenzothiazoles, b) the proposed mechanism for the thermolytic electrocyclic fragmentation 
cyclisation reactions of N-aryliminodithiazoles that directly produce 2-cyanobenzothiazoles and c) the use of 
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The Reese reaction was reported as an electrocyclic fragmentation cyclisation that produced 
predominantly the imidoyl chloride but could be pushed to form more of the 2-cyanobenzothiazole 
by having more electron donating groups on the ring. McCutcheon, Prescher and co-workers later 
reverted to the original reaction and found that they could produce the 2-cyanobenzothiazole in good 
yield (80 %), presumably without forming any of the imidoyl chloride, by heating the N-
aryliminodithiazole in sulfolane (Scheme 4.2). This suggested that sulfolane played an important role 
in the selectivity of the reaction since Reese et al originally reported a lower yield (60 %) for the same 
reaction in toluene.9 Of course, despite the relatively good yields, the methodology still has many 
limitations, arguably the biggest drawback is its lack of generality. For example, D-aminoluciferin 
cannot be efficiently accessed from this reaction since its precursor, 4-nitro-N-aryliminodithiazole, 
produces predominantly the imidoyl chloride as opposed to the 2-cyanobenzothiazole (60 and 9 %, 
respectively) from the thermolysis.10 With this in mind, it was theorised that ortho-bromination of the 
starting aniline might promote benzothiazole formation and would therefore allow for the reaction to 
be applied to more electron deficient systems. In fact, this had already been demonstrated to be true 
in a study where o-bromo-N-aryliminodithiazoles with electron withdrawing groups on the ring were 
heated to exclusively afford the corresponding benzothiazole (Scheme 4.3).10 
 
Scheme 4.3. Proposed Cu assisted electrocyclisation and fragmentation process 
It was therefore decided to further investigate whether this particular reaction could be used in the 
context of a luciferin synthesis and to confirm if indeed o-bromination would improve the overall 
reaction sequence. In addition to improving the thermolysis (Scheme 4.3) and oxidative coupling 
reactions (Scheme 4.1), it was also of interest to explore whether or not it was possible to completely 
shift the mechanistic mode of cyclisation, away from oxidative coupling and electrocyclic reactions, 
through ortho-bromo introduction.  
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O-Bromination reportedly shifts mechanism of cyclisation 
From previous work done in the Jardine research group and others,11 it was known that benzothiazoles 
could also be accessed from the mild base-mediated cyclisation of ortho-bromothioanilides. Unlike 
the oxidative coupling and electrocyclisation process, these reactions were reported to proceed via 
an SN2Ar type mechanism (Scheme 4.4).12-13 
 
Scheme 4.4. Benzothiazole forming reactions of thioanilides 
What this meant practically was that o-bromothioanilides that react under C-S coupling or 
electrocyclisation conditions to afford a benzothiazole could also simply be reacted with a relatively 
mild base such as NaOMe to afford the same product via a different mode of cyclisation.12, 14-15 This is 
important because the mechanism dictates functional group tolerability and hence determines which 
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Aims and Objectives  
The aim was to improve on known methods of luciferin syntheses by employing reactions previously 
not used in the context of luciferin synthesis and evaluating them against the known reactions. More 
specifically, it was to probe the effects of o-bromo functionalisation of thioanilides on their reactivity 
in the electrocyclisation reaction as well as to evaluate the base-mediated cyclisation as an alternative 
cyclisation mode.  
The objectives were thus; 
i) The evaluation of the effects o-bromination of thioanilides on previously used, low 
yielding intra-molecular C-S cross-coupling reactions. 
ii) The evaluation of the effects of o-bromination on the thermolytic electrocyclisation 
reaction. 
iii) An investigation into whether ortho-brominated cyanothioformanilides could be cyclised 
using a mild base, such as NaOMe, and if cyclisation was indeed possible, an investigation 
into the use of a single base to both fragment and cyclise N-aryliminodithiazoles, thus 
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Controlled Monobromination of Activated Arenes 
Selective monobromination of p-anisidine was necessary for the proposed investigation. However, 
Selective monobromination of activated arenes via electrophilic aromatic substitution (SEAr) is a 
known synthetic challenge due to the increased reactivity of such aromatic compounds. Several 
common brominating reagents generally afford an inseparable mixture of the mono- and di-
brominated products, as well as starting material.16-17  
Monobromination through conventional SEAr becomes increasingly difficult in cases where the 
aromatic substrates are highly activated and thus more nucleophilic. There are many reports of the 
bromination of such activated compounds resulting in di- or tri-brominated products, although some 
control was reportedly observed when the brominations were carried out at low temperatures, 
typically between 0 and 5 oC.18-19 The investigation into an improved and unique luciferin synthesis 
met its first challenge here, since o-brominated p-substituted activated anilines were required to start 
the synthesis. Unexpectedly, there was not much in literature on the controlled monobromination of 
1,4-substituted activated anilines. In fact, the general procedure for brominating activated anilines 
seems to follow from the conversion of the amino group to its corresponding acetamide. The 
acetamide is less electron donating than the amine moiety due to delocalisation of electrons from the 
benzene ring into the acetyl group. Thereafter, monobromination is carried out on the isolated 
acetamide. Then in a separate step, the acetamide is hydrolysed to afford the mono-brominated 
aniline. Since the aim was to improve on the previous synthesis of D-luciferin, including 
acetylation/deacetylation steps would be counterproductive. To this end, an investigation into the use 
of sodium perborate and potassium bromide for monobrominating activated anilines was undertaken.  
Sodium perborate is a relatively mild, safe, and cheap oxidant, and its use in the monobromination of 
1,4-substituted deactivated anilines has been reported.16 It was therefore envisioned that perborate 
method could also be used to brominate p-anisidine, by the slow addition of the electrophilic bromine 
solution to the activated aniline at low temperature. 
 
Scheme 4.5. Reagents and conditions: i) ) NaBO3.H2O / KBr / CH3COOH / rt / 24 h 
 As reference, p-anisidine, potassium bromide and sodium perborate were suspended in acetic acid 
and allowed to stir at room temperature for 11 h, in accordance with the original method. TLC analysis 
of the reaction revealed incomplete conversion of starting material after 11 h.16 TLC analysis also 
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indicated the formation of multiple products, most likely due to the lack of selectivity. The same 
reaction was then repeated at 0-5 oC. TLC analysis here indicated the formation of two major products 
(similar in Rf), originally believed to be the mono, and di-brominated products, which proved difficult 
to separate by silica chromatography. The 1H-NMR spectrum of the crude mixture was complex but 
showed two dominant aromatic splitting patterns, as shown in figure 4.2.  
 
Figure 4.2. 1H-NMR spectra of a) the crude mixture from the bromination reaction, b) the isolated mono-
brominated product, and c) an unknown 1,4-substitued product, all in CDCl3 
The expected 1,2,4-splitting pattern was observed, in which the three signals seemingly integrated for 
one proton each. In addition to this, a second set of doublets (J = 9.0 Hz) was observed, which possibly 
corresponded to a separate 1,4-substituted ring. This proved to be a good initial result because the 
1,2,4-splitting pattern was indeed expected for a mono-brominated product. However, the 
accompanying dd resonance was not expected, in fact what was expected was a single aromatic 
resonance corresponding to the di-brominated product. It was possible that the dd signal was due to 
unreacted starting material, but TLC studies had already suggested otherwise. Furthermore, the 
observed proton resonances were significantly more deshielded than the starting material. This 
suggested that some chemistry had possibly occurred at the amine moiety, resulting in a shift in the 
aromatic resonances. In an effort to isolate the unknown product, the reaction was repeated without 
the addition of KBr, and it was found that the starting material had converted into a slightly more non-
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dd signals previously observed. A possible explanation for this was that the amino group was being 
oxidised by the sodium perborate, to an azo or azoxy complex, previously reported to form under 
similar conditions.16, 20-23 This particular reaction had been reported previously, wherein the amine of 
p-anisidine was oxidised to a nitro group, in the presence of sodium perborate at 55 oC. In this case 
however, it was not the nitro analogue that was being isolated, but instead, the azoxy intermediate, 
which forms at room temperature. This was supported by melting point analysis, where it was 
demonstrated that the presumed azoxy material had a melting point of 160 oC, which was comparable 
to the literature melting point recorded at 155-158 oC. In addition, the determined melting point was 
also much lower than that of the starting material p-anisidine, which had a melting point of 274-
278 oC. Further support for the formation of the azoxy complex was found in IR and NMR analysis, 
where data for the synthesized material was found to be comparable to that previously reported. 
 
Scheme 4.6. Perborate mediated oxidation of anilines to azo and azoxy complexes 
While perborate mediated oxidation of the amine moiety was of course very interesting, there was in 
fact no use for the resultant azoxy complex, and hence its formation during the bromination reaction 
was undesired. For this reason, sodium perborate and potassium bromide were stirred in acetic acid 
to generate the required electrophilic bromine perborate complex. That solution was then added 
dropwise to a stirring suspension of aniline in acetic acid, maintained below 5 oC. The reaction progress 
was monitored by TLC. This method resulted in mono-bromination almost exclusively. Furthermore, 
the generality of this procedure was demonstrated in the attempted mono-bromination of various 
other anilines that were to be used in the synthesis of D-luciferin 6’-analogues. Table 4.1 shows the 
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Table 4.1. Controlled monobromination of activated arenes 
 
 X Y Major Product Yield, % m.p. °C 
(lit m.p.) 












4 NH2 SH Disulfide* 
 
77 138-140 
5 CH3 SH Disulfide* 
 
64 48-50 
* Thiol oxidation takes priority to give the disulfide, followed by mono-bromination. Brominated products were 
characterised by 1H-NMR spectroscopy, melting points and LRMS and the products from the bromination 
reactions were used in the synthesis of C6-substituted 2-cyanobenzothiazoles. Based on average isolated yields  
The results concluded that monobromination of activated anilines were possible with sodium 
perborate/potassium bromide and that conversion of activated anilines to their corresponding 
anilides prior to bromination was, in fact, not always necessary. In addition, amino and thiol 
functionalities could also be oxidised under the same conditions required for bromination, which may 
be useful since it allows for multiple functional group transformations to be achieved in one synthetic 
step. The mono-bromination of activated anilines demonstrates the subtleties associated with the 
order in which reagents are added and the synthetic chemist’s practical control over functional group 
transformations. Much like the reactions of epoxides, where the order of addition of acid and 
nucleophile dictates the distribution of products (regio- and stereoisomers). So too, does the order of 
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addition of NaBO3 and KBr allow control over the distribution of N/S-oxidation and bromination 
products. In theory, this reaction could allow for the selective production of o-brominated nitro 
systems from 1,4-substituted anilines. Where the amino functionality is used to direct bromination 
and, upon heating, is oxidised to produce the corresponding o-bromo-nitrobenzene, perfect for SNAr. 
Alternatively, oxidation could precede bromination, in which case m-bromo-nitrobenzene could be 
generated. The versatility of this reactions was kept in mind in subsequent syntheses. The products 
from the bromination reactions were then used to evaluate various methods of cyanobenzothiazole 
preparation, all of which were aimed at developing improved syntheses of luciferins. 
C-S Oxidative coupling of o-brominated thioanilides  
 
Scheme 4.7. Reagents and conditions: i) Appel’s salt / DCM / Py / rt / 4 h, ii) DBU / DCM / 5 oC / 1 h, iii) PdCl2 / 
CuI / TBAB / DMSO:co-solvent (1:1) / 120 oC / 4 h 
With the o-bromoanilines in hand, it was decided to first evaluate the effects of the bromine on the 
previously described low yielding oxidative coupling. The precursors for the C-S coupling were 
prepared using methods detailed earlier, involving the condensation of o-bromoanilines to N-
aryliminodithiazoles which were subsequently fragmented to afford the corresponding 
cyanoformanilide.3 The cyclisation was attempted using three different anilines and the result are 
summarised in table 4.2. 
Table 4.2. Yields from intramolecular C-S cross coupling reaction  




Yield from unsubstituted 
thioanilide 
OMe 23 25 25 
I 21 21 3 
NO2 13 20 8 
*Based on average isolated yields: a) co-solvent = DMF and b) co-solvent = NMP 
Contrary to what was expected, o-bromination had very little effect on the yield, with generally low 
yields observed across all analogues. This suggests that it was perhaps the combination of reagents 
used in the reaction that were not optimised and that alternate catalysts, choice of base and even 
catalyst loading should have been explored. One of the more interesting discoveries from these 
reactions was that a small amount (<5 %) of 2-cyanobenzothiazole product was being formed in the 
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DBU mediated fragmentation step, observed by TLC analysis and 1H-NMR spectroscopy. This was later 
demonstrated to be as a result of nucleophilic substitution of the resultant thiolate with bromine. It 
was also demonstrated that the 2-cyanobenzothiazole product was not formed in any isolatable 
quantity when the starting o-bromothioanilide was heated in the absence of the coupling reagents. 
This suggested that only N-aryliminodithiazoles could cyclise in this manner. 
Electrocyclisation of o-brominated N-aryliminodithiazoles 
 
Scheme 4.8. Reagents and conditions: CuI / Py / 160 oC / 1 h 
The same precursors were subsequently used in a thermolytic electrocyclisation reaction, where the 
o-bromo-N-aryliminodithiazoles were heated both neat and in solvent to afford the corresponding 2-
cyanobenzothiazoles. The electrocyclic reaction was expected to be superior to the preceding C-S 
oxidative coupling in terms of scalability and cost, since intra-molecular cyclisation could be achieved 
by simply heating the N-aryliminodithiazole neat. The resultant yields from these reactions are 
summarised in table 4.3. 
Table 4.3. Yields from electrocyclisation fragmentation reaction of o-bromo-N-aryliminodithiazoles 
 o-bromo-N-arylimine  N-arylimine 
R 120 oC neat 120 oC, DMF 120 oC, Py 120 oC, CuI, 
Py 
160 oC, CuI, 
Py 
120 oC DMF 
OMe 58 59 60 63 84 60 
I 3 - 70 70 74 19 
F 75 80 52 85 80 30 
H 35 - 45 40 67 23 
NO2 41 58 32 65 68 9  
*Based on average isolated yields 
In all cases, it appeared that the o-brominated precursors were afforded in higher yields when 
compared to the unsubstituted N-arylimininodithiazoles. What was striking was the increase in yield 
observed for EWG’s such as the nitro and fluoro analogues, when comparing unsubstituted and o-
bromo-N-aryliminodithiazoles. In the McCutcheon/Prescher et al synthesis that involved thermolysis 
of the unsubstituted N-arylamine, D-aminoluciferin could not be efficiently accessed using this route. 
With o-bromination however, the same method can now be applied in aminoluciferin synthesis. 
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Furthermore, it was also apparent that the CuI and Py directly promoted the formation of the 
benzothiazole product, since yields were generally increased by their addition. There were cases 
however where CuI/Py addition had little/no effect on the observed yield. Overall, the 
electrocyclisation fragmentation of o-bromo-N-aryliminodithiazoles proved to be quite effective and 
generally applicable in luciferin synthesis.  
Metal-free base-mediated cyclisation  
The electrocyclisation reaction was clearly superior to the C-S coupling reactions under the conditions 
reported, but its use was limited to the cyclisation of N-aryliminodithiazoles formed exclusively from 
the condensation of anilines and Appel’s salt. Appel’s salt is of course a notoriously toxic reagent that 
is produced from sulfur monochloride and chloroacetonitrile.24 It was predicted that a base-mediated 
SN2Ar like cyclisation could be used to cyclise all thioanilides irrespective of ring constituents. The base 
mediated method involved reacting a thioanilide with NaOMe to generate the thiolate anion which 
undergoes an intra-molecular nucleophilic substitution to afford the corresponding benzothiazole.12 
The benzothiazoles were formed in good-excellent yields under the conditions shown in scheme 4.9. 
 
Scheme 4.9. Reagents and conditions: i) NaOMe / NMP / 150 oC / 2 h 
Interestingly, the same reaction in the absence of base did not produce any of the corresponding 
benzothiazoles which suggests that thiolate formation is indeed key and that weaker bases will have 
no effect on promoting product formation.  
One pot, Metal-free base-mediated cyclisation from N-aryliminodithiazoles 
In the previous fragmentation of o-bromo-N-aryliminodithiazoles, the consistent formation of a small 
amount (<1-5 %) of unsubstituted 2-cyanobenzothiazole was noted along with the expected 
fragmentation product. It was predicted that the benzothiazole was being formed from the DBU 
generated thiolate nucleophilic substitution of the bromine. As a result of this, a one-pot base 
mediated fragmentation cyclisation reaction was developed. Using previously prepared o-mono-
brominated anilines, subsequent imine formation, fragmentation, and cyclisation was attempted in 
one-pot. The initial reaction involved stirring the o-brominated-p-anisidine in DCM at room 
temperature and to that suspension was added a slight excess of Appel’s salt. After conversion of the 
starting material to the imine, monitored by TLC, the reaction was cooled to 0 oC and DBU was added 
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dropwise over 30 minutes. The reaction was then allowed to warm to room temperature and stirred 
for an additional 3 hours. The crude reaction mixture was concentrated in vacuo and purified through 
a short pad of silica, eluting with hexanes to afford the benzothiazole product in good yield (60-67 %). 
The 1H-NMR spectrum of the product matched that of the previously synthesised benzothiazole 
scaffold formed from the low yielding C-S metal mediated cross-coupling reaction. The melting point 
of the product, which was in good agreement with the reported literature value (129-131 oC, lit. 129-
131 oC), further supported the success of the one-pot reaction.  
Improved alternate routes to luciferins   
Based on all the exploratory synthetic work concerning the development of an improved and unique 
luciferin synthesis; two relatively short, scalable and arguably cheaper sequences toward luciferin 
substrates were produced. 
1) Route A; DBU cyclisation using o-bromo-N-aryliminodithiazoles 
2) Route B; NaOMe cyclisation of o-bromoanilides  
The first route, shown in scheme 4.10, makes use of the previously described one-pot DBU mediated 
fragmentation cyclisation. The sequence starts with the monobromination of a p-substituted aniline 
which is subsequently converted into an N-aryliminodithiazole and thereafter its corresponding 
cyanobenzothiazole, by the slow addition of DBU. Lastly, the 2-cyanobenzothiazole is reacted with 
D-Cys to afford a luciferin. The condensed synthesis of the benzothiazole scaffold greatly improved 
the overall synthesis of D-luciferin by decreasing the number of individual synthetic steps, increasing 
the overall yield (from 9 to 49 %), and eliminating the need for metal catalysts. 
 
Scheme 4.10. Reagents and conditions: i) NaBO3 / KBr / AcOH / rt / 16 h,  (R = OMe, 71%; R= I, 89%; R = NO2, 
99%), ii) Appel’s salt / DCM / 1-2 h, (90-98%), iii) DBU / DCM / 5 oC, 3-4 h, (60-63%), iv a) PyHCl / DMF / 150 oC / 
1 h, (99%), iv b) Zn / NH4Cl / MeOH / rt / 20 min, (99%), v) D-Cys / K2CO3 / MeOH or CH3CN / rt / 20 min, (99%) 
Furthermore, this sequence, unlike the one-pot method demonstrated by McCutcheon et al, can be 
used to prepare D-aminoluciferin since the o-bromination allows for improved cyclisation in cases 
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where R=EWG (Scheme 4.10). One disadvantage, as mentioned in the preceding section, is the use of 
Appel’s salt and excessive amounts of DBU. In light of this, a sequence that still used a base-mediated 
cyclisation but not the Appel’s salt was investigated. Here, a sequence that resembles the natural 
product synthesis by White et al was employed, characterised by C2-modification post-benzothiazole 
formation. The sequence is shown in scheme 4.11 and involved forming 6-iodo-2-methylbenzothiazole 
from an o-bromoaniline. The C2-methyl was then converted to a C2-nitrile over two steps to afford 
the corresponding cyanobenzothiazole. The 6-iodo-benzothiazole could then be converted to various 
other functional groups and then to the corresponding luciferins. The 6-iodo functionality was 
targeted because the starting aniline (4-iodoaniline) was relatively cheap and readily available. 
It should be noted that the synthesis of the C6-iodo 2-cyanobenzothiazole was also attempted using 
the Prescher et al Appel’s salt method. The results from that attempt suggested that an alternative 
cyclisation method, which did not employ an intramolecular C-S coupling reaction, would be necessary 
to construct an iodinated 2-cyanobenzothiazole, since the coupling reaction also resulted in the loss 
of the iodo functional group. 
This iodo functionality was particularly appealing because the Prescher et al method made use of 
different anilines as starting materials, depending on which luciferin was being targeted. For example, 
if D-luciferin was being synthesised, p-anisidine would be used in the first step, whereas if the target 
was D-aminoluciferin, p-nitroaniline would be used instead. With the iodo functionality both luciferins, 
as well as others, could potentially be accessed from the 2-cyano-6-iodobenzothiazole formed from 
4-iodoaniline 4.1.  
 
Scheme 4.11. Reagents and conditions: i) NaBO3.H2O / KBr / CH3COOH / rt / 24 h, ii) Ac2O / Py / 100 oC / 2 h, iii) 
Lawesson’s reagent / toluene / 7 h / 100 oC, iv) NaOMe / NMP / 150 oC / 2 h, v) SeO2 / dioxane / 150 oC / 4 h, vi) 
NH3OHCl / NEt3 / Phthalic anhydride / rt / 2 h 
In this sequence, p-iodoaniline 4.1 was ortho-brominated using a solution of sodium perborate and 
KBr in acetic acid. The resultant 2-bromo-4-iodoaniline 4.2 was then acetylated in acetic anhydride 
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4.4, and sodium methoxide mediated cyclisation of 4.4 afforded the benzothiazole 4.5. Further 
modification at C2 generated the aldehyde 4.6 and then the nitrile 4.7. 
 
Figure 4.3. 1H-NMR spectrum of 4.2 in DMSO 
The products from the bromination and acetylation reactions were characterised by their melting 
points and by 1H-NMR spectroscopy, further characterisation was not necessary since these were 
commonly prepared compounds. The 1H-NMR spectrum of the brominated product 4.2 displayed the 
correct three aromatic protons, as well as a broad singlet arising from its amine protons. Both the 
spectrum and the broad melting point indicated that the product also contained trace impurities. 
These impurities were not dealt with immediately; instead, the impurities were carried over to the 
thionylation step, since column chromatography is generally used in this reaction to remove the 
thionylation product from the Lawesson’s reagent by-product. The 1H-NMR spectra of the acetamide 
4.3 and the thioacetamide 4.4 are shown in figure 4.4. It should be noted that there were still smaller 
signals in the 1H- and 13C-NMR of the acetamides (4.3, 4.4) that persisted even after repeated 
purification. These smaller resonances were most likely due to conformational isomers of the 



















Figure 4.4. 1H-NMR spectra of 4.3 and 4.4 in DMSO 
Of note in the 1H-NMR spectrum of 4.3 is the absence of the amine resonance, formerly observed in 
the precursor, and the presence of two signals at 2.59 and 11.45 ppm which are diagnostic for the 
acetamide functionality. In the 1H-spectrum of 4.4 the diagnostic acetamide proton resonances are 
conserved, but have shifted significantly when compared to the starting material (NHAc shifted from 





















Figure 4.5. 1H-NMR spectrum of 4.5 in DMSO 
The thioacetamide 4.4 was then reacted with sodium methoxide in NMP at 150 oC to afford the 
cyclised product 4.5 in good yield. Interestingly, the mechanism by which the reaction proceeds has 
not yet conclusively been established. What is certain is that the role of the sodium methoxide is to 
form the thioenolate from the thioacetamide. The thioenolate then displaces the bromine to form the 
cyclised product 4.5. What is ambiguous is the process of how the thioenolate goes about displacing 
the bromine. Normally, a reaction like this would be considered SNAr, since it proceeds via the 
thioenolate. However, the system lacked an EWG group ortho/para to the bromine capable of 
stabilizing the resultant negative charge in the Meisenheimer intermediate and, therefore, a typical 
SNAr mechanism seemed unlikely. Scheme 4.12 shows two possible mechanisms for the substitution. 
The first is the concerted SN2Ar mechanism and the second is the, rarer, stepwise SN1Ar. 
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With the C2-methylbenzothiazole in place, a selenium dioxide oxidation was employed to generate 
the desired aldehyde (Scheme 4.13). Selenium dioxide has been used extensively in the oxidation of 
allylic carbons,25-27 and its use in the oxidation of the C2-methyl of a 2-methylbenzothiazole was 
reported, thus making it an ideal choice for the preparation of the aldehyde. However, complete 
consumption of the starting material afforded predominantly the acid and, because of this, it was 
decided to terminate the reaction before the starting material could be fully consumed and the 
aldehyde converted to acid. The shortening of the prescribed reaction time resulted in the isolation 
of an inseparable mixture (by column chromatography) of the starting material 4.5 and the 
aldehyde 4.6.  
 
Scheme 4.13: Reagents and conditions: i) SeO2 / H2O / dioxane / 150 oC / 4 h (15% 4.6) 
 
 
Figure 4.6. 1H-NMR spectrum of 4.5 and 4.6 in DMSO 
The 1H-NMR spectrum clearly supported the formation of the aldehyde, however, it proved difficult 
to remove the residual starting material. Fortunately, the starting material 4.5 was predicted to be 
quite unreactive and proved to be so in the subsequent reaction, allowing a mixture of 4.5 and 4.6 to 
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condensation and dehydration was employed.28 The conversion involved reacting the aldehyde 4.6 
(containing residual 4.5) with hydroxylamine hydrochloride to form an oxime 4.9 which then reacted 
with phthalic anhydride to form an imidoyl or oxime ester 4.10 that underwent an elimination to form 
4.7, as demonstrated in scheme 4.14.   
 
Scheme 4.14. Proposed mechanism for nitrile formation 
The 1H-NMR of the pure starting materials and crude reaction mixture after two hours is shown in 
figure 4.7, which demonstrates the absence of the aldehyde proton in the crude reaction mixture, two 
hours post-phthalic anhydride addition. 
 
Figure 4.7. 1H-NMR spectra showing the conversion of 4.6 to 4.7 in DMSO 
The 2-cyano-6-iodobenzothiazole was purified using silica column chromatography in order remove 
the unreacted phthalic anhydride from the product. The 1H-NMR spectrum is shown in figure 4.9, 
where all the expected resonances were observed. In addition, the infrared spectrum of 5.7 displayed 
a weak band at 2250 cm-1 which supported the presence of the nitrile functionality (figure 4.8) and the 
13C-NMR displayed the expected eight resonances, further supporting its successful preparation. 


















Figure 4.8. IR spectra of the aldehyde 4.6 and the nitrile product 4.7 
 As a result of the low yielding oxidation step (15 %), the 2-cyano-6-iodobenzothiazole was 
unfortunately prepared in a low overall yield of 6-8 %. Attempts at improving the yield on the oxidation 
reaction were unsuccessful and generally resulted in increased production of the carboxylic acid. 
Despite the low overall yield, the iodo-functionality was still quite interesting since it could potentially 
be used to rapidly prepare 6’-analogues of D-luciferin.  
 
Figure 4.9. 1H-NMR spectrum of purified 4.7 in CDCl3 
The iodo functionality was expected to be a very good handle to introduce other functional groups 
through substitution reactions. This made the iodo-benzothiazole a particularly important compound 
since it could potentially be considered a common intermediate for D-luciferin, aminoluciferin, and 
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Bioluminescence of 6’-halogenated luciferins  
The 2-cyano-6-iodobenzothiazole was reacted with D-Cys to produce a 6’-iodo derivative of 
D-luciferin. The derivative’s bioluminescence was evaluated, alongside other 6’-analogues formed 
from the previously prepared C6-substituted 2-cyanobenzothiazoles, using purified Ppy luc according 
to the method described in the preceding chapters (Chapters 2-3). It was already known from previous 
work reported by White et al that derivatives of D-luciferin that had been fluorinated on the 
benzothiazole ring were found to be inactive in the bioluminescent reaction with luciferase. This was 
due to the halogen’s electron withdrawing effects and indeed, this was also demonstrated when the 
iodo-derivative was evaluated for bioluminescence. In addition to the 6’-iodo analogue, 6’-nitro, 
6’-methoxy and unsubstituted luciferins were also evaluated for the bioluminescent reaction, but 
none were found to emit significant bioluminescence when compared to D-luciferin under the same 
conditions (Figure 4.10).  
 
Figure 4.10. Bioluminescence emission of 0.1 µM D-luciferin and related 6’-analogues of D-luciferin, when 
treated with 10 nM luciferase. The RLU were determined 1 min post-enzyme addition and were recorded in 
triplicate and are represented as the mean ± SEM.  
These results suggested that only the electron donating free hydroxyl and amine could produce 
significant bioluminescence in the presence of O2, ATP and Mg2+ and luciferase. In addition, these 
results also eluded to the potential of a 6’-thiol analogue which, based on the observed 
bioluminescence for the different 6’-functionalities, was predicted to be bioluminescent. 
The common intermediate; could the C6-iodo 2-cyanobenzothiazole allow access to C6-OH, C6-NH2 
and the unreported C6-SH 2-cyanobenzothiazole 
In the preceding chapter, two project milestones were identified; one of which concerned developing 
a shorter and improved synthesis of C6-substituted 2-cyanobenzothiazoles through o-bromination. 
This chapter then demonstrated how o-bromination resulted in the condensed one-pot metal-free 
synthesis of the benzothiazole scaffold, which ultimately improved the overall synthesis of D-luciferin 



















































Control – 10 nM Luciferase in the 
absence of a luciferin  
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overall yield (from 9 to 49 % and 25 to 54 % for D-luciferin and D-aminoluciferin, respectively). In 
addition to the improved method, a potentially interesting C6-iodinated 2-cyanobenzothiazole was 
prepared, which was thought to be a good common intermediate for 6’-analogues of D-luciferin.   
At this point, it seemed that the synthetic development work had, in fact, laid the groundwork for the 
facile preparation of new D-luciferin 6’-analogues. At the time, all known bioluminescent 6’-derivitives 
of D-luciferin were based on 6’-amino analogues. Since the bioluminescence associated with both the 
hydroxyl and amino groups were relatively well reported, attention was turned to preparing the first 
6’-thio analogue of D-luciferin, whose luminescent properties and potential applications were still 
unexplored. 
First attempt at C6-iodo substitution 
It was proposed that the C6-iodobenzothiazole be reacted in the presence of various nucleophilic 
coupling partners to evaluate whether or not it could be successfully converted to a C6-hydroxy, amino 
or thiol derivative under standard C-S palladium mediated coupling conditions (Scheme 4.15).  
 
Scheme 4.15. Proposed conversion of 2-cyano-6-iodobenzothiazole to O, N, S-substituted benzothiazoles 
Interestingly, Miller et al reported that a palladium-mediated coupling reaction, although not reported 
for the 2-cyano-6-iodobenzothiazole, could be used to construct 6-amino derivatives from the bromo 
and fluoro-precursors.29 This was an encouraging result as it reinforced the usefulness of the 6-
halogenated 2-cyanobenzothiazoles. It should be noted however, that this publication was released 
only after the iodo-benzothiazole work highlighted here was completed. Miller et al went on to further 
demonstrate the generality of the C6-fluoro 2-cyanobenzothiazole by preparing the first published 
examples of C6-sulfur 2-cyanobenzothiazoles, via an SNAr reaction. Miller et al reported two sulfide 
analogues but did not report the free thiol, which further warranted its synthesis. 
Miller et al synthesis of 6-substituted 2-cyanobenzothiazoles; challenges associated with aryl-
halide substitutions  
In the 2017 publication, a library of D-luciferin C6-analogues were prepared from 2-cyano-6-
fluorobenzothiazole.29 It was reported that the fluoro-precursor exclusively underwent SNAr type 
reactions to afford the corresponding benzothiazoles (Scheme 4.16), whereas the bromo-derivative 
could not react in this way and, instead, had to be reacted under standard Buchwald-Hartwig 
amination conditions to afford the same products. Miller et al also commented on the reactivity of 
 Chapter 4: Improved Syntheses of 2-Cyanobenzothiazoles 
103 
 
the nitrile moiety to which they attributed their low yielding substitutions. As mentioned previously, 
Miller et al (via the 2-cyano-6-fluorobenzothiazole) made a very significant contribution to the 
plethora of 6’-luciferin analogues, however, what noticeably remained to be seen was the free thiol. 
 
Scheme 4.16. Miller et al method of preparing 6’-analogues of D-luciferin 
Miller et al also commented on the bioluminescent activity of the sulfides, which were found to not 
be bioluminescent active. This could of course have been predicted based on the reactivity of the 
hydroxyl parent, where the free hydroxyl is bioluminescent active while the O-alkylated/arylated 
derivatives are not. Presumably, Miller et al was not able to produce the free thiol because the sulfides 
were not amenable to alkyl/aryl deprotection to provide the free thiol.  
Towards D-thioluciferin 
Since the value of a 6’-thiol analogue of D-luciferin was becoming increasingly apparent, it was decided 
to first try and form the C6-thio 2-cyanobenzothiazole from the C6-iodo precursor. This was proposed 
to be done via reacting the 6-iodobenzothiazole with potassium thioacetate, thioacetic acid or 
thiourea, under standard Pd-coupling conditions. The pursuit of the C6 -thio analogue of D-luciferin 
follows in Chapter 5. 
In conclusion 
In the previous syntheses of D-luciferin and D-aminoluciferin, the 2-cyanobenzothiazole forming 
palladium-mediated cyclisation, a reaction common to both luciferin syntheses, was found to be 
limiting and was the main contributor to the poor overall yields. A number of different methods were 
attempted to increase the efficacy of the palladium C-S coupling reaction. Ultimately, ortho-
bromination of the starting anilide lead to a successful cyclisation and afforded the cyclised products 
in generally improved yields (54-85 % relative to 9-25 %) and was demonstrated to have better 
functional group tolerability with respect to the C6-substituent. An unrelated route involving a C6-
iodo functional group on the benzothiazole was also explored as an alternative intermediate, which 
unlocked new possibilities for method improvement. The iodo functionality was however 
incompatible with the previously reported palladium chemistry and was better suited for ortho-
brominated reactions.  
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Synthesis and Evaluation of D-Thioluciferin Bioluminescence 
Abstract 
 
D-Luciferin is the light emitting molecule responsible for the bioluminescence observed in the 
American Firefly Photinus pyralis. Modifications to the natural substrate have resulted in new 
luminogenic substrates with often improved properties that have been exploited in the development 
of sensitive luciferin-based probes for in vivo imaging. Most of these probes however, are based on 
the release of either natural D-luciferin or a 6’-amino analogue thereof. This has limited D-luciferin 
based applications, particularly in terms of linking bioluminescence and sulfur biology. To date, there 
are only a few reported examples of bioluminescent probes used in cellular redox imaging and, as 
previously mentioned, all known D-luciferin bioluminescent technologies are derived from either D-
luciferin or it’s amino analogue. In an effort to provide a new functional luciferin analogue, a 6’-thiol 
derivative was investigated. 
Herein, a relatively short synthetic route toward the 6’-thiol analogue of D-luciferin is reported. The 
synthetic route is based on a thiol-protecting group strategy, which allowed for the rapid preparation 
the 6’-thiol analogue, aptly named D-thioluciferin. D-Thioluciferin was successfully synthesised over 
five steps (34 % yield) using a thioacrylate protecting group strategy,  where the new luminogenic 
substrate displayed a lower Km (0.1 µM relative to the 8 µM of D-luciferin) and a more red-shifted 
maximum emission (λmax 600 nm compared to the 557 nm of D-luciferin), but with a much lower 
luminescent output relative to D-luciferin. Overall, it was found to be a promising alternative to 













Synthesis and Evaluation of D-Thioluciferin Bioluminescence 
Introduction 
When White first synthesised D-luciferin, he ushered in the era of bioluminescence assays and 
bioluminescence imaging (BLI). His subsequent work involved changing the 6’-hydroxyl of D-luciferin 
to an amine, to birth D-aminoluciferin. Similarly, D-aminoluciferin’s arrival was accompanied by an 
exponential increase in the development of luciferin-based assays where the amine moiety was used 
as a link to construct probes based on amide hydrolysis. Since then, many different derivatives have 
been prepared by various research groups in an effort to yield new bioluminogenic substrates and 
probes that may be applied in bioimaging. However, all of the derivatives are based on modifications 
of either the natural (6’-hydroxy) D-luciferin or D-aminoluciferin, limiting their utility to O and N-linked 
chemistry.  
In Chapter 4, it was proposed that a 6’-thio analogue of D-luciferin would be of interest since its 
preparation would allow for the evaluation of the effects of replacing the 6’-oxygen with sulfur. The 
effects of replacing the 6’-oxygen with nitrogen on the bioluminescent reaction have already been 
demonstrated and these results, coupled with the bioluminescence data from a 6’-thio analogue, 
could provide further insight into how the 6’-heteroatom of D-luciferin effects the photobiology. In 
addition, if the thiol were prepared and was found to be bioluminescent, then it would undoubtedly 
pave the way for the generation of novel bioluminescent probes, which may find application in areas 
where D-luciferin and D-aminoluciferin could not easily be applied.   
 
Figure 5.1. Structures of D-luciferin, D-aminoluciferin and D-thioluciferin and select examples of luciferin-based 
applications 
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Replacing oxygen with nitrogen and sulfur 
The heteroatom substitution induced changes in the photophysical properties of many well-known 
chromophores have been investigated to both better understand the photophysics and, to allow for 
improved or novel applications. In publications concerning fluorescent chalcogenxanthylium dyes, it 
was demonstrated that replacement of the oxygen by a sulfur heteroatom resulted in the increase in 
the fluorescence emission maxima (Figure 5.2), this was reportedly due to a decrease in oscillator 
strength of the So – S1 transition as a result of having replaced the oxygen with a heavier atom, 
potentially via the heavy-atom effect.1-2 The heavy-atom effect is the enhancement of the rate of a 
spin-forbidden process by the presence relatively heavy atom, which is either part of, or external to, 
the excited molecular entity.3  
 
Figure 5.2 Examples of fluorescent compounds demonstrating the effects of heteroatom substitution on the 
fluorescence emission maxima 
In addition to empirical investigations, a number of TD-DFT studies have also looked into the effects 
of the heteroatom substitution on the photophysical properties of heteroaromatic fluorescent 
molecules, of which some examples are shown (Figure 5.2).4-5  These studies found that, in general, a 
more red-shifted fluorescence emission maxima was observed when replacing oxygen with sulfur and, 
that the shift in emission maxima was related to a decrease in the energy difference between the 
excited and ground state energy levels. It is of course already well known that the highest molecular 
orbitals (HOMOs) and lowest unoccupied orbitals (LUMOs) of the ground and excited state energy 
levels are important, not only to the spectral properties of the compound, but also to its reactivity.  
These same energy differences that govern the fluorescence emission maxima are also responsible for 
the observed bioluminescence emission maxima in bioluminescent reactions. The results from these 
fluorescent investigations are therefore also relevant to bioluminescence, since the effects of 
heteroatom substitution on the relative energies of the excited and ground state would be the same, 
while the source of energy resulting in excitation is different. Thus, it was predicted that D-
thioluciferin, if found to be luminescent active, would display more-red shifted luminescence emission 
maxima, when compared to D-luciferin.  
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Aims and Objectives   
The aim was to synthesise a 6’-thio analogue of D-luciferin and to evaluate its bioluminescence. If the 
analogue did retain luminescent activity, it would be further evaluated to determine the effects of the 
thiol on the wavelength of maximum emission and Km for purified Ppy luc (expressed from E. coli). In 
addition, the fluorescence properties of D-thioluciferin were also to be explored, along with the effects 
of thiol oxidation on its luminescent activity.   
The specific objectives were thus:  
i) The synthesis and characterisation of D-thioluciferin using standard analytical and 
spectroscopic techniques.  
ii) The evaluation of D-thioluciferin bioluminescence using purified luciferase expressed 
from E. coli (including the determination of its λmax, Km, burst Kinetics profile and emission 
half-life). 
iii) The evaluation of D-thioluciferin sulfide and disulfide bioluminescence using purified 
luciferase expressed from E. coli 
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Retrosynthesis of D-Thioluciferin 
2-Cyano-6-iodobenzothiazole was identified as a key intermediate for D-thioluciferin synthesis, where 
the iodo-functionality would act as a surrogate group that would later allow access to the thiol moiety. 
However, the synthesis of D-thioluciferin would first be attempted via methodologies formerly used 
in the synthesis of D-luciferin and D-aminoluciferin by Prescher et al. The synthesis would aim to utilise 
2-cyano-6-iodobenzothiazole as a key intermediate, where its preparation would involve the 
condensation, fragmentation and cyclisation of Appel’s salt and 4-iodoaniline (Scheme 5.1, Route A).  
It was already demonstrated (in Chapter 4) that the 2-cyano-6-iodobenzothiazole intermediate could 
be accessed using an alternate approach from the benzothiazole carboxaldehyde precursor 
(Scheme 5.1, Route B). While this route did allow for the successful preparation of 2-cyano-6-
iodobenzothiazole, it afforded the product in a low 6-8 % yield. It was therefore of interest to evaluate 
the Prescher method of benzothiazole preparation for comparison and, in doing so, perhaps 
demonstrate how o-bromination could be used to improve the overall synthesis of this new luciferin. 
From the 2-cyano-6-iodobenzothiazole, the thiol functionality would be accessed using reported aryl-
iodide coupling reactions. A general scheme outlining the two possible disconnections is shown in 
scheme 5.1.   
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Synthesis of D-Thioluciferin  
Iodo-Surrogate Strategy (Route A) 
 
Scheme 5.2. Proposed synthesis of 2-cyano-6-thiobenzothiazole 5.4 from 2-cyano-6-iodobenzothiaole 5.3 
The conversions of aryl-iodides to aryl-thiols are well documented.6 Typically, the reactions are carried 
out at high temperatures (100-150 oC), in polar aprotic solvents, in the presence of a palladium(II) 
and/or copper(I) catalysts and a nucleophilic source of sulfur. Thus, the iodo precursor 5.3 was 
prepared with the intention that it could be transformed into the desired aryl-thiol. The synthesis of 
the iodobenzothiazole started from the reaction of the p-iodoaniline with previously prepared Appel’s 
salt to afford a dithiazolimine, which was further fragmented to afford the cyanoformanilide 5.2. The 
isolated dithiazolimine and the fragmented product 5.2 were characterised by NMR and IR 
spectroscopy, as well as LRMS.  
 
Figure 5.3. 13C-NMR spectrum of dithiazolimine in DMSO 
The 1H-NMR spectrum of the dithiazolimine displayed the doublet of doublets expected of a 1,4-
substituted phenyl ring and the 13C-NMR spectrum displayed the correct six carbon resonances.  
The 13C-NMR spectrum of the fragmented iodo-nitrocyanoformamide 5.2 in DMSO is shown in figure 
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(note C-6 in figures 5.3 and 5.4). A similar signal was observed in the 13C-NMR spectra of the methoxy 
and nitro analogues. A clear doubling of all the NMR resonances were also observed in the spectra, 
this was most likely either due to the interconversion of 5.2 between its tautomeric (thione-thiol) 
forms or the existence of rotamers, previously observed in D-luciferin and D-aminoluciferin syntheses.  
 
Figure 5.4. 13C-NMR spectrum of 5.2 in DMSO  
With the iodo-nitrocyanoformamide 5.2 successfully prepared, an intra-molecular C-S cross-coupling 
reaction was attempted to form the benzothiazole (Scheme 5.3). Initially, there were concerns that 
the iodo would be reactive under the cross-coupling conditions which could result in the unwanted 
formation of inter-molecular cross-coupling products. However, Hrobàrik et al had already 
demonstrated an oxidative coupling on a similar system where the correct, cyclised product was 
predominantly formed and isolated in moderate yield (60 %).7 
 
Scheme 5.3. Reagents and conditions: i) PdCl2 / CuI / TBAB / DMF:DMSO (1:1) / 120 oC / 4 h 
The reaction was thus carried out and TLC analysis revealed the formation of two non-polar products. 
The compounds were isolated by standard silica chromatography and the structures determined by 
spectroscopic and analytical techniques. The less polar product isolated was unsubstituted 2-
cyanobenzothiazole, based on LCMS and NMR spectroscopy, and was also the major product formed 
from the reaction (33 %). The other product was the desired 2-cyano-6-iodobenzothiazole 5.3 which 
was isolated in very low yield (6 %). The remaining material (61 %) was highly water soluble and could 
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The formation of the unsubstituted benzothiazole was surprising but also very interesting since 
Hrobàrik did not make mention of such unwanted side reactions. In addition, the substitution of the 
C6-iodo group with hydrogen necessitates a hydride source which was difficult to rationalise from the 
reagents used. It once again become apparent at this point that the oxidative C-S cross-coupling 
reaction was perhaps not the best methodology for benzothiazole synthesis, since poor yields were 
generally observed in the different luciferin syntheses and, it was particularly limiting with regards to 
the iodo-precursor where a generally poor yield was made worse because of the formation of the 
unsubstituted 2-cyanobenzothiazole. Nevertheless, enough material of the 2-cyano-6-
iodobenzothiazole was obtained for characterisation and its 1H-NMR spectrum is shown in figure 5.5.  
 
Figure 5.5. 1H-NMR spectrum of 2-cyano-6-iodobenzothiazole 5.3 in DMSO 
The 1H-NMR spectrum alone could not be used as conclusive evidence for the successful synthesis of 
the cyanobenzothiazole 5.3. The spectrum displayed a singlet integrating for one proton and another 
set of signals integrating for roughly four protons, that could support the presence of a C6-substituted 
benzothiazole. The IR spectrum of 5.3 revealed a weak peak at 2200 cm-1, corresponding to the nitrile 
C-N stretch, further supporting the formation of 5.3. The mass spectrum, unfortunately, did not 
display a mass ion peak corresponding to the molecular weight of 5.3 and could therefore not confirm 
that the cyclisation was successful. It did however display a mass ion peak corresponding to the 
molecular weight of the unsubstituted benzothiazole (M+-I). Although the sequence did not 
conclusively produce the desired 6-iodo-2-cyanobenzothiazole, it did produce some interesting results 
with regards to the influence of C6-substitution on the cyclisation reaction.  
Since the Prescher et al method did not efficiently nor conclusively allow access to the 6-iodo-2-
cyanobenzothiazole, it provided the perfect opportunity to apply the recently developed one pot, 










Scheme 5.4. one pot, metal-free base-mediated cyclisation from o-bromoaniline; reagents and conditions:  
i) NaBO3 / KBr / AcOH / rt / 16 h, 78 % ii) Appel’s salt / DCM / 3 h, iii) DBU / DCM / 5 oC / 3-4 h, 67 % 
2-Cyano-6-iodobenzothiazole was afforded in a good yield of 67 %, using the one-pot metal free 
method, starting from 2-bromo-4-iodoanilne 5.5. The reaction proved to be superior to both the 
Prescher et al reaction (6 % of 5.3), as well as the SN2Ar sequence described in Chapter 4 (8 %). The 
iodobenzothiazole was then reacted under standard coupling conditions in an attempt to produce the 
thiobenzothiazole 5.4 (Scheme 5.5). 
 
Scheme 5.5. Reagents and conditions: R = H; i) CuI / Sulfur powder / K2CO3 / DMF / 90 oC / NaBH4, R = Ac; 
i) Pd(OAc)2 / KSAc / DPPF / NaOtBu / dioxane / 100 oC or Pd2dba3 / KSAc / DPPF / DIPEA / toluene / reflux and, 
R = CHNNH2; i) CuI / thiourea / PEG / K2CO3 / 100 oC6, 8        
Various reported methods for the conversion of aryl-iodides to thiols and thioesters were attempted 
but none afforded the C6-thio derivative. This was presumably due to the reactivity of the C2-nitrile 
functionality, which may have reacted with the sulfur reagents in a manner similar to its reaction with 
D-Cys. The argument that the C6-nitrile was responsible for preventing the formation the 
thiobenzothiazoles 5.4, 5.6, and 5.7 was later supported by Miller et al, who noted that the reactivity 
of the C2-nitrile moiety was indeed a challenge in C6-halide substitution.9 
For the time being, the 2-cyano-6-iodobenzothiazole surrogate strategy was abandoned and focus 
was shifted to other potential methodologies. 
Diazotization Strategy  
Following on the unsuccessful attempted C6-iodo substitution, an alternative surrogate group was 
considered. Diazotization was attempted using previously prepared 6-amino-2-cyanobenzothiaozole, 
shown in scheme 5.6. The amine was reacted with sodium nitrite in concentrated HCl to produce the 
diazonium salt that was then reacted with potassium thioacetate and thiourea in separate reactions. 
Both reactions proceeded similarly and in both instances the products formed from the reaction could 
not be extracted from water, presumably because the nitrile had been hydrolysed to the acid. 









Scheme 5.6. Diazotization of 6-amino-2-cyanobenzothiazole. Reagents and conditions: i) NaNO2 / HClconc. / -
5 oC / 40 min, ii) KSAc or Thiourea / 30 min 
S-Protection Strategy  
Since attempts at introducing the thiol functionality via the iodo and amino surrogate groups failed, 
its preparation was next attempted with the sulfur functionality in place, pre-benzothiazole formation. 
Thus, the synthesis of D-thioluciferin was tried using a protected sulfur starting material and the 
Appel’s salt methodologies employed in the preparation of D-luciferin and D-aminoluciferin. The 
proposed synthesis of thioluciferin is shown in scheme 5.7. In the syntheses of D-luciferin and 
D-aminoluciferin, the nucleophilic C6’-hydroxyl and C6’-amine functionalities were introduced as 
protected/masked groups and liberated only after cyanobenzothiazole formation, by O-methyl 
deprotection and nitro reduction, respectively. Similarly, in the synthesis of D-thioluciferin a 
protecting group strategy using triphenylmethyl chloride (trityl chloride) was proposed. This was 
chosen on the basis of the starting material that was available, p-aminothiophenol 5.8, which would 
require a protecting group that would selectively protect the thiol in the presence of the amine. There 
are a number of reported methods for such chemoselective reactions, most of which exploit the 
basicity of the amine to achieve the desired selectivity.10-11 Practically, this means that the thiol is 
protected in acidic media, wherein the amine is protonated to form the less nucleophilic ammonium 
salt. In addition to being selective, the trityl group was chosen because it was predicted to be relatively 
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Scheme 5.7. Proposed synthesis of D-thioluciferin. Reagents and conditions: i) S2Cl2 / DCM / rt, ii) PG addition, 
iii) Appel’s salt / DCM / Py / rt, iv) DBU / DCM / 5 oC, v) PdCl2 / CuI / TBAB / DMF:DMSO (1:1) / 120 oC, vi) TFA / 
DCM / rt, vii) D-Cys / K2CO3 / MeOH:H2O (7:3) / rt 
To form the S-protected aniline, an S-trityl group was introduced. The S-trityl was however not stable 
to chromatography and all attempts at isolating the protected thiol made it increasingly clear that the 
S-tritylated aminothiophenol was indeed not stable, and that perhaps an alternive protecting group 
should be considered. The chemoselective acetylation of aminothiophenol was thereafter attempted 
using a mixture of acetic acid and acetic anhydride. Here, the amine reacted almost exclusively despite 
literature reporting otherwise.10 This method was thus also abandoned. 
Homodisulfide Protecting Group Strategy  
As a result of the failed previous attempts at S-protection, a somewhat unrelated strategy involving 
the protection of the thiol as a disulfide was pursued. This strategy was appealing because it too 
exploited differences in the chemical reactivity between the thiol and amino functionalities, in that 
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Scheme 5.8. Proposed synthesis of D-thioluciferin disulfide. Reagents and conditions: i) NaBO3 / AcOH / H2O / 
rt / 48 h, (98%) or i) I2 / DMSO:CHCl3 (1:1)/ rt / 4 h (93%), ii) Appel’s Salt / DCM / Py / rt / 4h, (68%) iii) DBU / 
DCM / 5 oC / 1 h 
To achieve the desired oxidation, p-aminothiophenol was stirred in a solution of NaBO3, acetic acid 
and water to generate the disulfide 5.13. The structure of the disulfide 5.13 was confirmed by 1H- and 
13C-NMR spectroscopy, and was further supported by mass spectrometry in which a mass ion peak 
corresponding to the calculated molecular weight of 5.13 was observed.  The disulfide was then 
reacted with Appel’s salt afford the corresponding dithioazolimine 5.14 in good yield (68 %). The 
subsequent base mediated fragmentation proved to be very problematic, possibly due to the large 
excess of DBU used (6 eq), and/or chemoselectivity issues arising from having two distinct disulfide 
moieties within the molecule, namely; the hetero-disulfide of the dithiazolimine and the homo-
aryldisulfide.12 A publication on the DBU-Mediated cleavage of aryl- and heteroaryl disulfides 
demonstrated that DBU, in addition to fragmenting the dithiazolimines, could also reduce aryl-
disulfides (Scheme 5.9). Interestingly, that publication was the first to report DBU as a nucleophile in 
the direct cleavage of aryl-disulfides and, to date, remains one of only a few literature examples 
demonstrating the lesser known thiophilic character of DBU. 
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LCMS of the crude reaction mixture of the DBU mediated fragmentation of 5.14 did not display a mass 
ion peak corresponding to the molecular weight of the fragmented product, and various attempts at 
isolating defined products were unsuccessful. Ultimately, the homo-disulfide thiol protecting strategy 
was also abandoned.  
Synthesis of D-thioluciferin vinyl sulfide via a thioacrylate protecting group  
Most of the challenges that manifested in the previously described attempted syntheses of 
D-thioluciferin were largely due to the incompatibility of the employed synthetic methodologies with 
the free thiol, protected thiol, and/or disulfide in various reactions. The free thiol was too reactive in 
the presence of Appel’s salt and could not be used directly, acid sensitive protecting groups (such as 
trityl) were not tolerated and the acylated thiol (or thioester) could not be selectively formed in the 
presence of the free amine. Furthermore, the same reaction that forms the benzothiazole from 
thioamides also generates benzothiofuran from thioesters. A surrogate group such as the C6’-iodo 
proved challenging to prepare as well and the disulfide strategy also presented issues concerning 
chemoselectivity in the fragmentation reaction, requiring a much larger excess of DBU and was 
therefore abandoned. The sulfides were generally not considered an option since harsh conditions 
would have been required to free the thiol. However, vinyl sulfides in the form of thioacrylates are 
reported to be readily reactive in the presence of S-nucleophiles and were therefore of interest, even 
though their use as protecting groups had not been reported.13-14 
Interestingly, the idea of using a thioacrylate as a protected thiol to synthesise thioluciferin came 
about from the design of a thiol/thiolate sensing probe (discussed in more detail in Chapter 6). Scheme 
5.10 shows the proposed mechanism of D-thioluciferin release in response to a reactive thiolate. The 
irreversible release of the less reactive aryl thiol (in this case D-thioluciferin) would be driven by the 
greater nucleophilicity of the incoming thiolate which forms a relatively more stable thioacrylate when 
compared to D-thioluciferin. 
 
Scheme 5.10. D-Thioluciferin probe and the proposed mechanism for thiolate mediated release of 
D-thioluciferin 
This meant that the thioacrylate could be prepared from p-aminothiophenol which could then be 
converted to D-thioluciferin and released upon reaction of the vinyl sulfide moiety with an alkyl 
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thiolate. Furthermore, it was hypothesised that D-Cys could be used to simultaneously both form and 
release D-thioluciferin. The synthesis involved the formation of the vinyl-sulfide functionality 
(thioacrylate) using the well-known thiol-yne (also known as the “thio-click”) reaction. The reaction 
normally involves an alkyne and an aryl- or alkyl-thiol reacted in the presence of a radical initiator in 
cases where the -yne moiety is not directly conjugated to a carbonyl. For this reaction, p-
aminothiophenol was reacted with propiolic acid to form a vinyl sulfide 5.16, where the free amine 
would later be used to construct the rest of the luciferin molecule, scheme 5.11. 
 
Scheme 5.11. Reagents and conditions: i) p-Aminothiophenol / DMF / rt / 24 h, (30%), ii) Appel’s salt / DCM / 
Py / rt / 3 h, (99%), iii) DBU / DCM / 5 oC / 30 min, iv) PdCl2 / CuI / TBAB / DMSO / 120 oC / 4 h, v) D-Cys  / K2CO3 
/ DMSO:H2O (2:1) / rt / 20 min 
It should be noted that the sequence starts off with the doubly nucleophilic p-aminothiophenol 
instead of p-nitrothiopenol or N-protected thiophenol. This is because the free thiol is a relatively soft 
nucleophile when compared to the amine and it was therefore predicted to be more reactive toward 
the alkyne. This assumption was proven to be correct as none of the vinyl amine was formed from the 
reaction of p-aminothiophenol and propiolic acid, as evidenced by 1H-NMR analysis. 
TLC analysis of the reaction revealed two new products observed as two distinct spots that were very 
close in Rf and significantly more polar than the starting amine. This was thought to be the cis and 
trans isomers resulting from addition to the alkyne. TLC analysis also showed significant conversion of 
the starting aminothiophenol to its oxidised disulfide, even under inert conditions. This was observed 
as the most polar spot and lead to the use of silica chromatography for the purification of the 
thioacrylate 5.16. The thioacrylate was easily separated from the disulfide but the cis and trans 
isomers were not separable. The purified products were characterised by 1H-NMR spectroscopy which 
showed that the cis:trans ratio was approximately 4:1. To avoid working with a mixture of isomers, 
the reaction was repeated at 0 and 100 oC. the 1H-NMR spectra of the products isolated from these 
reactions are shown in figure 5.6. 
5.16 5.17 




Figure 5.6. 1H-NMR spectra in DMSO (D2O wash) of mixtures of cis and trans thioacrylate 5.16 isolated from 
reactions performed at a) 100 oC and b) 0 oC. 
At 0 oC less than 10 % of the trans isomer was observed and at 100 oC less than 5 % of the cis isomer 
was observed, by 1H-NMR spectroscopy, where the cis and trans isomers were distinguishable by their 
J values for protons H-1/2 (cis J = 10.0 Hz, trans J = 14.8 Hz). These products corresponded to what 
was expected for a reaction under typical kinetic/thermodynamic control, where the more stable 
trans-isomer was favoured at increased temperatures, while the faster formed but less stable cis-
isomer is predominately isolated at lower temperature. 
Ultimately, neither pure cis nor trans was achieved from temperature control and thus a mixture of 
isomers were carried over to the next step. The next reaction in the sequence involved using the free 
amine of the thioacrylate to form an N-aryl-iminodithiazole that could be fragmented and cyclised to 
afford the terminal 2-cyanobenzothiazole. This was done by reacting the amine with an excess of 
Appel’s salt in DMF at room temperature. Again, there was the possibility of Appel’s salt reacting with 
the carboxylate of the vinyl sulfide, but that process has already proven to be reversible, unlike the 
formation of the imine. The product was isolated as mixture of cis and trans isomers (E:Z ratio 


















Figure 5.7. 1H-NMR spectrum of 5.17 in DMSO 
 
Figure 5.8. 13C-NMR spectrum of 5.17 in DMSO 
The 1H-NMR spectrum of 5.17 showed all the expected proton signals, a significant downfield shift in 
the aromatic protons H-3/4 were also observed relative to the starting material, reasoned to be due 
to the conversion of the donating amine group to the lesser donating imine functionality. The 13C-NMR 
spectrum which displayed the expected 18 resonances (9 for each E and Z isomer), along with a 
molecular ion peak in the mass spectrum, further supported the successful preparation of the 
dithiazolimine product. The fragmentation of the diathiazolimine 5.17 was then carried out by slow 
addition of DBU. Unexpectedly, the fragmented product was highly water soluble and, as a result, 
could not be easily separated from the polar DBU salts and DBU-thiolane by-product. For this reason, 











Scheme 5.12. Reagents and conditions: i) BnBr / Cs2CO3 / DMF / 0 oC / 2 h, (99%), ii) p-aminothiophenol / DMF 
/ rt / 24 h, (39%), iii) Appel’s salt / DCM / Py / rt / 3 h, (99%), iv) DBU / DMSO / 5 oC / 30 min, (61%), v) PdCl2 / 
CuI / TBAB / DMSO / 120 oC / 4 h, (62%), vi) D-Cys  / K2CO3 / DMSO:H2O (2:1) / rt / 20 min, (98%) 
To ensure that a more hydrophobic product would be produced by DBU fragmentation, the benzyl 
ester of propiolic acid was prepared. The benzylation was achieved by reacting the carboxylate with 
benzyl bromide at 0 oC. The 1H-NMR spectrum is shown in figure 5.9 and displayed the correct three 
expected signals. The ester was then reacted in the same way as the acid to afford the vinyl sulfide.   
 
 














Figure 5.10. 1H-NMR spectrum of the benzyl thioacrylate 5.19 in DMSO 
The propiolate ester was allowed to stir with p-aminothiophenol in DMF at rt for 24 h. The reaction 
was monitored by TLC analysis which revealed total consumption of p-aminothiophenol. Interestingly, 
only one of the two possible isomers was formed as revealed by TLC analysis which was subsequently 
confirmed by NMR spectroscopy. TLC analysis once again showed conversion of aminothiophenol to 
the more polar disulfide which lead to the use of chromatography for purification. The 1H-NMR 
spectrum of the benzyl thioacrylate is shown in figure 5.10. The spectrum displayed all the expected 
proton resonances, confirming that only the trans isomer was formed from the reaction with the ester, 
based on the coupling constants for the alkenyl protons (H-3/2, J = 15.0 Hz). The steric bulk of the 
benzyl moiety may have had a directing effect in the formation of the thioacrylate since a mixture of 
isomers were produced under the same conditions but in the absence of the benzyl. The reaction was 
also repeated at increased temperature (100 oC) to lessen reaction time. This however, yielded an 
unexpected result whereby the free amine also reacted with the propiolate ester to form a vinyl 
amine, observed as a non-polar spot by TLC. The vinyl sulfide-vinylamine product was isolated and 
fully characterised. Subsequent reactions were then maintained at 25 oC and 24 h, to ensure the 
formation of only one product. Gratifyingly, this result meant that the next reaction could be 
attempted using one analytically pure isomer. The dithiazole was then formed from the reaction of 
the free amine with Appel’s salt. The reaction was monitored by TLC which confirmed the formation 












Figure 5.11. 1H-NMR spectra of a) benzyl thioacrylate 5.19 and b) its Appel’s salt adduct 5.20 in DMSO 
The 1H-NMR spectrum of the benzyl thioacrylate dithiazolimine is shown in figure 5.11. The formation 
of the dithiazole was supported by the 1H- and 13C- NMR spectra. Most obvious in the 1H-NMR 
spectrum was the downfield shift of the aromatic protons H-4/5 due to the conversion of the amine 
to an imine, which was further supported by the absence of the amine resonance at 5.5 ppm, 
previously observed in the starting material. A reduction in the coupling constant for H-3 (from J = 
15.0 to 13.5 Hz) could suggest that complete isomerisation of the double bond had occurred, however 
the corresponding stereoisomer would have been needed to confirm this and, overall, this was 
thought to be unlikely. The 13C-NMR spectrum (figure 5.12) further supported the formation of the 
dithiazole since two more carbon resonances were observed in the spectrum of the product relative 
to the starting material.  
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The 13C-NMR displayed the correct 14 resonances expected for the adduct with diagnostic signals 
observed at 147.3 and 160.7 ppm for the dithiazolimine carbons (C-13, 14). Further support for the 
successful installation of the dithiazolimine was provided in the mass spectrum, figure 5.13, where a 
molecular ion peak corresponding to [M+H] at m/z 420.9890 was observed. 
 
Figure 5.13. HRMS of the benzyl thioacrylate Appel’s salt adduct 5.20 
The adduct 5.20 was then subjected to DBU mediated dithiazole fragmentation to afford the 
cyanoformanilide 5.21 required for cyclisation. The fragmentation was achieved without any 
complications and the product was isolated in relatively good yield (67 %).  The 1H-NMR spectrum of 
the fragmented product is shown in figure 5.14. The spectrum displayed all the expected signals with 
the key thioamide resonance observed as a broad, highly deshielded singlet integrating for one proton 
at 13.52 ppm. Interestingly, a major reduction in the coupling constant for signal H-3 was observed 
(from J = 13.5 Hz in the dithiazole precursor, to J = 8.6 Hz in the fragmented product 5.21). This 
reduction meant that isomerization about the double bond had occurred, rearranging the compound 
from its starting trans geometry to the cis geometry shown in figure 5.14. This can be rationalized 
through the role of the DBU, which through a Michael addition and subsequent elimination results in 




































Figure 5.14. 1H-NMR spectrum of the fragmented product 5.21 in DMSO 
The thioamide was then cyclised using the previously described intramolecular C-S cross-coupling 
reaction to afford the 2-cyanobenzothiazole thioacrylate. The product was isolated and characterised 
by spectroscopic and analytical techniques and the 1H-NMR spectrum is shown below (Figure 5.15). 
The benzothiazole ring protons were clearly displayed (H-4,5,6) which was indicative of a successful 
cyclisation. Furthermore, the mass spectrum displayed molecular ion peaks corresponding to [M+2H] 
at m/z 354.9664 and [M+2H+Na] at m/z at 378.0146 and the IR spectrum displayed a weak band at 
2182 cm-1 supporting the conservation of the C2-nitrile. The material was then used in the next 
reaction to produce D-thioluciferin, even though NMR spectroscopy and EA data suggested that some 
organic impurities were present, observed in the aromatic region of the 1H-NMR spectrum of figure 
5.15. This was done because the reaction that affords D-thioluciferin involved an acid-base extraction 
were organic impurities would later be dealt with. 
 





















Scheme 5.13. D-Cys mediated formation and release of D-thioluciferin 
The proposed reaction sequence for the synthesis of D-thioluciferin from the 2-cyanobenzothiazole 
precursor is shown in scheme 5.13. Two equivalents of D-Cys were reacted in the presence of 
potassium carbonate with the cyanobenzothiazole precursor to afford D-thioluciferin. Scheme 5.13 
shows that the first equivalent of D-Cys reacts with the cyanobenzothiazole to form D-thioluciferin 
thioacrylate, after which D-Cys substitutes the vinyl sulfide to release D-thioluciferin. It was in fact not 
known prior to performing the reaction whether D-Cys cyclisation would occur first, followed by 
elimination or vice versa, or whether both reactions would occur simultaneously under the standard 
reaction conditions. The order that the reaction proceeds in was eventually investigated since it was 
important to consider for D-thioluciferin thioacrylate application (discussed later). After the reaction 
was completed, as evidenced by TLC, an acid-base extraction was employed to isolate pure 
D-thioluciferin. The 1H-NMR spectrum of D-thioluciferin is shown in figure 5.16. With the removal of 
the thioacrylate, the expected five proton resonances were observed. Of note in figure 5.16 is the ɑ-
proton H-8, observed as a triplet integrating for one proton. The ɑ-carboxyproton is a key signal in 
supporting successful D-luciferin synthesis, since the ɑ-carboxyproton of free D-Cys is normally 
observed at 4.25 ppm, while the cyclised D-Cys dithiazole ɑ-proton is observed much further 
downfield in the 1H-NMR spectrum (5.40, 4.93 and 5.46 ppm for D-luciferin, D-aminoluciferin and D-
thioluciferin, respectively). 
 
Figure 5.16. 1H-NMR spectrum of D-thioluciferin in DMSO  
Additional support for the successful synthesis of D-thioluciferin was found in the 13C-NMR spectrum, 
where an expected total of 11 carbon resonances were observed and in the mass spectrum where 
molecular ion peaks at m/z 319.0002 and 294.9907 corresponding to [M+Na] and [M+H] were 
displayed (Figure 5.17).  
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Figure 5.17. HRMS of D-thioluciferin 
The optical purity of thioluciferin was also measured using chiral HPLC where a major peak was 
observed in the HPLC chromatogram (82-89 % ee, by HPLC using a Diacel Chiracel OD column, eluting 
with hexane:i-propanol 7:3). This suggested the stereochemistry of D-Cys had largely been conserved 
and that a small degree of racemisation had occurred during the formation of D-thioluciferin. The 
optical rotation of the synthesised material was also recorded for reference ([α]20
𝐷 obs
: -11o, DMF, c = 
1). After confirming its structure and assessing optical purity, focus was shifted to the mechanism by 
which D-thioluciferin release proceeds. The reaction of the cyanobenzothiazole thioacrylate was 
repeated using one equivalent of D-Cys. TLC analysis of the organic extracts from the reaction revealed 
multiple products and the subsequent NMR experiments further supported that there was no or very 
little selectivity in the reactivity of D-Cys toward the nitrile and vinyl sulfide. The reaction was then 
repeated at 0 oC and this time, it reacted almost exclusively at the C2-nitrile to form the D-thioluciferin 
thioacrylate. The 1H-NMR spectrum of the adduct is shown in figure 5.18 where all the previously 
described thioluciferin resonances were displayed, along with the signals from the acrylate. The 
thioluciferin thioacrylate was also subjected to LCMS where a molecular ion peak corresponding to its 
molecular weight was observed. The isolated adduct was then reacted again with D-Cys and potassium 
carbonate to afford D-thioluciferin. Of course, at this point it was no longer necessary to use D-Cys 
specifically to deprotect D-thioluciferin and hence a number of reactive thiolates were evaluated for 
D-thioluciferin deprotection.  The effect of the different thiols on the rate of deprotection is discussed 
later (Chapter 6) in the context of thiolate sensing. 
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Figure 5.18. 1HNMR spectra of D-thioluciferin and D-thiolucifeirn thioacrylate in DMSO 
 
Improvements to the D-thioluciferin synthesis  
It should be noted that improved methods of cyanobenzothiazole preparation were attempted but 
proved unsuccessful. The previously described method of monobromination was employed to prepare 
a disulfide protected mono-brominated aminothiophenol, scheme 5.14 a. However, both the Appel’s 
salt reaction and the subsequent base mediated fragmentation proved to be very problematic, 
possibly due to the large excesses of Appel’s salt and DBU used (6 eq) in the attempted 
transformations. Thus, the improved cyclisation could not be carried out. Monobromination of the 
sulfide was also attempted, scheme 5.14 b, but instead resulted in the loss of the thioacrylate 
functionality, based on 1H-NMR analyses of the reaction. 
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Scheme 5.14. Reagents and conditions; a) i) NaBO3 / KBr / AcOH / rt / 16 h, 75 %, ii) Appel’s salt / DCM / 3 h, b) 
i) NaBO3 / KBr / AcOH / rt / 16 h 
As a result, a relatively low overall yield was observed in the D-thioluciferin synthesis, however, studies 
concerning the conversion of the 2-cyano-6-iodobenzothiazole analogue to a C6-thiol is ongoing. 
Nevertheless, the results from the investigation into D-thioluciferin synthesis indicated that D-
thioluciferin could be prepared rapidly, albeit in a modest yield, from the described thioacrylate 
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Bioluminescent Evaluation of D-Thioluciferin 
D-Thioluciferin 
Based on previous work concerning synthetic luciferins and related derivatives it was predicted that 
the 6’-thio analogue of D-luciferin would be bioluminescent active and that it would display a more 
red-shifted maximum wavelength of emission, similar to that observed for aminoluciferin. In addition, 
the more oxidised disulfide of D-thioluciferin was expected to be non-luminescent active (provided its 
chemical reactivity was not different from the hydroxy-parent) and that could therefore allow for 
bioluminescence to be coupled to disulfide reduction. It was of course surprising that a thiol analogue 
had not yet been reported despite its obvious potential applications. Disulfide reduction/oxidation, 
particularly in the context of cellular redox homeostasis, is an important biomarker for stress and the 
ability to monitor induced stress is generally important.15-16 It was therefore a goal of this study to not 
only evaluate the bioluminescence of D-thioluciferin, but also its oxidised disulfides, scheme 5.15.  
 
Scheme 5.15. Structure of D-thioluciferin and its disulfide 
Sulfur and Biology 
Sulfur provides a range of chemical reactivity and provides a degree of structural flexibility in biology 
and its biological incorporation is believed to have evolved directly for protein folding and to regulate 
three-dimensional structure.17 As a result of this, much of biological function is supported by sulfur, 
hence technologies that potentially enable the monitoring of sulfur related chemistries are constantly 
being explored. The thiol handle of D-thioluciferin is very appealing in this regard, since it can directly 
link luminescence to sulfur biology. At this point, it is important to reiterate that for the effective 
application of D-thioluciferin based probes, two criteria must be met; the first, D-thioluciferin must 
retain luminescent activity and the second, modifications to the thiol-functionality of D-thioluciferin 
should result in a loss of luminescent activity. 
.       
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Purified Luciferase Assay: 
D-Thioluciferin was reacted with luciferase and the resultant luminescence measured in RLU using a 
Luminoskan Ascent luminescence plate reader. The luciferase enzyme was prepared as a standard 
10 nM solution in enzyme buffer where luciferase lyophilized powder was dissolved in previously 
prepared luciferase enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 0.8 mg/mL 
BSA). Luminescence assays were initiated by adding 30 μL of luciferase in luciferase enzyme buffer to 
60 μL of D-thioluciferin in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 
4 mM ATP) in a white 96-well plate. The final concentration of D-thioluciferin was varied from 0.1 µM 
to 3.56 µM, 10 µM and 100 µM. Bioluminescence was recorded one minute after enzyme addition 
and the results are shown in figure 5.19. 
 
Figure 5.19. Graph of luciferase luminescence at a final enzyme concentration of 10 nM, at varying 
D-thioluciferin concentrations 1 min after enzyme addition. The assays were performed in triplicate and are 
represented as the mean ± SEM. 
The results from the luminescence assay showed that D-thioluciferin was indeed luminescent active 
under the standard conditions previously used to demonstrate D-amino and D-luciferin luminescence. 
Control 1 contained a 10 nM Luciferase solution in enzyme buffer, and Control 2 comprised of 0.1 µM 
D-thioluciferin in substrate buffer to which a “blank” solution (enzyme buffer not containing 
luciferase) was added. No significant luminescence was detected from either control. However, when 
the blank solution was exchanged for the 10 nM luciferase containing solution, a significant light 
output was observed. Moreover, increased light output was observed for increasing concentrations 
of D-thioluciferin, further supporting thioluciferin luminescent activity. After confirming luminescent 
activity, D-thioluciferin was then treated with luciferase to determine its bioluminescence emission 

















































Control 1 – Luciferase in the 
absence of substrate   
Control 2- Substrate in the 
absence of enzyme  
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Bioluminescence Emission spectrum: 
Purified luciferase in enzyme buffer was rapidly injected into a cuvette containing D-thioluciferin in 
substrate buffer to a final enzyme concentration of 100 nM and a final substrate concentration of 
10 μM. The peak emission (measured from 200 to 800 nm) was recorded using a Varian Carry Eclipse 
Fluorimeter. The bioluminescence emission spectrum of D-thioluciferin, along with D-luciferin and D-
aminoluciferin for reference, is shown in figure 5.20. Peak bioluminescence emission for 
D-thioluciferin was observed at 599 nm while peak emission for D-luciferin and D-aminolucifeirn were 
observed at their respective maxima of 550 and 595 nm, respectively. The longer λmax for 
D-thioluciferin relative to D-luciferin was expected both because of empirical trends as well as from 
TD-DFT studies.  
 
Figure 5.20. Bioluminescence spectrum for 10 nM luciferase with 0.1 µM D-thioluciferin, D-luciferin and 
D-aminoluciferin 
Burst Kinetics profile of D-thioluciferin:  
As previously discussed, when purified firefly luciferase is treated with D-luciferin or aminoluciferin, a 
high initial rate of light emission (burst) was observed in the first few seconds, which was then 
followed by a substantial decrease in the rate of sustained light output. It has been reported that this 
effect is more pronounced for D-aminoluciferin and related analogues, than for D-luciferin under the 
same conditions.18 The kinetic profile for D-thioluciferin was shown to follow this trend (Figure 5.21). 
Burst Kinetics Profile of D-thioluciferin
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However, relative to D-luciferin treated with the same luciferase, the initial rate of photon flux was 
much higher, and subsequent decay to a steady light output occurred more rapidly. Despite the faster 
rates observed in D-thioluciferin, it generally appeared to achieve constant light about 1 min post-
enzyme addition, which was the same for D-luciferin. The over-all emission however was greatly 
reduced for D-thioluciferin relative to D-luciferin although it should be noted that previous analogues, 
such as aminoluciferins, also have greatly reduced emission 1 minute after substrate addition 
(consistent with product inhibition as the primary factor limiting the light emission in vitro).19-20 This 
means that D-luciferin is superior in terms of luminescent output when treated with purified 
luciferase. D-thioluciferin does however still offer advantages in terms of its chemical reactivity, where 
it can form reducible disulfides for measuring redox potentials. However, the requirement for 
application in redox sensing is that the oxidised thioluciferins should be non-luminescent active and/or 
inhibitors of luminescence, while the reduced free thiol is luminescent. Thus, an investigation into the 
luminescent properties of sulfides and disulfides was warranted.  





















































































































Figure 5.22. a) Luminescence output of 0.1 µM of protected D-thioluciferin thioacrylate, D-thioluciferin disulfide, 
and D-thioluciferin and b) relative luminescence of the core luciferins at 0.1 µM substrate concentration and at 
a final luciferase concentration of 10 nM. The RLU were determined in triplicate and are represented as the 
mean ± SEM 
Figure 5.22 shows the luminescence output for D-thioluciferin, its protected thioacrylate 4.23 (i.e 
sulfide) and disulfide. From graph a it can be seen that neither pure luciferase in enzyme buffer nor 
pure thioacrylate (control 1) in substrate buffer emitted light. It can also be seen that when a 0.1 µM 
thioacrylate solution was treated with luciferase in enzyme buffer (thioacrylate labelled bar, figure 
5.22a), the luminescence output remained negligible. This reinforced that the thioacrylate of 
D-thioluciferin was not luminescent active, and perhaps by extension that all sulfides of D-thioluciferin 
are luminescent inactive, as is the case with D-luciferin and its 6’-O-alkyl analogues. Control 2 
contained only D-thioluciferin disulfide and control 3 only D-thioluciferin, both in substrate buffer at 
a) b) 
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a final concentration of 0.1 µM. In both cases, in the absence of luciferase, a small degree of 
luminescence was detected. The luminescence increased significantly when D-thioluciferin and its 
disulfide were treated with luciferase to a final enzyme concentration of 10 nM. What was interesting 
was that the disulfide treated with luciferase had a much higher luminescence output than its control 
(control 2) when compared to the sulfide and its corresponding control (control 1), since both were 
predicted to be non-luminescent active. This was most likely due to the reduction of non-luminescent 
D-thioluciferin disulfide to the luminescent-active free thiol by reducing agents in the enzyme buffer, 
namely DTT. This was confirmed by experiments later discussed in the context of D-thioluciferin 
applications. It should be noted that the assay could not be done in the absence of DTT since it is a 
crucial component of the enzyme buffer solution and, in addition, the same results were observed 
when DTT was replaced with tris(2-carboxyethyl)phosphine (TCEP), an alternative reductant.  
With either DTT or TCEP, the free thiol displayed five times more luminescence than the disulfide, 
again a promising result for future redox based applications. Of concern was the relatively low light 
output generated by D-thioluciferin when compared to natural D-luciferin. D-luciferin was found to 
emit light at 100 times the intensity of D-thioluciferin while D-aminoluciferin had an emission 10 times 
more intense than that of the thio-analogue (but still far less than D-luciferin, figure 5.22). This is 
commonly observed when bioluminescence of new analogues are compared to D-luciferin with the 
wild-type enzyme and often relate to the quantum yield. Such an example is shown in figure 5.23, 
where the luminescence of a new 6’-amino analogue of D-luciferin, CycLuc7, is compared to D-
luciferin. With the WT enzyme D-luciferin emits light at 100 times greater intensity than CycLuc7.18-19 
This suggested that the new analogues have to be used at higher concentrations to achieve the same 
relative light output as D-luciferin. This limitation is now being overcome by luciferase screening, 
where luciferase mutants are evaluated for increased luminescence with non-natural substrates and 
a similar screening performed with D-thioluciferin could be envisioned in the near future. 
 
Figure 5.23. Bioluminescence of D-luciferin and CycLuc7 treated with purified WT and mutant luciferases 
reported by Mofford et al.18 
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Relative rates of luminescence: 
In most D-luciferin purified enzyme assays, luminescence is quantitated one-minute post enzyme 
addition. This is to maximise reproducibility and consistency by ensuring that luminescence is read at 
a point where minimal fluctuation in light emission over time is observed. This is significantly different 
for a number of in vivo assays (luciferin administered intraperitoneally or subcutaneously) where peak 
luminescence was observed between 10 and 20 minutes after injection, followed by a gradual decay 
in light emission.21 Unfortunately for D-luciferin, the relatively consistent light output was in fact not 
so and decayed at fairly consistent rate post peak emission. D-Thioluciferin was evaluated in this 
respect and was found to generate a more stable light output (post luminescence burst) and had a 
longer luminescence half-life than both D-luciferin and D-aminoluciferin. This was confirmed by kinetic 
experiments where the luminescence resulting from the addition of luciferase (10 nM in enzyme 
buffer) to substrate (0.1 µM in substrate buffer) was recorded over a 20 min period. The rate in 
reduction of bioluminescence was then calculated after 1 , 5 and 20 minutes (Table 5.1).  
Table 5.1. Relative rates of reduction in luminescence 
 Rate 1 min post-
peak emission 
Rate 5 min post- 
addition 
Rate 20 minutes 
post addition 
D-Luciferin - 9.300 ± 0.9815 0.3400 ± 0.05773 
D-Aminoluciferin - 1.216 ± 0.1305 0.1510 ± 0.007506 




*Rates are measured for 15 seconds post-specified times and reported in RLU/s 
It was noted that compared to D-luciferin and aminoluciferin, D-thioluciferin had a relatively slower 
rate of luminescence decay. This is advantageous since a slower rate of decay would mean that the 
luminescent output over time fluctuates much less over the given time-period. The slower rate is 
desirable for consistency and reproducibility between experiments and also implies that 
D-thioluciferin will have a longer half-life of emission since its rate of decay is generally slower.  
Absorbance and Fluorescence Properties: 
In addition to its bioluminescence properties, the fluorescent properties of D-thioluciferin were also 
explored. The absorbance spectrum of a DMSO solution of D-thioluciferin was obtained using a UV-
Vis spectrophotometer where absorbance maxima were observed at 200, 320 and 410 nm. A 
fluorometer was then used to determine fluorescence emission and excitation maxima (at a final 
concentration of 1 mg/mL in the appropriate solvent).  
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Excitation/Emission Spectra  of D-thioluciferin


















Excitation/Emission Spectra  of D-thioluciferinvinylsulfide




















Figure 5.24. Excitation/Emission spectra of D-thioluciferin in DMSO 
Generally, absorbance/excitation was measured between 380-430 nm and emission was observed 
between 500-600 nm, depending on the wavelength of excitation. At an excitation of 520 nm a strong 
emission response with a maximum at 600 nm was observed (Figure 5.24). Furthermore, the sulfide 
of D-thioluciferin, unlike free D-thioluciferin, did not emit a strong fluorescence signal at 600 nm when 
irradiated at 520 nm. This meant that the conversion of the sulfide to the free thiol could potentially 
be monitored using fluorescence as well as bioluminescence. The emission maxima of D-thioluciferin 
and its sulfide are shown in figure 5.25.  
Emision Spectra of D-Thioluciferin and
D-Thioluciferinvinylsulfide at 360 nm




















Emision Spectra of D-Thioluciferin and
D-Thioluciferinvinylsulfide at 390 nm


















Emision Spectra of D-Thioluciferin and
D-Thioluciferinvinylsulfide at 450 nm


















Emision Spectra of D-Thioluciferin and
D-Thioluciferinvinylsulfide at 520 nm



















Figure 5.25. Emission spectra for D-thioluciferin and D-thioluciferin thioacrylate irradiated at varying 
wavelengths 
When irradiating at D-thioluciferin’s maximum absorbance, corresponding to lower wavelengths (360-
380 nm), an emission maximum at around 500 nm is observed. The emission at 500 nm is useful in 
that it is much more red-shifted relative to the excitation wavelength, whereas at longer wavelengths 
of excitation the difference between excitation and emission is smaller. This trend was in agreement 
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with that previously observed for other luciferins where the bioluminescence maxima is always more 
red-shifted that its corresponding fluorescence signal at the excitation wavelength corresponding to 
its absorbance maximum.18 
Enzyme Kinetics: 
New luciferins are often evaluated by assessing the affinity of luciferase for the new substrate. For 
single substrate reactions Michaelis-Menten kinetics are employed to determine enzyme affinity. It 
must however be noted that while Michaelis-Menten kinetics is generally employed in luciferin 
analogue evaluation, many high affinity substrates do not fit this analysis well. 














































Figure 5.26. Michaelis-Menten kinetics of D-thioluciferin. The assays were performed in triplicate and 
represented as the mean and each curve was fit to the Michaelis–Menten equation by nonlinear regression 
(GraphPad 5.0) to determine apparent Km and Vmax values  
Using a plot of initial rates, the apparent Km of D-thioluciferin was calculated, and as reference; 
D-luciferin and D-aminoluciferin. As predicted, D-thioluciferin displayed the expected increase in rate 
of emission with increasing concentration (Figure 5.26). The apparent Km was calculated at 0.1169 µM, 
which was in the same order as that previously calculated for D-aminoluciferin (0.62 µM) and related 
analogues. The Km was surprisingly much lower than that of the native substrate, D-luciferin (8.3 µM), 
despite the lower emission intensity (this again suggests that the D-thioluciferin/luciferase light 
emitting reaction may have a lower quantum yield), however, The lower Km indicates that less 
substrate is required by the enzyme to become saturated and it will thus reach its maximum velocity 
faster because of the lower Km (This however does not affect the greater light output observed for D-
luciferin). Recently, Mofford et al reported that lower Km values, coupled with increased lipophilicity, 
can improve imaging in the brain which is a known challenge with current luciferin technologies.22 The 








Table 5.2 highlights some of D-thioluciferin’s luminescence properties with amino- and D-luciferin as 
reference. D-Thioluciferin was found to have a longer bioluminescence wavelength of emission when 
treated with purified WT luc, expressed and purified from E. coli. D-Thioluciferin also displayed a much 
lower Km relative to D-aminoluciferin and D-luciferin. D-luciferin was found to have a Km = ~8 μM and 
is therefore unlikely to reach saturating conditions when used in live cells and organisms (where a Km 
of <1 μM is required).23 In this regard, D-thioluciferin (Km ~0.1 μM) may prove advantageous since less 
of it is required to saturate the enzyme. 
Table 5.2. Comparison of luciferin luminescent properties 
 
D-Luciferin D-Aminoluciferin  D-Thioluciferin 
λmax 553 nm 597 nm 599 nm 
λmax (lit.) 551 nm 594 nm - 
Vmax 57 + 13 RLU/s 
 
13 + 2.2 RLU/s 0.7597 + 0.1071 RLU/s 
Vmax (lit.) 
 
1626 + 24 photons/min24 
1.027 ± 0.036 x 10-5 RLU/s25 
169 + 2.6 photons/min24 - 
Km (App.) 8.3 + 0.5 µM 0.39 + 0.08 µM 0.1169 + 0.01163 µM  
Km (lit.) 9.15 ± 1.32 µM25-26 
16 ± 1 µM24 
14.8 ± 1.9 µM25 
7 µM27 
0.62 + 0.05 µM24 - 
Fluorescence 
emission maxima 




528 nm18 517 nm18 - 
  
The longer wavelength and lower Km are indeed promising properties, and if it is found that 
D-thioluciferin has improved bio-distribution relative to known luciferins, then it will surely be a 
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Low Molecular Weight Thiols and Glutathione Reductase  
Abstract  
Biological low molecular weight thiols (LMWTs) are involved in many different biochemical processes. 
Most organisms make use of varying strategies which involve LMWTs to regulate cellular protein and 
free thiol reduction/oxidation. These biological LMWTs and their associated enzymes have been 
reported to be upregulated as a result of oxidative stress. One such enzyme is glutathione reductase 
(GSR), which is reported to be significantly upregulated in response to various chemical stresses. 
Herein, it is demonstrated how a modified luciferin can be applied in the monitoring of glutathione 
reductase activity and, by extension, how it can be applied to imaging cellular oxidative stress. The 
technology described in this chapter centres around bioluminescence that results from disulfide 
reduction. A mixed disulfide of D-thioluciferin and the LMWT glutathione (GSH) was prepared, where 
the disulfide was demonstrated to be non-bioluminescent. When the disulfide was reduced by GSR, it 
afforded the detectable bioluminescent substrate, D-thioluciferin. The bioluminescent emission 
varied significantly depending on the amounts of disulfide substrate and GSR enzyme present. The 
thioluciferin-GSH hetero-disulfides was found to be a relatively good substrate for GSR (Km of 0.89 mM 
relative to 0.51 mM for glutathione disulfide, GSSG) and, further to that, the hetero -disulfide 
demonstrated a good correlation between its resulting luminescence signal and disulfide reduction, 
upon treatment with luciferase at increasing concentrations of GSR in a physiological buffer. 
Furthermore, GSR activity was monitored over time using the luciferin technology and the data 
obtained was found to be comparable to commonly used colorimetric GSR assays, where induced 
changes in GSR activity are observed as fluctuations in sample absorbance at 340 nm as a result of 
NADP oxidation by the GSR enzyme.  These initial studies reported here lay the groundwork for further 









Low Molecular Weight Thiols and Glutathione Reductase  
An introduction to biological low molecular weight thiols (LMWTs) 
Sulfur and Biology 
The many exceptional properties of the thiol functionality, such as its pKa, nucleophilicity, metal ion 
affinity, unique bonding characteristics, and redox properties make it a versatile functionality for 
metabolic processes.1-2 The thiol functionality present in organic compounds infer versatility and 
reactivity, it therefore comes as no surprise that many biochemical processes essential for normal cell 
functioning involve thiol-containing compounds.3 The unique chemistry of the thiol group is partially 
attributed to the many oxidation states of sulfur. Sulfur can exist in either its free thiol form, or in 
more oxidised forms, with each having different properties and reactivity. Sulfur can also act as either 
an electron donor or an electron acceptor, making the thiol moiety one of the most interesting 
functional groups, capable of partaking in a wide range of chemical or biochemical reactions.1, 3 The 
thiol functionality allows for metal binding in which the sulfur atom acts as a soft base. These sulfur-
metal interactions are essential for cellular function and research involving such interactions are well 
documented.4-6 In addition, thiols are also involved in cellular molecular recognition processes, 
electron transport, protein folding, signal transduction, and thiol-based redox homeostasis.6-8  
Low Molecular Weight Thiols 
Biological thiols are found in the form of non-protein low molecular weight thiols (LMWTs) and larger 
protein thiols. Of the many antioxidants found in the human body, LMWTs constitute the major and 
most abundant form of antioxidant.3 LMWTs play their role in cellular defense by reacting with 
reactive oxygen species (ROS) and, consequently, abnormal levels of native cellular thiols have been 
noted in various medical disorders including chronic renal failure, stroke, diabetes mellitus, alcoholic 
cirrhosis, to name a few.3, 9-10 Thus, technologies that enable the quantitation and evaluation of cellular 
thiol fluctuations and related enzymes are of great interest. 
The thiol functionality present in cellular thiol-containing compounds are known to be a central and 
adaptable site for the biochemical processes required for normal cell function.1 Most organisms 
contain a multitude of LMWTs which are involved in varying biochemical processes. As previously 
mentioned, one of the characteristics of LMWTs, and thiols in general, is that they are readily oxidised 
in the presence of oxygen and heavy metals. Consequently, the oxidation states of sulfur-containing 
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cellular components are highly regulated in order to maintain normal cellular functions. The sensitivity 
of the thiol functionality to oxidation has been known to differ significantly depending on the type of 
thiol and its molecular structure.11  
The oxidation of thiols may also directly result in the production of reactive oxygen species (ROS) as 
co-products that can be highly toxic to cells.1 Thus, most organisms make use of varying strategies to 
minimise the occurrence of undesired thiol oxidation and to mitigate its consequences.12 The use of 
small molecule thiols to buffer redox metabolism is a key strategy in regulating the redox environment 
of cells. The response of a cell to chemical stress often involves changes in the intracellular thiol 
content. Apart from their role in thiol-based redox homeostasis, LMWTs are also generally consumed 
in reactions that protect the cell as they remove harmful compounds, and are consequently replaced 
through either the reduction of disulfides or de novo synthesis.6 In some cases, changes in the 
intracellular LMW thiol content has even been used as a biomarker of cell toxicity and stress.13 It is 
therefore no surprise that research concerning the antioxidant role of LMWTs have become more 
important in health and disease. The major groups of non-protein LMWTs include cysteine-based 
compounds and histidine-based compounds. Figure 6.1 displays the structures of select examples of 
LMWTs which include; glutathione (GSH) 6.1, trypanothione (TSH) 6.2, bacillithiol (BSH) 6.3, mycothiol 
(MSH) 6.4 and coenzyme A (CoASH) 6.5. The histidine-based compounds include ergothioneine (ESH) 
6.6, and the ovothiols (OSH); ovothiol A (OSHA) 6.7, ovothiol B (OSHB) 6.8, and ovothiol C (OSHC) 6.9. 
All these reported thiols are important for normal function/survival and, in general, play a role in redox 
homeostasis.  
Most eukaryotes make use of GSH 6.1 to regulate cellular redox homeostasis. TSH 6.2 is a natural 
derivative of GSH, containing two molecules of GSH which are covalently linked via a spermidine 
linker.14-15 Both TSH and GSH play a role in the defence against oxidative stress, TSH however, unlike 
GSH, is found in parasitic protozoa, trypanosomes, known to cause sleeping sickness.15 BSH 6.3 and 
MSH 6.4 also play the same defensive role and are both considered to be substitutes for GSH in certain 
organisms, gram positive bacteria in particular. Mycobacterium tuberculosis for example, lack the 
redox protective molecule GSH and instead produce cysteine based MSH 6.4 and histidine based ESH 
6.6 as their principal LMWTs.16 In most organisms, CoASH 6.5 plays an important role in fatty acid 
metabolism. The ovothiols 6.7-6.9 are also highly reducing antioxidant thiohistidine derivatives found 
in various organisms.17-19  
 
 




Figure 6.1. Select examples of LMWTs, including; L-Cysteine, GSH 6.1, TSH 6.2, BSH 6.3, MSH 6.4, CoASH 6.5 
and L-Histidine, ESH 6.6, OSHA 6.7, OSHB 6.8, and OSHC 6.9 
Most living organisms contain high concentrations of one or more of the aforementioned LMWTs, 
which act as redox buffers to protect cells and cellular machinery against a variety of reactive chemical 
species.20 The concentration and free thiol/disulfide ratios of these different LMWTs influence the 
redox potential of the intracellular reducing environment that is essential for metabolic processes and 
stress signaling.20 Changes in cellular LMWT content are closely associated with increased oxidative 
stress and it is for that reason that technologies that enable LMWT quantitation have become so 















Humans and eukaryotes in general, make use of GSH to regulate cellular redox homeostasis and this 
particular thiol will form the focus of this Chapter. GSH is the major and most abundant antioxidant in 
humans (recorded at a cellular concentration of around 5 mM in animal cells).14 The structure of GSH 
is shown in Scheme 6.1, GSH is a tripeptide formed from a gamma peptide linkage between its 
constituent glutamate and cysteinylglycine residues. GSH prevents damage to cellular components 
caused by ROS through reductive disulfide exchanges. It was mentioned previously that thiols are 
exceptionally susceptible to oxidation. This makes them ideal reducing agents, and for that reason, a 
thiol such GSH is maintained at relatively high cellular concentrations. GSH reacts with potentially 
harmful oxidising species and forms glutathione disulfide (GSSG) in the process (Scheme 6.1). In the 
blood plasma of humans, around 15 % of GSH is found in the disulfide form GSSG. The ratio of GSH to 
GSSG within cells can be used as a measure of oxidative stress and new technologies that could 
potentially allow for the monitoring of this ratio are constantly being investigated.21-22  
 
Scheme 6.1. a) The cellular oxidation/reduction reaction of GSH/GSSG, where GSH is converted to GSSG by 
oxidants and GSSG is reduced, predominantly via an NADPH dependant reduction, to reform GSH. The levels of 
GSH and GSSG are generally conserved but fluctuations as a result of increased oxidative stress is commonly 
observed, b) demonstrates the idealised shifting of the redox equilibrium in response to oxidative stress or 
increased GSH.  
In addition to its well-established roles in cellular redox homeostasis, GSH is also known to function 
directly and/or indirectly in many other important biological phenomena, including the synthesis of 
proteins and DNA, transport, enzyme activity, metabolism, and protection of cells.23-24 GSH is also a 
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co-enzyme in various enzymatic reactions where it conjugates with foreign compounds (e.g. drugs) 
and results in their effective metabolism. Interestingly, GSH levels are strongly associated with its 
transport out of cells, where inhibition of such transporters results in drastic decreases in blood 
plasma GSH concentrations.7 The relatively high concentrations of GSH is however not purely 
attributed to its role as an antioxidant. Instead, its high concentrations presumably speak to its role as 
a storage and transport form of cysteine.25  
REDOX reactions of GSH and GSSG 
Glutathione Oxidation 
Biologically, GSH is readily converted to GSSG in presence of oxygen and specific oxidising enzymes 
whose distributions vary quite significantly depending on their locality.26 Initially, the biochemical 
conversion of GSH was purely attributed to the activity of a GSH oxidase enzyme. Such oxidase activity 
was found, to varying degrees, in the homogenate of different tissue, including kidney, epididymis, 
jejunum, choroid plexus.14 It was also discovered quite early on that not all GSH oxidations are 
controlled by GSH oxidase. In addition to the enzyme mediated oxidation, GSH is also non-
enzymatically oxidised via disulfide exchange reactions between GSH and cysteinyl-bis-glycine, or 
between GSH and any mixed disulfide for that matter. These types of oxidations were inhibited by 
EDTA and are thus considered to be mechanistically mediated by metal ions.14 It is probably worth 
noting that the spontaneous oxidation of other biological thiols, such as cysteinylglycine and cysteine 
is more rapid than that of GSH, which may further support its role as a storage compound. The rates 
of oxidation for GSH and its two precursors are as follows; cysteinylglycine > cysteine > GSH.  
Glutathione Peroxidase 
The biochemical conversion of GSH to GSSG is also achieved through the consumption of H2O2. The 
reduction of H2O2 by GSH is catalysed by the enzyme GSH peroxidase (Scheme 6.2). This enzyme is 
present in various tissue and catalyses the reduction of H2O2 by GSH to produce GSSG and, by 
extension, NADPH.   
 
Scheme 6.2. GSH peroxidase catalysed reduction of H2O2 
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This cycle constitutes the major pathway of H2O2 metabolism in cells and allows for the regulation of 
H2O2 concentrations. Thus, it protects the membrane lipids and various other cellular components 
against oxidation.  
Glutathione Reductase 
Glutathione reductase (GSR) is a widely distributed flavoprotein, which catalyses the NADPH mediated 
reduction of GSSG to GSH. The biochemical reduction is essentially irreversible and accounts for the 
very high GSH:GSSG ratios found in cells (0.9:0.1).27  Early studies suggested that the enzyme could 
exclusively catalyse the reduction of GSSG and mixed disulfides formed from GSH and 
γ-glutamylcysteine, and the mixed disulfide formed from GSH and coenzyme A.27 However, it has since 
been demonstrated that most mixed disulfides of GSH are suitable substrates for GSH reductase and, 
in some cases, are even better substrates than native GSSG. GSH reductase contains a cysteine residue 
that undergoes reduction and oxidation during the catalytic cycle and makes use of NADPH as the 
reducing agent (Scheme 6.3).   
 
Scheme 6.3. GSR catalysed reduction of GSSR to GSH 
Because of the great importance of these enzymes in regulating redox states and maintaining the 
GSH:GSSG ratios, many technologies have been developed that allow for quantitating and monitoring 
GSR, as well as GSH peroxidase activity. Generally, these technologies involve the use of GSH mixed 
disulfides, formed from GSH and alkyl/aryl thiols that can easily be detected when in the free thiol 
form.  Similarly, it was an aim of this project to prepare a complementary bioluminescent technology 
from the conjugation of D-thioluciferin and GSH. The design of the probe that would couple 
bioluminescence and GSR activity was based on a direct disulfide linkage between D-thioluciferin and 
GSH (Scheme 6.4).  




Scheme 6.4. Luciferin-GSH conjugate for monitoring GSR activity and redox flux 
Of course, for the technology to be successful, it was necessary for the disulfide to be non-
bioluminescent while also being a substrate for GSR. Based on the exploratory work discussed in 
Chapter 5, the Thioluciferin-GSH disulfide was predicted to not be a suitable substrate for luciferase 
and, therefore, the mixed disulfide would not be bioluminescent active. In addition, it was also 
predicted that the disulfide would be a substrate for GSR, since the GSR mediated reduction of various 
GSH mixed disulfides had been reported.28  
The thioluciferin-GSH conjugate would then be introduced into a sample lysate, cell line, or organism 
and, depending on the redox state and GSR concentration, some of the conjugate (or probe) would 
be reduced by GSR and potentially other reducing agents to release free D-thioluciferin, which in the 
presence of luciferase would produce a quantifiable luminescent signal which would then be used as 
a reference for a particular redox state.  
A redox state is a term used very loosely in relation to cellular oxidative stress. It is used as a general 
term referring to relative changes that are not well defined or quantitated.29 Initially it was envisioned 
that changes in GSR activity, and resultant changes in the GSH:GSSG ratio would be used as a proxy 
for redox state since many studies show that certain pathophysiological conditions result in a decrease 
in the free GSH:GSSG ratio.3, 9 Thus, in samples or areas that have increased or decreased oxidative 
stress, corresponding increased or decreased bioluminescence would be observed due to probe 
reduction. The significance of such technologies have already been established, but to further 
emphasise this, a select few examples demonstrating how protein thiol concentrations and redox 
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Thiol status in various disorders  
LMWTs in Tuberculosis  
Parasitic protozoa and bacteria are responsible for a number of diseases and it is well documented 
that LMWTs are integral for the detoxification of reactive chemical species used by the host in defense 
against infection. In response to infection from such parasitic protozoa or bacteria, a host organism 
often uses a myriad of strategies to defend against the parasite. One such strategy is the use of 
reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and hydroxyl radicals generated 
by their metabolism as a component of the host antimicrobial response.30 ROS damage membrane 
fatty acids, proteins, and DNA. However, LMWTs and their associated proteins help protect these 
pathogens against oxidative damage. By controlling their local redox environments, pathogenic 
bacteria and protozoa can limit unwanted oxidation of cellular components essential for survival. 
Thus, LMWTs and their associated redox enzymes are not only of interest for monitoring disease 
progression/regression but are also potential drug targets for drug development.  
Not only do these pathogenic organisms withstand the barrage of oxidative radicals by the immune 
system, they do so using several antioxidant and detoxification systems to cope with the hosts’ 
immune response. An example of an organism that exploits this protective mechanism is Tuberculosis.  
Tuberculosis (TB) is an infectious disease caused by the pathogenic gram positive bacterium, 
Mycobacterium tuberculosis(M. tb).31 TB remains one of the most wide spread diseases, with an 
estimated 9 million people infected annually32 and is one of the leading causes of mortality in 
developing countries. It is believed that the success of M. tb is largely attributed to its ability to persist 
in host tissue.33 One of the factors contributing to M. tb persistence is its use of the LMWT, mycothiol 
(MSH), which is involved in the protection of M. tb from toxic oxidants and antibiotics.12 Studies 
showed that MSH has significant antioxidant activity as well as the ability to detoxify a variety of toxic 
compounds. As a result, MSH is able to contribute to the protection of M. tb from inactivation by the 
host during infections and thus influences M. tb resistance to anti-tuberculosis drugs.12 In the host, 
increased oxidative tension is observed in areas affected by the pathogen, which translates to a local 
upregulated GSR concentration and a decreased GSH:GSSG ratio. Technologies that are responsive to 
changes in the oxidative state of blood plasma and cells allows for drugs to be evaluated in ways other 
than measuring their toxicity.34  
 
 
 Chapter 6: LMWTs and Glutathione Reductase 
153 
 
LMWTs in Malaria  
Malaria is yet another chronic infectious disease where the major, and most fatal form is caused by 
the protist, Plasmodium falciparum (P. falciparum). As was the case with M. tb,  
P. falciparum also makes use of LMWTs to protect against the oxidants produced by the host in 
response to infection, which may also play a role in malarial drug resistance. The principal LMWT in 
the malaria parasite is GSH. Studies show that inhibition of enzymes which regulate GSH allows cells 
to remain in an increased oxidative stressed state and consequently aids in killing the malarial 
parasite.35-36 Here, the differences in GSH and GSR activity could be used to measure the effects of 
drugs on the malarial parasite. A number of optical imaging strategies have since been developed in 
an attempt to exploit these differences.37 
LMWTs in kidney disease and diabetes 
Studies show there is a well-defined relationship between thiol redox status and kidney disease.9 This 
correlation between chronic renal failure and the presence of oxidative stress has been shown to 
result in decreased levels of free plasma thiols.38-39 This again provides an application opportunity for 
a disulfide-based sensing tool such as the GSH-luciferin conjugate. There have also been reports 
indicating decreased plasma thiol levels in patients suffering from type 2 diabetes mellitus. Similarly, 
this relationship could potentially be used as a basis to support diagnoses of diabetes and/or other 
diseases.40-41 
LMWTs in Cancer 
There are many reports that suggest that cancer cells exhibit increased oxidative stress due to ROS, 
primarily because of oncogenic stimulation and increased metabolic activity. The escalated ROS 
generation in cancer cells serves as an endogenous source of DNA-damaging agents that promote 
genetic instability and development of drug resistance.42-43 These conditions allow for cancer cells to 
be easily distinguishable from normal cells via technologies that evaluate the degree of oxidative 
stress. However, direct detection of ROS and other free radicals is often difficult because of their 
greater reactivity. Thus, oxidative damage is generally analysed by measuring secondary products such 
as lipid peroxidation and related ROS regulating enzymes. A common method for measuring changes 
in ROS is by measure of antioxidant activity. The cellular levels of ROS are controlled not only by 
LMWTs but also antioxidant enzymes. The antioxidant enzymes, superoxide dismutases (SODs), play 
critical roles in scavenging superoxide and there are many commercially available assays that measure 
SOD activity which can be used as measure for oxidative stress in a variety of samples, including; 
serum, plasma, cells, tissues and erythrocyte lysates.44-45 In addition to the antioxidant enzymes, 
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glutathione processing enzyme levels were also shown to be significantly different between cancer 
and normal cells. 
Reduced GSH and oxidised GSSG, GSR and glutathione S-transferase (GST) activities in 38 tumoral lung 
tissues and 17 normal lung tissues were determined to obtain a comprehensive profile of the lung 
glutathione and glutathione processing enzymes in cancer. These enzyme levels in tumoral tissues 
were found to be significantly higher than those in normal tissues. Reduced glutathione levels were 
found to be higher in normal tissues than those in tumoral tissues.46 Diagnostic technologies that 
exploit such differences are becoming increasingly popular, particularly in pre-clinical studies were a 
variety of assays are employed to gather biological data. It was therefore an aim of this study to enable 
similar investigations using D-thioluciferin and, as previously outlined, couple D-thioluciferin 
bioluminescence to the GSH/GSSG redox reaction and the GSR enzyme. 
GSR and Cellular Redox Potential Sensing  
There are many ways of measuring GSH and GSR activity, including colorimetric, fluorescent and 
bioluminescent assays. A popular assay kit for quantitating GSH and GST activity is commercially 
available from Promega. The GSH-Glo™ Glutathione Assay is a luminescence-based assay designed 
specifically for detecting and quantifying GSH. The assay is based on the conversion of a luciferin 
derivative, Luc-NT, into D-luciferin in the presence of glutathione, catalysed by GST. The signal 
generated in a coupled reaction with luciferase is proportional to the amount of glutathione present 
in the sample. Luminescence is generated in less than one hour and the assay reportedly generates a 
stable luminescent signal and is easily adaptable to multiwell formats such as 96- and 384-well plates. 
Cells can be grown, treated, lysed and assayed for GSH changes in the same plate. This assay was also 
used to detect and quantify GSH in various other biological samples, a scheme providing an overview 
of the assay is shown below (Scheme 6.5). 
 
Scheme 6.5. Promega Luc-NT probe for quantitively measuring GSH and oxidised GSSG in samples 
There are very few examples of D-luciferin based technologies such as GSH-Glo, where D-luciferin had 
been directly coupled to GSH and/or GSR. The GSH system is undoubtedly governed by its thiol 
functionality and, since examples of bioluminescent thiol containing luciferins were limited, it was not 
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possible to directly link a luciferin to GSH via a disulfide linkage. There are however examples of 
luciferin linkers containing a disulfide moiety. The D-luciferin molecule has been coupled to various 
molecules of interest and sometimes the coupling is done indirectly through what is referred to as a 
spacer or linker moiety. In one publication, D-luciferin was a coupled to a membrane bound 
transporter protein via an alkyl linker.47 The linker, which contained a disulfide moiety that was 
susceptible to disulfide reduction, was attached to D-luciferin via its C6-hydroxyl (Scheme 6.6).  
 
Scheme 6.6. Example of D-luciferin collapsible linker technology 
Although these molecules contained disulfides, their application focused on cell uptake rather than 
redox sensing. A publication dealing with the design, synthesis, and evaluation of conjugates of 
arginine-rich transporters and luciferin reported that the release of D-luciferin was observed only after 
entry into cells that were stably transfected with luciferase.47 The conjugates provided a method to 
assay uptake and release of free luciferin as a function of variations in the R functionality. The linker 
in this case was only required since a direct disulfide linkage could not be formed between D-luciferin 
and the peptide of interest. In contrast, a thio-analogue such as D-thioluciferin may be able to achieve 
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Aims and Objectives  
The primary aim concerned coupling bioluminescence to GSH redox to enable the quantitation of GSH 
and GSSG as well as to enable the monitoring of GSR and GSH peroxidase activity, of relevance in 
evaluating the degree and effects of oxidative stress. Based on previous work concerning synthetic 
luciferins and related derivatives, it was already well established that the 6’-thio analogue of 
D-luciferin was luminescent active and that it resulted in a more red-shifted maximum wavelength of 
emission, similar to that observed for aminoluciferin. In addition, the more homo disulfide of 
D-thioluciferin was non-luminescent active which formed the premise for the proposed luminescence-
coupled GSR mediated reduction assay (Scheme 6.7).  
 
Scheme 6.7. D-Thioluciferin luminescence 
It was demonstrated in Chapter 5 that D-thioluciferin bioluminescence was ‘turned off’ after it had 
been oxidised to its homodisulfide, which was of course a promising result for intended GSR activity 
monitoring. This meant that the mixed disulfides formed from D-thioluciferin would likely behave in 
the same way and could therefore be used to measure GSR activity, provided of course that the 
thioluciferin disulfides were substrates for GSR. Thus, the thioluciferin disulfides would have to be 
separately evaluated as substrates for both GSR and luciferase in order to successfully measure GSR 
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Scheme 6.8. demonstrates the potential use of a D-thioluciferin disulfide in the monitoring of cellular 
redox potentials. In cells, the local redox potential varies as a result of many and often interrelated 
factors. Oxidative stress, which results from increased cellular oxidants, causes a shift in the redox 
potential equilibrium which in turn would affect the ratio of the thiol/disulfide forms of D-thioluciferin 
thus resulting in differences in observed luminescence for the stressed cells relative to normal cells.   
 
Scheme 6.8. D-Thioluciferin luminescence coupled to redox equilibrium 
To lay the groundwork for D-thioluciferin redox sensing applications, D-thioluciferin bioluminescence 
would first be evaluated in the presence of GSR, GSH and GSSG. This chapter focused on the evaluation 
of the thioluciferin-GSH disulfide as a substrate of GSR and whether changes in GSR activity could be 
evaluated using the D-thioluciferin-disulfide.  
The specific objectives were thus: 
i) The synthesis and characterisation of a thioluciferin-GSH disulfide probe  
ii) The evaluation of mixed disulfide bioluminescence using purified luciferase assays 
iii) The evaluation of the prepared disulfide probe as a substrate for GSR and subsequent 
quantitation of GSR activity using the disulfide probe 
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Synthesis and Evaluation of Luciferin-Based Probes  
One of the most common methods for monitoring GSR activity in samples is a colorimetric assay that 
monitors the oxidation of NADPH to NADP+ by the GSR enzyme. The assay involves monitoring GSR 
activity via a change in absorbance at 340 nm over time. Generally, a decrease in absorbance is 
observed over time as a result of NADPH consumption/oxidation upon GSR mediated GSSG reduction. 
To couple luminescence to GSR activity, modified disulfide substrates were prepared, in the hope that 
GSR would reduce the substrates and, in doing so, release a detectable bioluminescent analyte. The 
bioluminescent signal could then be used in addition, or as an alternative to NADPH monitoring. One 
of the disadvantages of monitoring GSR by NADPH reduction concerns potential interference from 
compounds that also absorb in same region. To this end, GSSG, D-thioluciferin disulfide and GSH-
luciferin disulfide were prepared. The GSSG was prepared as a standard and means of comparison 
against the newly prepared thioluciferin-GSH disulfide.  
 GSR probe preparation  
Synthesis of homo-disulfides  
It has been demonstrated that various mixed disulfides of GSH can be reduced by GSR in the presence 
of NADPH. To evaluate the thioluciferin-GSH disulfide, a GSSG standard was first prepared from the 
perborate mediated oxidation of GSH. The homo-disulfide of D-thioluciferin was prepared similarly. 
Scheme 6.9 shows the preparation of the GSR substrates.  
 
Scheme 6.9. Synthesis of GSR homo-disulfide substrates, reagents and conditions; A) NaBO3 / CH3COOH / H2O / 
rt / 48 h (88 %), B) I2 / CHCl3 / DSMO / 0 oC / 1 h (99 %) 
The homo-disulfides of GSH was achieved using a perborate oxidation reaction, while the homo-
disulfide of D-thioluciferin was prepared using an I2 mediated oxidation. The I2 oxidation was used 
6.9 
GSSG 
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instead of perborate because of isolation challanges experienced when attempting to oxidise 
D-thioluciferin using an aqueous solution of sodium perborate. Nevertheless, both compounds were 
isolated in exceptional yields (>90 %) and were characterized using standard techniques. The disulfide 
of D-thioluciferin, like its free thiol, was unstable to storage (as revealed by TLC analysis) and was 
prepared strictly before use. The mixed disulfides proved more challenging to prepare and required 
the synthesis of an intermediate sulfide transfer reagent. 
Synthesis of GSH hetero-disulfide  
Mixed disulfides of GSH were prepared using aldrithiol mixed disulfide methodology. There are 
relatively few methods available to form unsymmetrical disuflides, and the aldrithiol method was 
chosen for two reasons, the first being that it has previously been used to prepare mixed disulfides of 
GSH and the second being that the thiopyridine formed from the substitution can be used to monitor 
disulfide reduction as it absorbs strongly at 430 nm. The GSH mixed disulfide was formed by reacting 
GSH and 2,2’-aldrithiol 6.10 to form an activated mixed disulfide 6.11. The disulfide 6.11 was 
subsequently reacted with D-thioluciferin to produce a GSH-luciferin mixed disulfide 6.12, the GSR 
probe. 
 
Scheme 6.10. Synthesis of GSR hetero-disulfide substrates. Reagents and conditions: i) DCM / MeOH / rt / 2 h 
(99 %), ii) H2O / MeOH / CH3COOH / rt / 20 min (86 %) 
The disulfides were characterised by standard techniques and were evaluated alongside the GSSG 











As a reference, the affinity of GSSG for GSR was measured using spectrophotometry and measuring 
the change in absorbance of NADPH with time. Test samples were prepared by dissolving GSSG in a 
previously prepared phosphate buffer containing NADPH. The solution was then incubated, after 
which the absorbance was recorded at 340 nm until a steady reading was observed. After a constant 
absorbance reading was achieved, the GSR enzyme was then rapidly injected into the solution and  
the change in absorbance at 340 nm was measured over a 30 min period. The results from the 
GSSG/GSR assay are shown in figure 6.2. The Rate of GSSG reduction clearly decreased with increasing 
substrate concentration. This was due to the increase in the amount of NADPH consumed in the GSR 
mediated reduction of GSSG. The rates observed were then plotted against their associated 
concentrations to determine the substrate affinity using Michaelis-Menten kinetics. The observed Km 
was 0.024 mM and was of the same order as reported Km values for GSSG (0.061 mM-0.51 mM).48-49 
Absorption spectra of NADPH at 340 nm



















Michaelis-Kinetic Plot for GSSG














Figure 6.2. a) Change in absorbance associated with NADPH oxidation measured at 340 nm and b) resultant 
Michaelis-Menten plot  
Next the thiopyridine-GSH disulfide was evaluated as a substrate. Here, the same process was 
repeated as that used for GSSG evaluation, except that instead of recording NADPH reduction at 
340 nm, an increase in 2-thiopyridine at 340 nm was measured. The release of 2-thiopyridine would 
result in a net increase in absorbance over time since thiopyridine has a much higher extinction co-
efficient at 340 nm than NADPH (7060 and 0.00622 M-1cm-1, respectively).50 Figure 6.3 displays the 
absorption spectra of thiopyridine, where a strong absorbance maximum is observed at 340 nm. 
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Figure 6.3. Absorption spectrum of 2-thiopyridine 
The change in absorbance for the reduction of the thiopyridine-GSH disulfide is shown in figure 6.4, 
where an initial linear increase in absorbance is observed over time. The different rates observed at 
varying concentrations of the GSH-thiopyridine substrate were used, as before, to determine the 
affinity of the enzyme for the substrate. The Km for the non-natural GSH-thiopyridine disulfide was 
calculated at 0.1696 mM, which was in the same order as that previously calculated for the native 
substrates. As expected, GSSG was a better substrate for GSR, however the GSH-Aldrithiol disulfide 
was still an interesting molecule since it could be used to better monitor GSR activity at 340 nm. 
Absorption spectra of 2-thiopyridine at 340 nm





















Michaelis-Kinetic Plot for GSSR













Figure 6.4. a) Change in absorbance associated with NADPH oxidation measured at 340 nm and b) resultant 
Michaelis-Menten plot. R = 2-thiopyridine 
The D-thioluciferin GSH disulfide was then evaluated. The evaluation was done using both colorimetric 
and bioluminescent readings so as to demonstrate that the disulfide was indeed a substrate for GSR 
and that the rate of reduction was comparable to GSSG. The absorbance maxima of D-thioluciferin 
were previously reported (Chapter 5) and based on that, an absorbance of 360 nm was used to 
measure thioluciferin-GSH reduction. An increase in absorbance over time as well as concentration 
dependant increases in observed rates clearly demonstrated that the thioluciferin-GSH disulfide was 
indeed a substrate for GSH reductase.  
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Absorption spectra of thioluciferin at 360 nm





















Michaelis-Kinetic Plot for GSSR













Figure 6.5. a) Change in absorbance associated with NADPH oxidation measured at 360 nm and b) resultant 
Michaelis-Menten plot. R = thioluciferin 
Furthermore, the observed Km was of the same order as those previously calculated for natural 
disulfides (0.85 mM and 0.51 mM for the thioluciferin-GSH and GSSG disulfides, respectively). The 
relatively good affinity and response meant that D-thioluciferin had potential for GSR monitoring. 
What was needed was to further evaluate whether or not the thioluciferin-GSH could be coupled to 
the light producing luciferase reaction and whether the bioluminescent emission would afford similar 
rates and Km as those observed using the calorimetric assay. Scheme 6.1 shows the intended reaction 
pathway for the thioluciferin-GSH disulfide. 
 
Scheme 6.11. GSR-luciferase coupled bioluminescence 
Prior to evaluating the thioluciferin-GSH disulfide 6.12 for GSR monitoring activity, the lack of 
bioluminescent activity had to be confirmed. Figure 6.6 shows the luminescence output for D-
thioluciferin, its homo-disulfide and the thioluciferin-GSH hetero-disulfide 6.12. Figure 6.6 shows that 
pure 6.12 in substrate buffer emitted no light. It is also demonstrated that when a 0.1 µM solution of 
6.12 was treated with luciferase in enzyme buffer a much lower emission intensity was observed 
relative to a 0.1 µM solution of D-thioluciferin treated with luciferase, supporting that the disulfide is 
not a substrate for the light emitting reaction.  
6.12 
a) b) 





















































Figure 6.6. Bioluminescence output of 0.1 µM D-thioluciferin, D-thioluciferin homo-disulfide, and thioluciferin-
GSH disulfide. The RLU were determined in triplicate and are represented as the mean ± SEM 
The homodisulfide of D-thioluciferin when treated with luciferase had a much higher luminescence 
output than the D-thioluciferin, and the luminescence that was observed for the homodisulfide was 
assumed to be as a result of DTT mediated reduction of the disulfide in solution, as discussed in 
Chapter 5. Interestingly, in the case of the thioluciferin-GSH disulfide, no significant luminescence was 
observed. This could suggest that DTT is in fact not responsible for the bioluminescence observed 
when the homodisulfide was treated luciferase, however further studies would be required to confirm 
this. After assessing the bioluminescence of the disulfide 6.12, it was next evaluated for the GSR 
monitoring assay. 
The bioluminescence resulting from the GSR mediated reduction of thioluciferin-GSH disulfide 6.12 
was recorded by pre-treating the samples with the luciferase enzyme prior to GSR addition. The 
reaction was then monitored using a luminescence plate reader and the resultant data is shown in 
figure 6.7.  
GSR activity via change in RLU








6.12+Luc 10 s post
reductase addition
6.12+Luc 5 min post
reductsae addition























Figure 6.7. Bioluminescence emission of 0.1 mM D-thioluciferin-GSH disulfide 6.12 treated with both 
10 nM luciferase in luc enzyme buffer and 0.5 unit/mL GSR in GSR buffer 
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A clear increase in the bioluminescence emission intensity was observed for the disulfide 6.12 upon 
treatment with GSR. This was a promising result since it meant that GSR addition clearly promoted a 
stronger bioluminescence emission and could therefore be used as a measure for GSR activity. What 
was also interesting was that the homodisulfide of D-thioluciferin was found to not be substrate for 
GSR as a significant change in absorbance was not observed at 340 and 360 nm upon treatment with 
GSR. This suggests that only the thioluciferin-GSH mixed disulfide can be used for the monitoring of 
GSR. It should be noted that a significant baseline emission was also observed prior to GSR addition, 
which meant that the thioluciferin-GSH disulfide itself was producing some luminescence while in 
solution with luciferase. This was not expected since a previous study, where the hetero disulfide 6.12 
was incubated with luciferase in the absence of GSR, did not produce any luminescence. That reaction 
was however carried out using a less concentrated solution of the disulfide compared to the GSR 
coupled assay (0.1 µM in the purified protein assay relative to 0.1 mM in the GSR coupled assay). The 
reason why the GSR coupled reaction was not done at a concentration where the luminescence of the 
disulfide 6.12 was previously tested was so that a better comparison could be made between the 
bioluminescent and colorimetric assays. The concentration of the disulfide was therefore maintained 
at millimolar levels during the assay since the previous GSSG and GSH-aldrithiol assays were carried 
out in this range. Despite the significant baseline luminescence, the effects of GSR addition on the 
emission intensity was still clearly demonstrated. As a precautionary measure, the baseline was also 
observed over twenty minutes where a relatively stable luminescence reading was recorded. After 
twenty minutes the baseline reading started to decrease over time which may suggest that the GSR 
coupled bioluminescence assay might be challenged where extended periods of GSR monitoring is 
required.  
Another method of monitoring GSR activity is by measuring free GSH, either indirectly via enzymes 
such GST or directly using GSH responsive detectable molecules. There are many examples of thiol 
sensing molecules and the importance of the selective detection of thiols using reaction-based probes 
and sensors in basic research and in disease diagnosis have already been highlighted. The disulfide 
probe allowed for directly coupling GSR reduction to D-thioluciferin bioluminescence, could the thiol 
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Thioacrylate Thiolate Sensing  
Previously prepared D-thioluciferin thioacrylate was predicted to be reactive in the presence of GSH 
in the same way that it reacted with D-Cys to afford free D-thioluciferin, scheme 6.12.    
 
Scheme 6.12. Proposed reaction pathway of D-thioluciferin thioacrylate  
Preliminary studies were conducted to evaluate the potential thiol sensing applications, which 
involved a spectrophotometric analysis of the reaction. First, the rate of thiolate deprotection of the 
thioacrylate 6.13 was monitored via the change in absorbance at 360 nm upon addition of various 
thiolates. Unfortunately, a clear and linear increase in the absorbance over time was not observed 
when the thioacrylate was treated with various thiols/thiolates, including; potassium thioacetate 
(KSAc), Cys and GSH (Figure 6.8). What was discovered instead was that the thioacrylate in solution, 
prior to treatment with GSH, Cys and KSAc did not produce a steady baseline reading in solutions of 









 Chapter 6: LMWTs and Glutathione Reductase 
166 
 
0.625 mM Thioacrylate and KSAc







Before addition of 0.167 mM
KSAc



















0.625 mM Thioacrylate and L-Cys








0.167 mM L-Cys and
K2CO3
10 s After addition of
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Figure 6.8. Thiolate release studies of D-thioluciferin thioacrylate 6.13 
The fluctuating baseline readings were thought to be related to the solubility of 6.13 in the 
water:DMSO/CH3CN solutions. Thus, different ratios of the organic and aqueous solvents were tested 
but proved to have little effect on achieving a steady pre-assay reading. Thiolate addition was thus 
only initiated after an eventual steady reading was recorded for at least 1 min prior to the addition. 
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After addition of the thiolate to the thioacrylate, an increase in absorbance (approximately 0.2 unit 
increase) across all samples was observed. The rate at which the absorbance increased could however 
not be determined, presumably because the reaction had gone to completion before the post-
thiol(ate) addition readings were recorded. The thiolate sensing of the D-thioluciferin thioacrylate was 
not further explored in this context but did provide some interesting results for future endeavours. 
Summary and Conclusions 
GSH detection using the thioacrylate of D-thioluciferin could provide a useful means for quantifying 
thiolates in solution, however, the stability of the thioacrylate may prove to be an issue, especially 
since the D-thioluciferin component is known to be quite unstable, particularly in basic and acidic 
media.  
The luciferase-GSR coupled assay demonstrated that the D-thioluciferin thiol functionality has the 
potential to be coupled to GSR monitoring and perhaps redox reactions in general. The disulfide was 
demonstrated to be a suitable substrate for GSR and, moreover, it was demonstrated that GSR activity 
could be determined using thioluciferin bioluminescence, in the same way that GSR activity was 
determined using the absorbance of NADPH at 340 nm. Further investigations relating to the 
differences in limits of detection between the colorimetric and bioluminescent assays should still be 
explored, since the sensitivity of bioluminescence assays are known to be greater than their non-
bioluminescent counterparts. It is well established that monitoring the change in NADPH absorbance 
to provide a measure of GSR activity is extremely limited in terms of in vivo and cell-extract based 
applications. These limitations might be overcome through the use of a D-thioluciferin 
bioluminescence assay alternative, whose bioluminescence signal is easily distinguishable and is not 
affected by the presence of other biological components. 
Based on these preliminary studies, there is strong evidence that the D-thioluciferin molecule could 
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Conclusions and Future Work 
 
Conclusions 
D-luciferin and the non-natural C6-amino analogue, D-aminoluciferin, were successfully prepared in 
overall yields of 12 % and 20 %, respectively. Their spectroscopic and relative bioluminescent 
properties were found to be in good agreement with previously reported data. 
In both instances, the 2-cyanobenzothiazole scaffold was identified as a key intermediate for luciferin 
preparation. The C2-nitrile moiety of the benzothiazole scaffold was used to construct the thiazole 
carboxylic acid component of D-luciferin upon reaction of the nitrile with D-Cys. This particular 
reaction was highly efficient and produced the resultant luciferin quantitively. As a result of the high 
yield and generally good stereospecificity, most reported synthesis of D-luciferin and related 
analogues make use of a key 2-cyanobenzothiazole intermediate. However, these syntheses, despite 
their common target, differ significantly in how the 2-cyanobenzothiazole scaffold is prepared. For 
most reported syntheses, the 2-cyanobenzothiazole is formed in poor yield and over multiple 
functionalisation steps. 
For the synthesis of D-luciferin and D-aminoluciferin, the 2-cyanobenzothiazole forming 
palladium-mediated cyclisation, a reaction common to both luciferin syntheses, was found to be 
limiting and was the main contributor to the poor overall yields. Since both these compounds were 
highly sought after for various bioluminescence applications, an investigation into further optimising 
as well exploring other methods of preparation was undertaken. A number of different methods were 
attempted to increase the efficacy of the palladium C-S coupling reaction. These included, among 
others, exploring the use of different palladium catalysts, reverting to a classical thermolytic 
electrocyclisation reaction, and exploring the effects of ortho-bromination on the thioanilide 
cyclisation.   Ultimately, ortho-bromination of the starting anilide lead to a successful cyclisation and 
afforded the cyclised products in generally improved yields (60-85 %) and was demonstrated to have 
better functional group tolerability with respect to the C6-substituent. An unrelated route involving a 
C6-iodo functional group on the benzothiazole was also explored as an alternative intermediate, which 
unlocked new possibilities for method improvement.  
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After reaction optimisation and method development, attention was turned to the preparation of new 
C6-analogues of D-luciferin. With both the 6’-hydroxy and 6’-amino luciferins in hand, the obvious 
target became a 6’-thio analogue. Synthesis of the thio-analogue proved challenging, but it was 
eventually prepared using a synthetic route based on a thiol-protecting group strategy. The thio-
analogue, D-thioluciferin, was successfully synthesised over six steps (34 % yield) using an 
unconventional thioacrylate protecting group. The new luminogenic substrate displayed a lower Km 
(0.1 µM relative to the 8 µM of D-luciferin) and a more red-shifted maximum emission (λmax 600 nm 
compared to the 557 nm of D-luciferin), but with a much lower luminescent output (100-fold less) 
relative to D-luciferin.  
After preparing and evaluating the bioluminescence of the novel C6-thio analogue, its thiol 
functionality was exploited to produce a disulfide probe/sensor for GSR activity. First, a mixed disulfide 
of D-thioluciferin and GSH was prepared and evaluated as a substrate for the enzyme luciferase, since 
it was important that the disulfide probe be non-luminescent active until reduced. The results from 
that study demonstrated that the disulfide was indeed non-bioluminescent in the presence of the 
luciferase enzyme. Thereafter, the disulfide was shown to be a relatively good substrate for GSR (Km 
of 0.85 mM relative to a Km of 0.51 mM for GSSG) which meant that D-thioluciferin bioluminescence 
could indeed be coupled to GSR monitoring. A bioluminescence assay of GSR activity was then carried 
out and was shown to be a viable method of GSR monitoring.  
In addition to monitoring GSR activity, D-thioluciferin was also evaluated for thiol/thiolate sensing. 
The protected thioacrylate was shown to react with thiols in basic media to produce D-thioluciferin.  
 
Scheme 7.1. Mechanism of thiolate-mediated D-thioluciferin release  
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However, the rate at which the reaction occurred was relatively fast and did not allow for 
differentiation of various thiols/thiolates based on their relative reaction rates. Despite this, the 
acrylate is still an exciting prospect for thiol sensing and should be explored further. 
Future Work 
After D-aminoluciferin was introduced to the research community, an exponential increase in luciferin 
application-based research was observed. This was, in part, due to the C6-amino handle that 
D-aminoluciferin provided. The thiol functionality should be viewed similarly, as it too provides a 
unique chemical handle that might allow D-thioluciferin to be applied in areas relatively untouched by 
its bioluminescent predecessors. This relates specifically to the monitoring of biological thiols and their 
processing enzymes. 
The groundwork for such applications have been explored here but still does not cover any in vivo 
testing of the thio-analogues. The cellular uptake, localisation, distribution and stability in biological 
media should be further explored. It has already been demonstrated here how the oxidation state of 
the C6-thiol moiety of D-thioluciferin governs the molecule’s ability to produce light with the luciferase 
enzyme. What should be explored next is whether the thiol functionality is responsive to changes in 
redox states within cells and whether those changes can be observed through bioluminescence.  
In cells, abnormal changes in redox equilibria or cellular redox potentials are observed as a result of 
increased oxidative stress, which in turn affect biological free thiol/disulfide ratios. These changes in 
redox states are often directly linked to certain diseases and it would be interesting to evaluate 
whether such redox state changes could be observed using the thioluciferin molecule. 
As an example, this could be done by evaluating differences in bioluminescence emission between a 
luciferase expressing cancer cell line and a healthy luciferase expressing cell line. Another potential 
study could involve plant stress monitoring.  The thioluciferin-GSH probe could be tested in the 
evaluation of the degree of stress induced by dehydration in luciferase expressing plants. Where 
dehydrated plants are treated with the thioluciferin-GSH probe alongside plants that have not been 
dehydrated to evaluate differences in their cellular redox states based on observed differences in 
bioluminescence. Such differences in bioluminescence could then be used as part of a measure of how 
well plants cope with dehydration and hence as a method of screening for drought resistance among 
mutant plants. 
Future work concerning LMWTs and their conjugation to the D-thioluciferin molecule should also be 
considered. Other LMWT mixed disulfides of D-thioluciferin should be explored for potential 
 Chapter 7: Conclusions and Future work 
175 
 
reductase monitoring, for example, a thioluciferin-MSH disulfide could in theory be used to monitor 
mycothione reductase activity, just as how the thioluciferin-GSH conjugate was used to measure GSR 
activity. MSH is of course a LMWT found in M. tb and is, in part, responsible for the protection of M. tb 
from oxidants. Studies show that MSH and mycothione reductase are upregulated in response to 
oxidative stress. Their concentration and activity could therefore be used for bioluminescence imaging 
and as a measure of drug efficacy.  
In terms of the synthesis of the luciferin molecules, there are a number of investigations that should 
be undertaken to further improve the one-pot metal free DBU methodology. The priority would 
probably be to replace DBU with another base that could be more easily removed from the reaction 
mixture, while still retaining the ability to fragment and cyclise the dithiazole. The excessive amounts 
of DBU required for the transformation is definitely one of the biggest disadvantages of the method. 
There are publications that report on the use of phosphine reagents that are able to fragment 
dithiazoles, however, based on the mechanism, they most likely would not be able to bring about 
cyclisation at room temperature.  It might therefore be of interest to explore the joint use of both an 
amidine base and a phosphine additive or, alternatively, a reagent that has both a basic nitrogen and 
phosphine functionality. Another interesting approach could be to immobilize a recyclable amidine 
base onto a solid support for a simpler purification. 
Recently, there have been far more publications concerning the applications and bioluminescent 
properties of D-luciferin derivatives than publications relating to improved methods of luciferin 
preparation. However, both are required for sustainable D-luciferin research within a 
chemistry/chemical biology context. 
Thus, improvements in both the synthesis and properties of these very important research molecules 















General procedures  
All reactions were carried out in oven-dried glassware under an inert nitrogen atmosphere, unless 
otherwise stated. Reagents were obtained from commercial sources (Sigma–Aldrich, Merck) and used 
as received unless otherwise stated. Solvents were evaporated under reduced pressure at 40 °C using 
a Buchi Rotavapor, unless otherwise stated. Reaction temperatures were achieved with heat/silicone 
oil (for > 25 ⁰C), ice/NH4Cl salt (for 0 °C), and acetone/liquid nitrogen (< -20 °C). Aqueous solutions 
were prepared using distilled water. All reactions were monitored by TLC using aluminium-backed 
Merck silica-gel 60 F254 plates, and compounds were visualised on TLC under a UV-lamp and/or were 
sprayed with a 2.5 % solution of p-anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v), 
iodine vapour, or ceric ammonium sulfate solution and then heated using a 1600 W heat gun. Normal 
phase column chromatography was carried out using silica-gel (Fluka Silica Gel 60, 40-63 microns) and 
compounds eluted with the appropriate solvent mixtures. Reverse phase chromatography was 
effected by using a Biotage KP-C-18-HS and compounds were eluted with millipore water and AR 
methanol (gradient from water to a mixture of water/MeOH), unless otherwise stated. All compounds 
were dried under vacuum before yields were determined and spectroscopic analyses performed. 
Purity was determined using an analytical Agilant HPLC 1260 equipped with an Agilent infinity diode 
array detector (DAD) 1260 UV-Vis detector, with an absorption wavelength range of 210 - 640 nm. 
The compounds were eluted using a mixture of 10 mM NH4OAc/H2O and 10 mM NH4OAc/MeOH at a 
flow rate of 0.9 mL.min−1 (10 % NH4OAc/MeOH between 0 and 1 min, 10 - 95 % NH4OAc/MeOH 
between 1 and 3 min, 95 % NH4OAc/MeOH between 3 and 5 min). 
Nuclear Magnetic Resonance (NMR) spectra (1H and 13C) were recorded on either a Bruker XR400 MHz 
spectrometer (1H at 400.0 MHz and 13C at 100.6 MHz), Varian Mercury XR400 MHz spectrometer (1H 
at 400.0 MHz and 13C at 100.6 MHz), a Varian Mercury XR300 MHz spectrometer (1H at 300.1 MHz and 
13C at 75 MHz) or a Bruker unity spectrometer (1H at 600 MHz and 13C at 151 MHz) and were carried 
out in CDCl3, DMSO-d6 and D2O as the solvents, unless otherwise stated. Chemical shifts (δ) and J-
coupling values were reported in units of ppm and Hz respectively. Chemical shifts for 1H and 13C were 
recorded using tetramethylsilane (TMS) as the internal standard. Assignments were confirmed by 
COSY, APT and HSQC analysis, when required. 
Elemental analyses were performed using a Fisons EA 1108 CHNS elemental analyser. Infrared (IR) 
spectroscopy was performed on a Bruker FT-IR Spectrometer with vibrations measured in units of  
 Chapter 8: Experimental 
177 
 
cm-1. Melting points were obtained using a Reichert-Jung Thermovar hot stage microscope (HSM) and 
are uncorrected. Optical rotations were obtained using a Perkin Elmer 141 polarimeter at 20 °C. The 
concentration c refers to g/100 mL. UV-Vis studies were conducted on UV-Vis spectrophotometer 
Agilent technology Cary 60 and the spectrums were processed using Scan Application version 5.0.0.99. 
Mass Spectrometry (MS) determinations were carried out using electron impact (EI) on a JOEL GC 
Matell instrument. LCMS analyses were carried out with a UHPLC Agilent 1290 Infinity Series 
(Germany), accurate mass spectrometer Agilent 6530 Quadrupole Time Of Flight (QTOF) equipped 
with an Agilent jet stream ionisation source (positive ionization mode) (ESI+) and column (Eclipse + 
C18 RRHD 1.8 μm.2.1 X 50, Agilent, Germany). All UV-vis spectra were recorded with a Varian Cary 
100 spectrophotometer or a Shimadzu UV 1800 Probe at constant temperature by attachment of the 
cell chamber to an external water bath. Hellma, Suprasil® quartz cuvettes of 1 and 10 mm pathlength 
in varied volume capacity were used for all measurements. A Varian Cary Eclipse fluorometer 
equipped with a regulated temperature cell holder was used to perform all steady-state fluorescence 
measurements. Hellma, Suprasil® quartz fluorescence cuvettes of 10 mm pathlength and 1.5 mL 
volume capacity were used for all measurements. 
Bioluminescence evaluation using purified protein (luciferase from Photinus Pyralis, Sigma-Aldrich) 
were performed using a Luminoskan Ascent at a final enzyme concentration of 10 nM and final 
substrate concentrations ranging from 0.1 to 100 µM. Data acquisition and analyses were performed 
with Ascent Software version 2.6 (detector range 270-670 nm, detecting at 545 nm). Bioluminescence 
imaging of transgenic luciferase expressing N. Tabacum plant leaves were carried out with a 3D-
luminometer consisting of a 0.5 square inch CCD camera and a field of view of 12.5 cm (Xenogen IVIS 
Lumina, Caliper, USA) at an exposure time of 300 s per leaf. Photon or count emission by luciferase 
expressing leaves was quantified using the Living Image software (Caliper, USA). The GFP assay was 
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Synthetic procedures   
The numbering scheme given for each compound is for assignment purposes only and not necessarily 
consistent with the IUPAC naming convention. 
Synthesis of D-luciferin1  
4,5-Dichloro-1,2,3-dithiazol-1-ium chloride2 
 
   
Sulfur monochloride (13 mL, 158 mmol, 5 eq) was added to a solution of chloroacetonitrile (2 mL, 
31.6 mmol, 1 eq) in anhydrous DCM (15 mL) in an oven-dried flask equipped with a gas outlet. 
Thereafter, the reaction mixture was swirled for a few seconds and then left to stand, without further 
agitation, for 24 h at room temperature under a nitrogen atmosphere. The resulting brown precipitate 
that had formed was filtered under vacuum, and washed copiously with DCM (3 x 200 mL) to afford 
Appel’s salt as a green solid (5.30 g, 80 %). Mp: 117-130 oC. MS (ESI+): m/z Calculated for C2Cl3NS2 







Appel’s salt 1 (3.39 g, 16.3 mmol, 1 eq) and p-anisidine (2.00 g, 16.3 mmol, 1 eq) were suspended in 
anhydrous DCM (30 mL). The resulting mixture was stirred at room temperature under a nitrogen 
atmosphere for 1 h. Thereafter, anhydrous pyridine (2.62 mL, 32.5 mmol, 2 eq) was slowly added to 
the suspension and the resulting red brown mixture was allowed to stir for an additional 2 h. The 
mixture was then concentrated in vacuo and purified using silica column chromatography, eluting with 
hexanes, to afford the dithiazole adduct as a yellow solid (2.72 g, 65 %). Mp: 87-88 oC (lit. 89 oC).3 1H-
NMR (300 MHz, CDCl3) δ 7.28 (2H, d, J = 8.9 Hz, H-4), 6.99 (2H, d, J = 8.9 Hz, H-5),  3.85 (3H, s, H-7) 
ppm. 13C-NMR (100.6 MHz, CDCl3) δ 158.1 (C-6), 156.9 (C-2), 147.8 (C-1), 143.3 (C-3), 122.1 (C-5), 115.4 









                         
 
 
DBU (1.12 mL, 7.72 mmol, 4 eq) was added dropwise to a 5 oC solution of N-[(5Z)-4-chloro-5H-1,2,3-
dithiazol-5-ylidene]-4-methoxyaniline 2.22 (0.50 g, 1.93 mmol, 1 eq) in anhydrous DCM (10 mL) under 
a nitrogen atmosphere. The resulting red brown mixture was stirred and maintained below 5 oC for 
30 min, after which it was allowed to warm to room temperature. The reaction mixture was then 
washed with saturated NH4Claq (3 x 10 mL), H2O (1 x 10 mL), and brine (1 x 10 mL). The organic phase 
was dried over Na2SO4 and concentrated in vacuo. The crude material was purified by column 
chromatography, eluting with 3:7 EtOAc:Hexane to provide the title compound as a red solid (0.27 g, 
73 %). Mp: 118-121 oC (lit. 118-119 oC).4 Thione; 1H-NMR (400 MHz, CDCl3) δ 9.79 (1H, br s, -NH-), 7.65 
(2H, d, J = 8.0 Hz, H-4), 6.87 (2H, m, H-5), 3.76 (3H, s, H-7) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 160.2 
(C-2), 158.7 (C-6), 131.4 (C-3), 124.8 (C-4), 114.6 (C-5), 113.2 (C-1), 55.9 (C-7) ppm. Thioenol; 1H-NMR 
(400 MHz, CDCl3) δ 9.52 (1H, br s, -SH), 7.23 (2H, d, J = 8.0 Hz, H-4’), 6.87 (2H, m, H-5), 3.76 (3H, s, 
H-7) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 164.9 (C-2’), 159.5 (C-6’), 131.6 (C-3’), 125.5 (C-4’), 122.0 






Palladium chloride (7.00 mg, 0.0350 mmol, 0.1 eq), copper iodide (33.0 mg, 0.174 mmol, 0.5 eq), TBAB 
(223 mg, 0.694 mmol, 2 eq) and 1-[(cyanocarbothioyl)amino]-4-methoxybenzene 2.23 (100 mg, 
0.347 mmol, 1 eq) were suspended in anhydrous 1:1 DMF:DMSO (2 mL). The resultant red brown 
mixture was placed under an inert nitrogen atmosphere and stirred vigorously at 120 oC for 3 h. The 
reaction mixture was cooled to room temperature and thereafter diluted with EtOAc (12 mL) and 
washed with H2O (4 x 10 mL). The organic layer was then dried over Na2SO4, filtered, and concentrated 
in vacuo. The crude material was further purified by column chromatography using 1:9 EtOAc:Hexane 
to provide the title compound as a pale yellow solid (9.00 mg, 14 %). Mp: 126-130 oC (lit. 129-131 oC).5 
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9.1, 2.4 Hz, H-5), 3.93 (3H, s, H-9) ppm. 13C-NMR (400 MHz, DMSO) δ 160.4 (C-2), 146.7 (C-6), 138.3 
(C-3), 134.1 (C-8), 125.8 (C-7), 119.1 (C-5), 114.1 (C-1), 106.0 (C-4), 56.52 (C-9) ppm. IR νmax (NaCl) / 





Pyridine hydrochloride (1.18 g, 10.2 mmol, 10 eq) and 6-methoxy-2-cyanobenzothiazole 2.8 (0.195 g, 
1.02 mmol, 1 eq) were combined in a rigorously dried sealed tube, purged and placed under an inert 
nitrogen atmosphere. The reaction mixture was then stirred at 180 oC for 1 h. The resulting red-brown 
residue was cooled to room temperature and then dissolved in EtOAc (20 mL) and washed with 
saturated NaHCO3 (1 x 20 mL), 1M HCl (1 x 10 mL), H2O (4 x 10 mL), and brine (1 x 10 mL). The organic 
layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified using 
column chromatography eluting with 3:7 EtOAc:Hexane to yield 2-cyano-6-hydroxybenzothiazole as a 
pale yellow solid (0.177 g, 98 %). Mp: 202-207 oC (lit. 205-207 oC).5-6 1H-NMR (400 MHz, DMSO) δ 10.51 
(1H, br s, -OH), 7.89 (1H, d, J = 9.0 Hz, H-4), 7.60 (1H, d, J = 2.4 Hz, H-7), 7.19 (1H, dd, J = 9.1, 2.4 Hz, H-
5) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 160.4 (C-2), 147.4 (C-6), 139.1 (C-3), 134.0 (C-8), 126.8 (C-7), 
119.8 (C-5), 114.4 (C-1), 107.5 (C-4) ppm. IR νmax (NaCl) / cm-1): 3430 (-OH), 2259 (-CN). MS (ESI+): m/z 






D-Cysteine hydrochloride monohydrate (30.0 mg, 0.171 mmol, 1.04 eq) and 2-cyano-6-hydroxy-
benzothiazole 2.9 (29.0 mg, 0.163 mmol, 1 eq) were dissolved in 2:1 MeOH:H2O (1 mL). The resulting 
solution was allowed to stir at room temperature for 5 min under a nitrogen atmosphere, after which 
potassium carbonate (23.0 mg, 0.164 mmol 1.01 eq) was added. The resulting bright yellow-green 
solution was allowed to stir for an additional 20 min, at room temperature, while maintaining the inert 
atmosphere. Upon consumption of 2-cyano-6-hydroxybenzothiazole, as evidenced by TLC analysis, 
the methanol was removed in vacuo and the remaining aqueous solution cooled to 0 oC and acidified 
2.9 
2 
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to pH 3 with 3 M HCl. The aqueous layer was then extracted with EtOAc (5 x 10 mL) and the combined 
organics were dried over Na2SO4, filtered, concentrated in vacuo and purified with column 
chromatography 3:6:1 DCM:EtOAc:MeOH to provide D-luciferin as a pale yellow solid (39.0 mg, 86 %). 
[α]𝟐𝟎
𝑫 obs
 = -29o, DMF, c = 1  ([α]20
𝐷 lit.
 = -34o, DMF, c = 1).7 Mp: 197-199 oC (lit. 196 oC).7 1H-NMR (400 MHz, 
MeOD) δ 7.93 (1H, d, J = 8.9 Hz, H-7), 7.35 (1H, d, J = 2.3 Hz, H-10), 7.10 (1H, dd, J = 8.9, 2.3 Hz, H-8), 
5.40 (1H, app t, J = 9.0 Hz, H-2), 3.79 (2H, m, H-3) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 172.1 (C-1), 
166.2 (C-4), 157.6 (C-9), 157.1 (C-5), 146.8 (C-6), 137.7 (C-11), 124.5 (C-7), 116.8 (C-10), 105.9 (C-8), 
78.2 (C-2), 34.5 (C-3) ppm. HRMS (ESI+): m/z Calculated for C11H8N2O3S2 [M+Na] 302.9874, found 
302.9868. 
 






Appel’s salt 2.25 (0.17 g, 0.80 mmol, 1.1 eq) and p-nitroaniline (0.10 g, 0.72 mmol, 1 eq) were 
suspended in anhydrous DCM (2 mL). The resulting mixture was allowed to stir at room temperature 
under a nitrogen atmosphere for 1.5 h. Thereafter, anhydrous pyridine (0.14 mL, 1.81 mmol, 2.5 eq) 
was added dropwise to the suspension, and the resulting red brown mixture was allowed to stir for 
an additional 2 h. The mixture was then concentrated in vacuo and purified by column 
chromatography, eluting with 1:9 EtOAc:hexane, to afford N-[(5Z)-4-chloro-5H-1,2,3-dithiazol-5-
ylidene]-4-nitroaniline as a yellow solid (0.101 g, 50 %). Mp: 161-165 oC (lit. 160 oC).10 1H-NMR 
(400 MHz, DMSO) δ 8.37 (2H, d, J = 12.0 Hz, H-5), 7.42 (2H, d, J = 12.0 Hz, H-4) ppm. 13C-NMR 
(100.6 MHz, DMSO) δ 162.9 (C-2), 157.5 (C-1), 147.0 (C-6), 145.0 (C-3), 126.5 (C-5), 120.8 (C4) ppm. 

















DBU (0.18 mL, 1.10 mmol, 3 eq) was added dropwise to a 5 oC solution of N-[(5Z)-4-chloro-5H-1,2,3-
dithiazol-5-ylidene]-4-nitroaniline 3.20 (0.100 g, 0.37 mmol, 1 eq) in anhydrous DCM (1.5 mL) under a 
nitrogen atmosphere. The resulting red-brown mixture was stirred and maintained below 5 oC for 
30 min, it was then allowed to warm to room temperature, after which it was left to stir for a further 
30 min, all under a nitrogen atmosphere. The reaction mixture was then washed with saturated 
NH4Claq (2 x 2 mL), H2O (1 x 2 mL), and brine (1 x 10 mL). The organic phase was dried over Na2SO4 and 
concentrated in vacuo. The crude material was purified by silica gel column chromatography, eluting 
with 4:6 EtOAc:Hexane to provide the title compound as a red-orange solid (0.270 g, 73 %). Mp: 122-
130 oC (lit. 128-130 oC).11 1H-NMR (400 MHz, CDCl3) δ 8.35 (2H, d, J = 9.3 Hz, H-4), 8.18 (2H, d, J = 
9.2 Hz, H-5). 13C-NMR (100.6 MHz, DMSO) δ 163.4 (C-2), 145.6 (C-3), 143.8 (C-6), 125.3 (C-5), 123.6 (C-





Palladium chloride (10.0 mg, 0.0590 mmol, 0.1 eq), copper iodide (56.0 mg, 0.295 mmol, 0.5 eq), TBAB 
(0.380 g, 1.18 mmol, 2 eq), and 1-[(cyanocarbothioyl)amino]-4-nitrobenzene 3.12 (0.123 g, 0.590 
mmol, 1 eq) were suspended in anhydrous 1:1 DMF:DMSO (2 mL). The resultant red-brown mixture 
was placed under an inert nitrogen atmosphere and heated at 120 oC for 3 h. The reaction was then 
allowed to cool to room temperature, diluted with EtOAc (12 mL) and washed with H2O (4 x 10 mL). 
The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. The crude product 
was purified by column chromatography 1:9 EtOAc:Hexane to provide 2-cyano-6-nitrobenzothiazole 
as a light yellow solid (25.4 mg, 21 %). Mp: 118-119 oC. 1H-NMR (400 MHz, CDCl3) δ 8.97 (1H, dd, J = 
2.2, 0.5 Hz, H-7), 8.55 (1H, dd, J = 9.6, 1.4 Hz, H-5), 8.42 (1H, dd, J = 9.1, 1.4 Hz, H-4) ppm. 13C-NMR 
(100.6 MHz, CDCl3) δ 155.3 (C-2), 147.3 (C-6), 141.8 (C-3), 135.6 (C-8), 126.1 (C-5), 123.0 (C-4), 118.6 
(C-7), 114.0 (C-1) ppm. FT-IR (ATR) νmax /  cm-1: 2217 (-CN). MS (ESI+): m/z Calculated for C8H3N3O2S 










Method A: 2-Cyano-6-nitrobenzothiazole 3.13 (0.100 g, 0.490 mmol, 1 eq) was dissolved in EtOH (5 
mL). SnCl2 (0.322 g, 1.30 mmol, 2.5 eq) was then added and the reaction mixture was heated to 60 °C 
under a nitrogen atmosphere and allowed to stir for 2 h. The reaction mixture was then cooled to 
room temperature and poured into chilled water (5 ml and the pH adjusted to pH 7 using NaHCO3. 
The resulting aqueous solution was extracted with EtOAc (5 x 2 mL), dried over MgSO4 and excess 
solvent removed in vacuo. The crude material was further purified by silica column chromatography 
4:6 EtOAc:Hexane to afford the amine as an orange solid (56.0 mg, 65 %).  
Method B: 2-Cyano-6-nitrobenzothiazole 3.13 (66.0 mg, 0.323 mmol, 1 eq) and ammonium chloride  
(170 mg, 3.23 mmol, 10 eq) were suspended in freshly distilled MeOH (3 mL) and allowed to stir for 
5 min at room temperature under a nitrogen atmosphere. Thereafter, Zn powder (0.420 g, 6.45 mmol, 
20 eq) was added and the resultant reaction was left to stir vigorously for a further 30 min. The 
reaction mixture was then filtered through Celite and the filtrate reduced in vacuo. The residue 
obtained was purified by silica column chromatography using 1:1 EtOAc:Hexane to afford the title 
compound as an orange solid (56.2 mg, 99 %). Mp: 136-140 oC.  1H-NMR (400 MHz, CDCl3) δ 7.87 (1H, 
d, J = 8.9 Hz, H-4), 7.13 (1H, d, J = 2.0 Hz, H-7), 6.98 (1H, dd, J = 9.0, 2.2 Hz, H-5), 6.10 (2H, br s, -NH2) 
ppm. 13C-NMR (100.6 MHz, CDCl3) δ 153.8 (C-2), 143.76 (C-3), 138.9 (C-6), 128.29 (C-8), 125.6 (C-5), 
117.9 (C-4), 114.7 (C-1), 102.7 (C-7) ppm. FT-IR (ATR) νmax /  cm-1: 3684 (-NH2), 2254 (-CN). MS (ESI+): 
m/z Calculated for C8H5N3S [M+H] 176.0282, found 176.0115. 
 
Potassium (S)-2-(6-aminobenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylate  
 
 
D-Cysteine hydrochloride monohydrate (81.2 mg, 0.462 mmol, 1.1 eq) and 6-amino-cyano-
benzothiazole 3.7 (71.0 mg, 0.405 mmol, 1 eq) were dissolved in 2:1 MeOH:H2O (1 mL). The resulting 
solution was allowed to stir at room temperature for 5 min under a nitrogen atmosphere, after which 
potassium carbonate (56.5 mg, 0.409 mmol, 1.01 eq) was added. The resulting bright yellow-green 
solution was allowed to stir for an additional 40 min, while maintaining an inert atmosphere. Upon 
3.7 
3.1a 
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consumption of 6-amino-cyanobenzothiazole, as evidenced by TLC analysis, the reaction mixture was 
diluted with water (4 mL) and washed with EtOAc (1 x 4 mL). The aqueous was then reduced and the 
resulting precipitate was filtered and washed with cold MeOH (2 x 1 mL). The precipitate was then 
further purified using reverse phase chromatography eluting with a gradient of 0-90 % MeOH in water 
to afford D-aminoluciferin potassium salt as a pale yellow solid (0.123 g, 96 %). [α]𝟐𝟎
𝑫 obs
: -14o (H2O, c = 
1). Mp: 111-123 oC. 1H-NMR (400 MHz, D2O) δ 8.32 (1H, d, J = 8.8 Hz, H-7), 7.79 (1H, s, H-10), 7.55 (1H, 
d, J = 8.0 Hz, H-8), 5.72 (1H, m, H-2), 3.8-4.2 (2H, m, H-3). HRMS (ESI+): m/z Calculated for C11H9N3O2S2K 
[M+H] 317.9773, found 317.9768. 
 
(S)-2-(6-aminobenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid  
 
 
D-Aminoluciferin potassium salt 3.1a (30.0 mg, 0.0950 mmol) was dissolved in water (1 mL). The 
solution was then cooled to 0 oC and acidified to pH 4 with 1 M HCl. The aqueous solution was then 
extracted with EtOAc (4 x 1 mL) and the organic extracts were combined, washed with brine (1 x 1 
mL), dried over MgSO4, filtered through Celite and concentrated in vacuo to afford the acid as a light 
yellow solid (10.0 mg, 37 %). 1H-NMR (400 MHz, DMSO) δ 7.73 (1H, d, J = 8.8 Hz, H-7), 7.07 (1H, d, J = 
2.2 Hz, H-10), 6.84 (1H, dd, J = 8.8, 2.2 Hz, H-8), 5.70 (2H, s, -NH2), 4.93 (1H, app t, J = 8.4 Hz, H-2), 
3.68-3.49 (2H, m, H-3) ppm. 13C-NMR (100.6 MHz, DMSO) δ 178.1 (C-1), 163.2 (C-4), 160.5 (C-5), 146.6 
(C-6), 144.1 (C-11), 135.9 (C-9), 124.2 (C-7), 114.5 (C-10), 103.9 (C-8), 81.8 (C-2), 34.5 (C-3) ppm. HRMS 
(ESI+): m/z Calculated for C11H9N3O2S2 [M+K] 317.9768, found 317.9768. 
 
Synthesis of D-thioluciferin  
3-((4-Aminophenyl)thio)acrylic acid  
 
 
Propiolic acid (60.0 mg, 0.810 mmol, 1.05 eq) and p-aminothiophenol (100 mg, 0.800 mmol, 1 eq) 
were stirred in anhydrous DMF (1 mL) at room temperature under a nitrogen atmosphere for 24 h. 
The resulting red-brown solution was diluted with EtOAc (10 mL), washed with brine (4 x 10 mL), dried 
over MgSO4 and then reduced in vacuo. The crude material was then further purified by silica column 
3.1b 
5.16 
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chromatography 3:7 EtOAc:Pet. ether to afford the title compound, a pale yellow solid, as a 1:9 
mixture of E:Z isomers (47.0 mg, 30 % yield). Mp: 113-207 oC. E-isomer; 1H-NMR (400 MHz, CDCl3) δ 
12.0 (1H, br s, -COOH), 7.67 (1H, d, J = 14.8 Hz, H-6), 7.14 (2H, d, J = 8.5 Hz, H-3), 6.65 (2H, d, J = 8.5 Hz, 
H-2), 5.95 – 5.39 (2H, br s, -NH2), 5.26 (1H, d, J = 14.8 Hz, H-5). 13C-NMR (100.6 MHz, CDCl3) δ 166.1 
(C-7), 150.1 (C-5), 149.6 (C-1), 135.8 (C-4), 115.3 (C-6), 114.8 (C-3), 112.2 (C-2) ppm. Z-isomer; 1H-NMR 
(400 MHz, CDCl3) δ 12.0 (1H, br s, -COOH), 7.26 (1H, d, J = 10.0 Hz, H-6), 7.14 (2H, d, J = 8.5 Hz, H-3), 
6.65 (2H, d, J = 8.5 Hz, H-2), 5.95 – 5.39 (2H, br s, -NH2), 5.80 (1H, d, J = 10.0 Hz, H-5). 13C-NMR 
(100.6 MHz, CDCl3) δ 167.5 (C-7), 153.0 (C-5), 149.9 (C-1), 133.3 (C-4), 120.0 (C-6) 114.9 (C-3), 113.0 
(C-2) ppm. 
3-((4-(((Z)-4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino)phenyl)thio)acrylic acid  
 
Appel’s salt (0.170 g, 0.850 mmol, 1.5 eq) and a 2:8 E:Z mixture of 3-((4-aminophenyl)thio)acrylic acid 
5.16 (0.110 g, 0.560 mmol, 1 eq) were suspended in DCM (4 mL). The resulting suspension was stirred 
at room temperature under a nitrogen atmosphere for 1 h. Thereafter, anhydrous pyridine (0.09 mL, 
1.12 mmol, 2 eq) was slowly added to the suspension, and the resulting mixture was allowed to stir 
for an additional 2 h. The reaction mixture was then concentrated in vacuo and purified by column 
chromatography, eluting with 3:7 EtOAc:Pet. ether to afford the title compound as a yellow solid with 
the ratio of geometric isomers conserved (185 mg, 99 % yield). Mp: 199-201 oC.  
E-isomer; 1H-NMR (400 MHz, CDCl3) δ 12.36 (1H, br s, -COOH), 7.77 (1H, d, J = 15.1 Hz, H-8), 7.65 (2H, 
d, J = 8.6 Hz, H-5), 7.40 – 7.14 (2H, m, H-4), 5.59 (1H, d, J = 15.0 Hz, H-7). 13C-NMR (100.6 MHz, CDCl3) 
δ 165.92 (C-9), 161.13 (C-1), 152.26 (C-2), 150.98 (C-7), 147.20 (C-6), 134.83 (C-3), 133.42 (C-8), 127.37 
(C-5), 121.42 (C-4) ppm. Z-isomer; 1H NMR (400 MHz, CDCl3) δ 12.36 (1H, br s, -COOH), 7.65 (2H, d, J 
= 8.6 Hz, H-5), 7.54 (1H, d, J = 10.0 Hz, H-8), 7.40 – 7.14 (2H, m, H-4), 5.95 (1H, d, J = 9.9 Hz, H-7). 13C-
NMR (100.6 MHz, CDCl3) δ 167.59 (C-9), 160.5 (C-1), 148.62 (C-7), 147.3 (C-2), 146.3 (C-3), 132.1 (C-6), 
121.06 (C-8), 117.0 (C-5), 114.47 (C-4) ppm. MS (ESI+): m/z Calculated for C11H7ClN2O2S3 [M+H] 
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3-((4-((Cyanocarbonothioyl)amino)phenyl)thio)acrylic acid  
 
Method A: DBU (0.3 mL, 1.80 mmol, 3 eq) was added dropwise to a 5 oC solution of 3-((4-((cyano-
carbonothioyl)amino)phenyl)thio)acrylic acid 5.17 (200 mg, 0.600 mmol, 1 eq) in freshly distilled DCM 
(5 mL) under a nitrogen atmosphere. The resulting red-brown mixture was stirred at 5 oC for 30 min, 
after which it was allowed to warm to room temperature and left to stir for a further 30 min. The 
reaction mixture was then washed with saturated ammonium chloride solution (2 x 2 mL), and H2O (1 
x 2 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. The crude material was 
purified by silica gel chromatography, eluting with 1:8.9:0.1 MeOH:EtOAc:TFA to provide the title 
compound as an orange oil (8.00 mg, < 5 % yield). 
Method B: DBU (0.3 mL, 1.80 mmol, 3 eq) was added dropwise, over 30 min, to a solution of 3-((4-
((cyanocarbonothioyl)-amino)phenyl)thio)acrylic acid 5.17 (0.200 g, 0.600 mmol, 1 eq) in DMSO (2 mL) 
at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 30 min, after 
which it was allowed to warm to room temperature and left to stir for a further 30 min. The reaction 
mixture was then diluted with saturated NH4Claq solution (6 mL), and washed with DCM (4 x 2 mL). 
The aqueous was concentrated under reduced pressure, MeOH (3 mL) was added and the resulting 
precipitate filtered under vacuum. The filtrate was then reduced in vacuo and diluted with additional 
MeOH (5 mL) resulting in the precipitation of trace NH4Cl salts. The precipitate was filtered and the 
filtrate reduced and lyophilised to afford the crude product. The crude material was purified by silica 
gel chromatography, eluting with 1:8.9:0.1 MeOH:EtOAc:TFA to provide the title compound, a  2:8 
mixture E:Z isomers, as a red-orange oil (52.0 mg, 33 % yield). E-isomer; 1H-NMR (400 MHz, DMSO) δ 
12.38 (1H, br s, -COOH), 9.91 (1H, br s, -NH), 7.42 (1H, d, J = 15.0 Hz, H-8), 7.59 (2H, d, J = 8.6 Hz, H-5), 
7.11 (2H, d, J = 8.6 Hz, H-4), 5.50 (1H, d, J = 15.0 Hz, H-7). Z-isomer; 1H NMR (400 MHz, DMSO) δ 12.38 
(1H, br s, -COOH), 9.91 (1H, br s, -NH), 7.65 (2H, d, J = 8.6 Hz, H-5), 7.56 (1H, d, J = 10.0 Hz, H-8), 7.40 
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Benzyl propiolate12  
 
Cesium carbonate (5.81 g, 17.9 mmol, 3 eq) was suspended in DMF (5 mL) and cooled to 0 oC. The 
reaction mixture was allowed to stir and propiolic acid (0.44 mL, 7.14 mmol, 1.2 eq) was added 
dropwise to the stirring cooled suspension. After the addition, the resulting solution was left to stir 
for a further 20 min, maintained at 0 oC. Benzyl bromide (0.71 mL, 5.95 mmol, 1 eq) was then slowly 
added and thereafter the reaction was allowed to warm to rt at which point it was left to stir for an 
additional 10 min. The reaction mixture was then diluted with Et2O (15 mL) and washed with a 
saturated brine solution (5 x 10 mL). The organic layer was dried over MgSO4 and reduced in vacuo to 
afford benzyl propiolate as a yellow oil (0.940 g, 99 % yield). 1H-NMR (400 MHz, CDCl3) δ 7.40 (5H, m, 
Ar-H), 5.23 (2H, S, H-4), 4.60 (1H, s, H-1) ppm.  13C-NMR (100.6 MHz, CDCl3) δ 152.3 (C-3), 135.34 
(Ar-q), 129.03 (Ar-H), 129.0 (Ar-H), 128.9 (Ar-H), 79.8 (C-2), 78.8 (C-1), 67.96 (C-4) ppm.  
 
Benzyl (E)-3-((4-aminophenyl)thio)acrylate  
 
Propiolic ester 5.18 (0.580 g, 3.63 mmol, 1 eq) and p-aminothiophenol (0.450 g, 3.63 mmol, 1 eq) were 
stirred in anhydrous DMF (2 mL) at room temperature under a nitrogen atmosphere for 24 h. The 
resulting red-brown solution was diluted with EtOAc (12 mL), washed with brine (4 x 6 mL), dried over 
MgSO4 and excess solvent reduced in vacuo. The crude residue was then subjected to column 
chromatography eluting with 3:7 EtOAc:Pet. ether and the material obtained was recrystallised to a 
constant melting point from boiling pet. ether to afford the geometrically pure product 5.19 as a 
brown solid (0.276 g, 39 %). Mp: 118-119 oC. 1H-NMR (300 MHz, CDCl3) δ 7.36 (5H, m, H-10 – 12), 7.32 
(1H, d, J = 14.8 Hz, H-6), 7.14 (2H, d, J = 8.5 Hz, H-3), 6.60 (2H, d, J = 8.5 Hz, H-2), 5.89 (1H, d, J = 14.8. 
Hz, H-5), 5.47 (2H, br s, -NH2), 5.13 (2H, s, H-8) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 165.8 (C-7), 154.6 
(C-6), 149.9 (C-1), 136.8 (C-5), 133.4 (C-3), 128.9 (C-10), 128.5 (C-11), 128.4 (C-12), 119.4 (C-9), 115.0 
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Benzyl (E)-3-((4-(((Z)-4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino)phenyl)thio)acrylate  
 
Appel’s salt (0.220 g, 1.08 mmol, 2 eq) and benzyl (E)-3-((4-aminophenyl)thio)acrylate 5.19 (0.150 g, 
0.540 mmol, 1 eq) were dissolved in DMF (4 mL). The resulting solution was stirred at room 
temperature under a nitrogen atmosphere for 1 h. Thereafter, anhydrous pyridine (0.05 mL, 
1.08 mmol, 2 eq) was slowly added to the solution, after which it was left to stir for an additional 2 h. 
The mixture was then concentrated in vacuo and purified by silica column chromatography, eluting 
with 1:9 EtOAc:Pet. ether, to afford the title compound as a bright yellow solid (0.225 g, 99 %). 
Mp: 130-152 oC. 1H-NMR (300 MHz, DMSO) δ 7.66 (3H, m, H-8,5), 7.41 (5H, m, H-12,13,14), 7.28 (2H, 
d, J = 8.5 Hz, H-4), 6.07 (1H, d, J = 13.3 Hz, H-7), 5.20 (2H, s, H-10). 13C-NMR (100.6 MHz, DMSO) δ 
165.8 (C-9), 160.6 (C-2), 151.2 (C-1), 150.3 (C-7), 147.2 (C-3), 136.6 (C-6), 132.7 (C-11), 132.3 (C-5), 
128.9 (C-13), 128.6 (C-14), 128.5 (C-12), 121.1 (C-4), 113.4 (C-8), 65.9 (C-10). MS (ESI+): m/z Calculated 
for C18H13ClN2O2S3 [M+H] 420.9905, found 420.9899. 
  
Benzyl (E)-3-((4-((cyanocarbonothioyl)amino)phenyl)thio)acrylate  
 
DBU (0.13 mL, 0.854 mmol, 3 eq) was added, dropwise over 30 min, to a solution of (E)-3-((4-(((Z)-4-
chloro-5H-1,2,3-dithiazol-5-ylidene)amino)phenyl)thio)acrylate 5.20 (0.120 g, 0.285 mmol, 1 eq) in 
anhydrous DMSO (2 mL) at room temperature under a nitrogen atmosphere. The resulting red-brown 
mixture was stirred for 40 min, after which it was diluted with EtOAc (12 mL). The reaction mixture 
was then washed with a saturated NH4Claq solution (3 x 6 mL) and H2O (1 x 10 mL). The organic phase 
was dried over Na2SO4 and concentrated in vacuo. The crude material was purified by silica gel column 
chromatography, eluting with 2:8 EtOAc:Hexane, to provide the title compound as a red solid 
(48.0 mg, 61 %). Mp: 96-97 oC. 1H-NMR (400 MHz, DMSO) δ 13.56 (1H, br s, -NH), 7.98 (2H, d, J = 
8.9 Hz, H-5), 7.67 (3H, app dd, J = 9.5, 7.7 Hz, H-8,4), 7.41 (5H, m, H-12,13,14), 6.10 (1H, d, J = 8.6 Hz, 
H-7), 5.20 (2H, s, H-10). 13C-NMR (100.6 MHz, DMSO) δ 165.8 (C-9), 161.8 (C-2), 149.2 (C-7), 137.9 
(C-3), 136.6 (C-6), 134.7 (C-11), 130.9 (C-5), 131.3 (C-12), 128.6 (C-13), 128.5 (C-14), 123.8 (C-4), 114.2 
5.20 
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(C-1), 113.9 (C-8), 66.0 (C-10). MS (ESI+): m/z Calculated for C18H14N2O2S2 [M+H] 355.0574, found 
355.0580. 
 
Benzyl (E)-3-((2-cyanobenzo[d]thiazol-6-yl)thio)acrylate  
 
 
Palladium chloride (4.00 mg, 0.020 mmol, 0.1 eq), copper iodide (19.0 mg, 0.099 mmol, 0.5 eq), TBAB 
(0.127 g, 0.394 mmol, 2 eq) and (E)-3-((4-(((Z)-4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino)-
phenyl)thio)acrylate 5.21 (70.0 mg, 0.197 mmol, 1 eq) were suspended in anhydrous DMSO (1 mL). 
The resultant orange-red mixture was placed under a nitrogen atmosphere and stirred at 120 oC for 4 
h. The reaction mixture was then diluted with EtOAc (6 mL) and washed with a saturated brine solution 
(4 x 2 mL). The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude product was purified by column chromatography 3:7 EtOAc:Hexane to provide the 2-
cyanobenzothiazole as a yellow solid (0.0430 g, 62 %). Mp: 113-120 oC. 1H-NMR (400 MHz, DMSO) δ 
8.59 (1H, d, J = 1.9 Hz, H-7), 8.29 (1H, d, J = 8.7 Hz, H-4), 7.85 (1H, dd, J = 8.7, 1.9 Hz, H-5), 7.78 (1H, d, 
J = 10.0 Hz, H-10), 7.41 (5H, m, H-14,15,16), 6.17 (1H, d, J = 10.0 Hz, H-9), 5.22 (2H, s, H-12). 13C-NMR 
(100.6 MHz, DMSO) δ 165.9 (C-11), 151.4 (C-2), 148.6 (C-9), 138.4 (C-3), 137.0 (C-8), 136.8 (C-6), 136.5 
(C-13), 130.1 (C-7), 128.9 (C-14), 128.6 (C-15), 128.6 (C-16), 125.6 (C-5), 124.3 (C-4), 114.5 (C-10), 113.7 
(C-1), 66.1 (C-12). FT-IR (ATR) νmax /  cm-1:1686 (C=C), 1735 (C=O), 2226 (-CN). MS (ESI+): m/z Calculated 
for C18H12N2O2S2 [M+H] 353.0418, found 353.0542. 
 
(S,E)-2-(6-((3-(benzyloxy)-3-oxoprop-1-en-1-yl)thio)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-
carboxylic acid  
 
 
To a stirring solution of benzyl (E)-3-((2-cyanobenzo[d]thiazol-6-yl)thio)acrylate 5.22 (4.00 mg, 
0.0110 mmol, 1 eq) in DMSO (0.4 mL) at room temperature under a nitrogen atmosphere was added 
D-Cysteine (2.00 mg, 0.0110 mmol, 1 eq) in H2O (0.6 mL). The solution was left to stir for 5 min, cooled 
5.22 
5.23 
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to 0 oC, and then potassium carbonate (15.0 mg, 0.0110, 1 eq) was added. The reaction mixture was 
then left to stir a further 10 min after which the pH was adjusted to pH 3 using 3 M HCl, all whilst 
maintaining a reaction temperature of 0 oC. The solution was then allowed to warm to room 
temperature and diluted with EtOAc (2 mL) and washed with H2O (4 x 1mL). The organic layer was 
then dried over MgSO4, filtered and evaporated under reduced pressure at 35 oC to afford a red oil. 
The crude material was further purified using silica column chromatography, eluting with 1:9 
MeOH:DCM to afford the title compound as a red oil (5.00 mg, 99 %). 1H-NMR (300 MHz, DMSO) δ 
8.47 (1H, d, J = 1.9 Hz, H-10), 8.20 (1H, d, J = 8.6 Hz, H-7), 7.76 (2H, m, H-8,13), 7.40 (5H, m, H-19,18,17), 
6.13 (1H, d, J = 10.1 Hz, H-12), 5.47 (1H, dd, J = 9.7, 8.5 Hz, H-2), 5.22 (2H, s, H-15), 3.77 (2H, m, H-3). 
MS (ESI+): m/z Calculated for C21H16N2O4S3 [M+H] 457.0350, found 457.0341. 
 
(S)-2-(6-mercaptobenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid  
 
 
D-Cysteine hydrochloride monohydrate (15.0 mg, 0.0790 mmol, 2.01 eq) and benzyl (E)-3-((2-
cyanobenzo[d]thiazol-6-yl)thio)acrylate 5.22 (14.0 mg, 0.0397 mmol, 1 eq) were suspended in DMSO 
(0.4 mL) at room temperature under a nitrogen atmosphere. Potassium carbonate (35.0 mg, 
0.119 mmol, 3 eq) dissolved in water (0.4 mL) was then added to the mixture, and the resulting bright 
orange solution was stirred under an inert atmosphere for a further 10 min. Upon consumption of 
benzyl (E)-3-((2-cyanobenzo[d]thiazol-6-yl)thio)acrylate, as evidenced by TLC analysis, the methanol 
was removed in vacuo and the remaining aqueous solution acidified to pH 3 with 3 M HCl. The aqueous 
was then extracted with EtOAc (5 x 1 mL). The combined organics were dried over NaSO4, filtered, 
concentrated in vacuo and purified with column chromatography 1:8.9:0.1 MeOH:DCM:TFA to provide 
D-thioluciferin 5 as a pale yellow solid (11.0 mg, 99 %). The ee was determined to be 93:7, by HPLC 
using a Diacel Chiracel OD column (hexane:i-Pr 7:3): flow rate: 1 mL/min: τmajor = 8.24 min.   
[α]𝟐𝟎
𝑫 obs
: -11o, DMF, c = 1. Mp: 89-90 oC. 1H-NMR (400 MHz, DMSO) δ 8.49 (1H, s, H-10), 8.18 (1H, dd, 
J = 8.7, 0.5 Hz, H-7), 7.78 (1H, dd, J = 8.7, 2.0 Hz, H-8), 5.45 (1H, dd, J = 9.8, 8.3 Hz, H-2), 3.75 (2H, m, 
H-3) ppm. 13C-NMR (100.6 MHz, DMSO δ 177.5 (C-1), 166.3 (C-4), 163.2 (C-11), 155.4 (C-5), 150.5 (C-
6), 130.0 (C-9), 125.5 (C-7), 123.0 (C-10), 121.9 (C-8), 82.1 (C-2), 34.5 (C-3) ppm. HRMS (ESI+): m/z 
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KBr (0.320 g, 2.65 mmol, 1.2 eq) and NaBO3 (0.371 g, 2.51 mmol, 1.1 eq) were suspended and left to 
stir in acetic acid (4 mL) at room temperature for 15 min. The resulting solution was added dropwise 
to a stirring suspension of p-anisidine (0.500 g, 2.28 mmol, 1.0 eq) in acetic acid (4 mL) at 0 oC. The 
reaction mixture was maintained at 0 oC throughout the addition. Thereafter, it was allowed to warm 
to room temperature and stirred for an additional 11 h. The reaction was quenched by the addition 
of chilled water (50 mL). The aqueous phase was then extracted with EtOAc (4 x 10 mL), the combined 
organic extracts were dried over MgSO4, filtered, and the solvent reduced in vacuo to afford 2-bromo-
4-methoxyaniline as brown oil that was used without further purification (0.480 g, 71 %). 1H-NMR 
(400 MHz, CDCl3) δ 7.56 (1H, d, J = 2.0 Hz, H-3), 7.28 (1H, d, J = 8.0 Hz, H-6), 7.24 (1H, d, J = 8 Hz, H-5), 
3.89 (H-7) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 148.4 (C-4), 140.0 (C-1), 119.5 (C-2), 118.4 (Ar-H), 118.3 





KBr (8.00 g, 67.2 mmol, 1.16 eq) and NaBO3 (9.80 g, 63.7 mmol, 1.1 eq) were suspended and left to 
stir in acetic acid (40 mL) at room temperature for 15 min. The resulting solution was added dropwise 
to a stirring suspension of p-nitroaniline (8.00 g, 57.9 mmol, 1 eq) in acetic acid (10 mL) at 0 oC. The 
reaction mixture was maintained at 0 oC throughout the addition. Thereafter, it was allowed to warm 
to room temperature and left to stir overnight. The reaction mixture was poured into chilled water 
(250 mL) and the resulting precipitate filtered and washed with copious amounts of water to afford 2-
bromo-4-nitroaniline as a yellow solid (11.2 g, 89 %). Mp: 100-101 oC (Lit. 104 oC).15 
 1H-NMR (400 MHz, CDCl3) δ 8.31 (1H, s, J = 1.9 Hz, H3), 7.56 (1H, dd, J = 8.0, 2.0 Hz, H-5), 6.95 (1H, d, 
J = 8 Hz, H-6), 6.21 (2H, br s, -NH2) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 153.3 (C-1), 142.1 (C-4), 129.5 
(C-2), 123.4 (Ar-H), 119.7 (Ar-H), 118.4 (Ar-H) ppm. 
4.1a 
4.1b 







p-Tolylthiophenol (0.100 g, 0.805 mol, 1 eq) and NaBO3 (0.190 g, 1.24 mmol, 1.54 eq) were suspended 
and stirred in a solution of DCM (2 mL) and acetic acid (0.2 mL) at room temperature for 48 h. The 
reaction was poured into chilled water (40 mL). The aqueous phase was then extracted with DCM (4 
x 10 mL), the combined organic extracts were dried over MgSO4, filtered, and the solvent reduced in 
vacuo to afford 4,4'-disulfanediylbis(2-bromoaniline) as a colourless solid (0.177 g, 90 %). Mp: 30-42 oC 
(Lit. 54 oC).17 1H-NMR (400 MHz, CDCl3) δ 7.54 (1H, s, J = 9.0 Hz, H-3), 7.21 (1H, d, J = 9.0 Hz, H-2), 2.21 
(1H, s, H-7) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 142.1 (C-4), 133.3 (C-1), 129.5 (Ar-H), 129.0 (Ar-H), 






p-Aminothiophenol (0.100 g, 0.799 mol, 1 eq) and NaBO3 (0.189 g, 1.23 mmol, 1.54 eq) were 
suspended and stirred in a solution of DCM (2 mL) and acetic acid (0.2 mL) at room temperature for 
48 h. The reaction mixture was then cooled to 0 oC upon complete consumption of the p-
aminothiophenol, as evidenced by TLC analysis. A suspension of KBr (0.200 g, 1.68 mmol, 2.1 eq) and 
NaBO3 (0.123 g, 0.799 mmol, 1 eq) in acetic acid (4 mL) was slowly added to the reaction mixture that 
was maintained at 0 oC throughout the addition. Thereafter, it was allowed to warm to room 
temperature and left to stir overnight. The reaction was quenched by the addition of chilled water (40 
mL). The aqueous phase was then extracted with EtOAc (4 x 10 mL), the combined organic extracts 
were dried over MgSO4, filtered, and the solvent reduced in vacuo to afford 4,4'-disulfanediylbis(2-
bromoaniline) as a yellow oil (0.250 g, 77 %). 1H-NMR (300 MHz, CDCl3) δ 7.52 (1H, s, H-3), 7.28 (1H, 
d, J = 8.0 Hz, H-5), 6.67 (1H, d, J = 8.0 Hz, H-6), 4.24 (2H, br s, -NH2) ppm. 13C-NMR (100.6 MHz, CDCl3) 
δ 144.4 (C-1), 128.2 (C-4), 130.8 (Ar-H), 129.4 (Ar-H), 118.1 (Ar-H), 117.8 (C-2) ppm. MS (ESI+): m/z 










Appel’s salt (0.875 g, 4.20 mmol, 2.1 eq) and 4,4'-disulfanediylbis(2-bromoaniline) 4.1d (0.812 g, 
2.00 mmol, 1 eq) were dissolved in DMF (6 mL). The resulting solution was stirred at room 
temperature under a nitrogen atmosphere for 1 h. Thereafter, anhydrous pyridine (0.29 mL, 
4.00 mmol, 2 eq) was slowly added to the solution, after which it was left to stir for an additional 2 h. 
The mixture was then diluted with EtOAc (30 mL), washed with saturated NH4Claq (3 x 10 mL), H2O (1 
x 10 mL), dried over MgSO4, and concentrated in vacuo. The crude material was purified by silica 
column chromatography, eluting with 1:9 EtOAc:Pet. ether, to afford the title compound as a yellow 
solid (1.16 g, 41 %). Mp: 217 oC. 1H-NMR (400 MHz, CDCl3) δ 7.67 (2H, s, H-5), 7.60 (2H, d, J = 8.0 Hz, 
H-8), 7.07 (2H, d, J = 8.0 Hz, H-7) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 157.7 (C-1), 149.2 (C-2), 143.6 





p-Aminothiophenol (0.100 g, 0.799 mmol, 1 eq) and NaBO3 (0.189 g, 1.23 mmol, 1.54 eq) were 
suspended and stirred in a solution of DCM (2 mL) and acetic acid (0.2 mL) at room temperature for 
48 h. Thereafter, chilled water (40 mL) was added to the reaction mixture. The aqueous phase was 
then extracted with EtOAc (4 x 10 mL), the combined organic extracts were dried over MgSO4, filtered, 
and the solvent reduced in vacuo to afford 4,4'-disulfanediyldianiline as a yellow oil (0.191 g, 96 %). 
1H-NMR (300 MHz, CDCl3) δ 7.03 (4H, m, H-3), 6.51 (4H, m, H-2), 5.07 (2H, br s, -NH2), 4.53 (4H, br s, 













Appel’s salt (0.378 g, 1.268 mmol, 2.1 eq) and 4,4'-disulfanediyldianiline 5.13 (0.150 g, 0.603 mmol, 
1 eq) were suspended in DCM (8 mL). The resulting solution was stirred at room temperature under a 
nitrogen atmosphere for 1 h. Thereafter, anhydrous pyridine (0.10 mL, 1.206 mmol, 2 eq) was slowly 
added to the solution, after which it was left to stir for an additional 2 h. The mixture was then diluted 
with EtOAc (30 mL), washed with saturated NH4Claq (3 x 10 mL), H2O (1 x 10 mL), dried over MgSO4, 
and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting 
with 1:9 EtOAc:Pet. ether, to afford the title compound as a yellow solid (1.16 g, 41 %). Mp: 227-
229 oC. 1H-NMR (300 MHz, CDCl3) δ 7.21 (4H, m, H-5), 6.56 (4H, m, H-4) ppm. 
 
General procedure for the Synthesis of monobrominated para substituted anilines 
KBr and NaBO3 were suspended and left to stir in acetic acid at room temperature. The resulting 
solution was added dropwise to a suspension of the appropriate aniline in acetic acid at 0 oC. The 
reaction mixture was maintained at 0 oC throughout the addition. Thereafter, it was allowed to warm 
to room temperature and left to stir overnight. The reaction mixture was poured into chilled water 






Following the above outlined procedure, KBr (5.70 g, 48.0 mmol, 1.2 eq) and NaBO3 (7.00 g, 
45.0 mmol, 1.1 eq) dissolved in acetic acid (60 mL) was added to p-iodoaniline (9.10 g, 42.0 mmol, 
1 eq) in acetic acid (1 mL) to obtain 2-bromo-4-iodoaniline as a brown solid (12.40 g, 99 %). Mp: 75-
76 °C (lit. 75-76 °C).18 1H-NMR (400 MHz, CDCl3) δ 7.67 (1H, d, J = 2.0 Hz, H3), 7.34 (1H, dd, J = 8.5, 2.0 
Hz, H-5), 6.52 (1H, d, J = 8.5 Hz, H-6), 4.44 (2H, br s, -NH2) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 144.1 










Following the above outlined procedure, KBr (3.86 g, 32.4 mmol, 1.2 eq) and NaBO3 (4.57 g, 
29.7 mmol, 1.1 eq) dissolved in acetic acid (40 mL) was added to p-fluoroaniline (3.00 g, 27.0 mmol, 
1.0 eq) in acetic acid (1 mL) to obtain 2-bromo-4-fluoroaniline as a pale yellow solid (5.13 g, 99 %). 
Mp: 39-41 °C (lit. 41 °C).19 1H-NMR (400 MHz, CDCl3) δ 7.23 (1H, dd, J = 8.0, 1.5 Hz, H-3), 6.91 (1H, td, 
J = 8.5, 1.2 Hz, H-5), 6.67 (1H, dd, J = 7.5, 5.0 Hz, H-6), 5.32 (2H, br s, -NH2) ppm. 13C-NMR (100.6 MHz, 
CDCl3) δ 148.9 (C-4), 142.8 (C-1), 121.5 (Ar-H), 210.1 (Ar-H), 118.9 (C-2), 117.7 (C-2) ppm. 
 
General procedure for the metal free synthesis of 6-substituted 2-cyanobenzothiazoles from 
monobrominated para-substituted anilines 
Appel’s salt and an aniline were allowed to stir in DCM for 1 h at room temperature under a nitrogen 
atmosphere. The solution was then cooled to below 5 oC and DBU was added, dropwise over 30 min, 
to the stirring solution maintained at 5 oC, all under a nitrogen atmosphere. After the addition, the 
resulting mixture was stirred for 30 min while allowing it to warm to room temperature, after which 
it was refluxed at 40 oC for 4 h. Upon cooling to rt, EtOAc was added. The reaction mixture was then 
washed with saturated NH4Claq solution, and H2O. The organic phase was dried over Na2SO4 and 






Following the above outlined procedure, Appel’s salt (0.260 g, 1.24 mmol, 1 eq) and 2-bromo-4-
methoxyaniline (0.250 g, 1.24 mmol, 1 eq) were combined and reacted with DBU (0.92 mL, 6.19 mmol, 
5 eq) to afford 2-cyano-6-methoxybenzothiazole as a pale yellow solid (0.150 g, 64 %). Mp: 129-130 oC 
(lit. 129-131 oC).5 1H-NMR (400 MHz, DMSO) δ 8.15 (1H, d, J = 9.1 Hz, H-4), 7.89 (1H, d, J = 2.4 Hz, H-
7), 7.33 (1H, dd, J = 9.1, 2.4 Hz, H-5), 3.93 (3H, s, H-9) ppm. 13C-NMR (400 MHz, DMSO) δ 160.4 (C-2), 
146.7 (C-6), 138.3 (C-3), 134.1 (C-8), 125.8 (C-7), 119.1 (C-5), 114.1 (C-1), 106.0 (C-4), 56.52 (C-9) ppm. 









Following the above outlined procedure, Appel’s salt (0.211 g, 1.01 mmol, 1.1 eq) and 2-bromo-4-
nitroaniline (0.200 g, 0.921 mmol, 1 eq) were combined and reacted with DBU (0.70 mL, 4.61 mmol, 
5 eq) to afford 2-cyano-6-nitrobenzothiazole as an orange solid (0.081 g, 43 %). Mp: 118-119 oC. 1H-
NMR (400 MHz, CDCl3) δ 8.97 (1H, dd, J = 2.2, 0.5 Hz, H-7), 8.55 (1H, dd, J = 9.6, 1.4 Hz, H-5), 8.42 (1H, 
dd, J = 9.1, 1.4 Hz, H-4) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 155.3 (C-2), 147.3 (C-6), 141.8 (C-3), 135.6 
(C-8), 126.1 (C-5), 123.0 (C-4), 118.6 (C-7), 114.0 (C-1) ppm. MS (ESI+): m/z Calculated for C8H3N3O2S 





Following the above outlined procedure, Appel’s salt (0.241 g, 1.16 mmol, 1.1 eq) and 2-bromo-4-
fluoroaniline (0.200 g, 1.05 mmol, 1 eq) were combined and reacted with DBU (0.79 mL, 5.26 mmol, 
5 eq) to afford 2-cyano-6-fluorobenzothiazole as a yellow solid (0.0870 g, 46 %). Mp: 86-87 oC. 1H-
NMR (400 MHz, DMSO) δ 8.04 (1H, dd, J = 8.0, 1.5 Hz, H-4), 7.64 (1H, dd, J = 7.5, 5.0 Hz, H-7), 7.26 (1H, 
td, J = 8.0, 1.5 Hz, H-5) ppm. 13C-NMR (100.6 MHz, DMSO) δ 158.5 (C-6), 147.2 (C-3) 136.7 (C-8), 138.1 





Following the above outlined procedure, Appel’s salt (0.154 g, 0.738 mmol, 1.1 eq) and 2-bromo-4-
iodoaniline (0.200 g, 0.671 mmol, 1 eq) were combined and reacted with DBU (0.50 mL, 3.35 mmol, 
5 eq) to afford 6-iodo-2-cyanobenzothiazole as pale yellow solid (0.104 g, 54 %). Mp: 131-132 oC. 
1H-NMR (400 MHz, DMSO) δ 8.52 (1H, d, J = 8.0 Hz, H-4), 7.90 (1H, d, J = 2.0 Hz, H-7), 7.43 (1H, dd, 
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(Ar-q), 131.9 (Ar-q), 123.2 (Ar-q), 113.3 (C-1), 92.1 (C-6) ppm. FT-IR (ATR) νmax / cm-1: 2254 (-CN).  MS 
(ESI+): m/z Calculated for C8H3IN2S [M+H] 286.9139, found 286.9134. 
 




To a stirring solution of sodium bicarbonate (4.09 g, 48.8 mmol, 1.54 eq) in water (350 mL) was added 
aniline (3.0 mL, 31.6 mmol, 1.2 eq). The resultant mixture was cooled to 0 oC and iodine (6.32 g, 
25.0 mmol, 1 eq) was added in small portions over 3 min intervals under intensive stirring during which 
the temperature of the reaction mixture was maintained below 15 oC. After the addition of the iodine, 
the mixture was allowed to warm to room temperature and was left to stir for an additional 40 min. 
Thereafter, the crude product was collected by centrifugation. The crude product was then 
recrystallised from pet. ether (30 mL) to afford 4-iodoaniline as a pale yellow solid (4.10 g, 72 %). Mp: 
57-61 °C (lit. 61-63 °C).20 1H-NMR (300 MHz, DMSO): δ 7.41 (2H, d, J = 8.0 Hz, H-3), 6.47 (1H, d, J = 8.0 
Hz, H-2), 3.67 (2H, s, -NH2) ppm. 13C-NMR (100.6 MHz, DMSO) δ 146.1 (C-1), 138.0 (C-3), 117.2 (C-2), 





p-Iodoaniline 4.1 (5.26 g, 24.0 mmol, 1 eq) and acetic anhydride (2.5 mL, 26.4 mmol, 1.1 eq) were 
dissolved in pyridine (10 mL). The resultant solution was allowed to stir for 2 h at 100 oC, after which, 
the solution was left to cool to room temperature. The reaction mixture was then poured into water 
(35 mL) and the resulting precipitate was collected by filtration and washed with cold water (2 x 
30 mL). N-(4-Iodophenyl)acetamide was isolated as a white solid (5.92 g, 95 %). Mp: 179-182 °C (lit. 
180-182 °C).20 1H-NMR (400 MHz, DMSO) δ 9.99 (1H, s, -NH-), 7.61 (2H, d, J = 8.0 Hz, H-3), 7.41 (2H, d, 
J = 8.0 Hz, H-2), 2.03 (3H, s, H-6) ppm. 13C-NMR (100.6 MHz, DMSO) δ 167.8 (C-5) 138.6 (C-1), 136.7 
(C-3), 119.1 (C-2), 85.8 (C-4), 23.7 (C-6) ppm. 
4.1 
4.1f 






Method A: KBr (0.320 g, 2.65 mmol, 1.2 eq), NaBO3 (0.320 g, 2.51 mmol, 1.1 eq) and N-(4-
iodophenyl)acetamide 4.1f (0.500 g, 1.90 mmol, 1.0 eq) were suspended in acetic acid (6 mL) at room 
temperature. The resulting mixture was allowed to stir for 24 h at room temperature after which H2O 
(30 mL) was added to the reaction mixture. The aqueous phase was then extracted with EtOAc (4 x 10 
mL), the combined organic extracts were dried over MgSO4, filtered, and the solvent reduced in vacuo 
to afford N-(2-bromo-4-iodophenyl)acetamide as a brown solid (0.480 g, 71 %).  
Method B: 4-Iodo-2-bromoaniline 5.5 (3.57 g, 12.0 mmol, 1 eq) and acetic anhydride (1.6 mL, 
13.2 mmol, 1.1 eq) were dissolved in pyridine (4 mL). The resultant solution was allowed to stir for 2 h 
at 100 oC, after which, the reaction mixture was poured into water (50 mL) and the resulting 
precipitate was collected by filtration and washed with cold water (2 x 10 mL). N-(2-Bromo-4-
iodophenyl)acetamide was isolated as a brown solid (5.92 g, 99 %). Mp: 145-147 °C. 1H-NMR 
(300 MHz, DMSO) δ 9.45 (1H, s, -NH-), 8.00 (1H, d, J = 2.0 Hz, H-5), 7.77 (1H, dd, J = 8.5, 2.0 Hz, H-3), 
7.43 (1H, d, J = 8.5 Hz, H-2), 2.07 (3H, s, H-8) ppm. 13C-NMR (100.6 MHz, DMSO) δ 169.0 (C-7), 146.8 




Method A: To a solution of N-(2-bromo-4-iodophenyl)acetamide 4.1 (1.10 g, 4.10 mmol, 1 eq) in DCM 
(60 mL) at room temperature was added P2S5 (1.70 g, 7.70 mmol, 1.9 eq), Al2O3 (0.0250 g, 0.250 mmol, 
0.06 eq) and elementary sulfur (0.0130 g, 0.410 mmol, 0.1 eq). The reaction mixture was refluxed at 
40 °C for 3 h. Once cooled to room temperature, the reaction mixture was poured into water (200 mL) 
and the aqueous layer extracted with diethyl ether (3 x 50 mL). The combined organic layers were 
washed with water (3 X 50 mL), brine (100 mL), dried over MgSO4 and the solvent removed under 
reduced pressure. The crude material was purified using silica column chromatography 1:9 EtOAc:Pet. 
4.3 
4.4 
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ether. The material was further purified by recrystallisation using aqueous EtOH to afford the title 
compound as a yellow solid (0.430 g, 38 %).  
Method B: N-(2-Bromo-4-iodophenyl)acetamide (3.53 g, 9.86 mmol, 1 eq) and Lawesson’s reagent 
(2.19 g, 5.43 mmol, 0.55 eq) were dissolved in toluene (35 mL) and allowed to stir for 6 h at  
110 °C under a nitrogen atmosphere .Thereafter, the resultant solution was allowed to cool to room 
temperature and poured into water (600 mL). The aqueous layer was extracted with DCM (3 x 50 mL), 
the combined extracts were washed with water (3 x 20 mL), brine (50 mL), and dried over MgSO4. 
Excess solvent was removed under reduced pressure and the resulting residue purified using silica 
column chromatography, eluting with 1:10 EtOAc:Pet. ether, to afford N-(4-iodophenyl)-
ethanethioamide as a brown solid that was further purified  by recrystallisation using aqueous EtOH 
(2.95 g, 84 %). Mp: 141-144 °C. 1H-NMR (400 MHz, DMSO) δ11.43 (1H, s, -NH-), 8.09 (1H, d, J = 1.9 Hz, 
H-5), 7.79 (1H, dd, J = 8.3, 1.9 Hz, H-3), 7.20 (1H, d, J = 8.3 Hz, H-2), 2.61 (3H, s, H-8) ppm. 13C-NMR 
(100.6 MHz, DMSO) δ 202.6 (C-7), 140.8 (Ar-H), 138.9 (C-1), 137.5 (Ar-H), 132.2 (Ar-H), 122.4 (C-6), 





A suspension of N-(4-iodophenyl)acetamide 4.1f (1.10 g, 4.20 mmol, 1 eq) and Lawesson’s reagent 
(1.15 g, 2.90 mmol, 0.7 eq) in toluene (20 mL) was heated for 6 h at 110 °C under a nitrogen 
atmosphere. Thereafter, the resultant solution was left to cool to room temperature and poured into 
water (200 mL). The aqueous layer was extracted with diethyl ether (3 x 50 mL), the combined extracts 
washed with water (3 x 50 mL), brine (50 mL), and dried over MgSO4. Excess solvent was removed 
under reduced pressure and the resulting residue purified using silica column chromatography, eluting 
with 1:10 EtOAc:Pet. ether, to afford N-(4-iodophenyl)ethanethioamide as a brown solid (0.760 g, 
94 %); Mp: 146-148 °C. 1H-NMR (400 MHz, DMSO) δ11.58 (1H, s, -NH-), 7.74 (2H, dd, J = 8.9, 1.5 Hz, 
H-3), 7.65 (2H, dd, J = 8.8, 1.5 Hz, H-2), 2.59 (3H, s, H-6) ppm. 13C-NMR (100.6 MHz, DMSO) δ 199.5 










Method A: N-(4-Iodophenyl)ethanethioamide (1.00 g, 3.60 mmol, 1 eq) was dissolved in 30 % NaOHaq 
(5 mL) and water (5 mL) and allowed to stir at 0 oC for 20 min. The resultant solution was added 
dropwise, over 4 h, to a stirring solution of K3[Fe(CN)6] (4.75 g, 14.5 mmol, 4 eq) in water (2 mL) at 
0 oC. The reaction mixture was allowed to warm to room temperature and the resultant precipitate 
was collected by filtration and washed copiously with water to produce 6-Iodo-methylbenzothiazole 
as a pale brown solid (0.426 g, 43 %).  
Method B: N-(2-Bromo-4-iodophenyl)acetamide (0.366 g, 1.03 mmol, 1 eq) and NaOMe (0.0670 g, 
1.24 mmol, 1.1 eq) were dissolved and allowed to stir in NMP (2 mL) at 150 oC for 2 hr, after which the 
NMP was reduced by distillation. The remaining residue was then dissolved in EtOAc (10 mL), washed 
with brine (3 x 2 mL), water (1 x 2 mL) and the excess solvent reduced in vacuo to afford the title 
compound as a pale orange solid (0.221 g, 78 %). Mp: 137-139 °C (lit. 140-141 °C).21 1H-NMR (300 
MHz, CDCl3) δ 8.46 (1H, d, J = 1.7 Hz, H-7), 7.93-7.48 (2H, m, H-4/5), 2.79 (3H, s, H-1) ppm. 
13C-NMR (100.6 MHz, CDCl3) δ 168.4 (C-2), 152.8 (Ar-q), 138.1 (Ar-H), 135.1 (Ar-q), 130.7 (Ar-H), 124.1 






6-Iodo-2-methylbenzothiazole (0.778 g, 2.83 mmol, 1 eq) and SeO2 (0.410 g, 3.67 mmol, 1.3 eq) were 
dissolved in a solution of dioxane (8 mL) and water (0.8 mL) and refluxed at 150 °C for 2 h. The reaction 
mixture was then cooled to room temperature, filtered through Celite, and the filtrate reduced in 
vacuo. The crude material was subjected to purification by flash chromatography and subsequently 
recrystallised from hexane to afford 6-iodobenzothiazole-2-carbaldehyde as a red solid (0.123 g, 
15 %). Mp: 129-131 °C (lit. 133-134 °C).22 1H-NMR (400 MHz, DMSO) δ 10.12 (1H, s, H-1), 8.75 (1H, d, 
J = 1.7 Hz, H-7), 8.04 (2H, m, H-4/5) ppm. 13C-NMR (100.6 MHz, DMSO) δ 173.7 (C-1), 163.8 (C-2), 
4.6 
4.5 
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152.7 (Ar-q), 147.9 (Ar-q), 135.3 (Ar-H), 130.4 (Ar-H), 125.1 (Ar-H), 90.1 (C-6), ppm. IR νmax (cm-1) 1732 





Method A: Triethylamine (0.10 mL, 0.800 mmol, 1.1 eq) and 6-iodobenzothiazole-2-carbaldehyde 
(0.200 g, 0.700  mol, 1 eq) was added to a solution of hydroxylamine hydrochloride (0.0600 g, 
0.800 mmol, 1.1 eq) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere. The reaction 
mixture was allowed to stir for 3 h at room temperature. Thereafter, phthalic anhydride (0.100 g, 
0.710 mmol, 1.01 eq) was added the solution refluxed for a further 8 h. The reaction mixture was then 
allowed to cool to room temperature at which point DCM (3 mL) was added resulting in the formation 
of a precipitate. The precipitate was filtered and the filtrate washed with 5 % NH4Cl (4 x 1 mL). The 
organic layer was dried over MgSO4 and the solvent reduced in vacuo to afford 2-cyano-6-
benzothiazole as a pale yellow solid (0.170 g, 85 %). 
Method B: Palladium chloride (6.00 mg, 0.0350 mmol, 0.1 eq), copper iodide (33.0 mg, 0.174 mmol, 
0.5 eq), TBAB (0.224 g, 0.694 mmol, 2 eq), and 1-[(cyanocarbothioyl)amino]-4-iodobenzene (0.100 g, 
0.347 mmol, 1 eq) were suspended in anhydrous 1:1 DMF:DMSO (2 mL). The resultant red-brown 
mixture was placed under an inert nitrogen atmosphere and heated at 120 oC for 4 h. The reaction 
was diluted with EtOAc (6 mL) and washed with H2O (4 x 2 mL). The organic layer was then dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified using silica column 
chromatography using 1:10 EtOAc:hexane to provide 2-cyano-6-iodobenzothiazole as a light yellow 
solid (7.00 mg, 7 %). Mp: 131-132 oC. 1H-NMR (400 MHz, DMSO) δ 8.52 (1H, d, J = 8.0 Hz, H-4), 7.90 
(1H, d, J = 2.0 Hz, H-7), 7.43 (1H, dd, J = 8.0, 2.1 Hz, H-5) ppm. 13C-NMR (100.6 MHz, DMSO) δ 150.5 
(C-6), 136.7 (C-2), 136.4 (C-1), 133.2 (Ar-q), 131.9 (Ar-q), 123.2 (Ar-q), 113.3 (C-1), 92.1 (C-6) ppm. MS 



















Appel’s salt (0.523 g, 2.51 mmol, 1.1 eq) and p-iodoaniline (0.500 g, 2.28 mmol, 1 eq) were suspended 
in freshly distilled DCM (3 mL). The resulting mixture was stirred under an inert nitrogen atmosphere 
at room temperature for 90 min. Thereafter, anhydrous pyridine (0.39 mL, 4.56 mmol, 2 eq) was slowly 
added to the stirring suspension and the resulting red-brown mixture was allowed to stir for an 
additional 2 h at room temperature. The mixture was then concentrated in vacuo and purified by silica 
column chromatography, eluting with hexanes, to afford N-[(5Z)-4-chloro-5H-1,2,3-dithiazol-5-
ylidene]-4-iodoaniline as a yellow solid (0.386 g, 65 %). Mp: 90-91 oC. 1H-NMR (400 MHz, CDCl3) δ 7.83 
(2H, d, J = 8.0 Hz, H-5), 7.03 (2H, d, J = 8.0 Hz, H-4) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 160.64 (C-1), 







DBU (0.23 mL, 1.52 mmol, 3 eq) was added dropwise to a 5 oC solution of N-[(5Z)-4-chloro-5H-1,2,3-
dithiazol-5-ylidene]-4-iodoaniline (0.180 g, 0.510 mmol, 1 eq) in anhydrous DCM (4 mL) under a 
nitrogen atmosphere. The resulting red-brown mixture was stirred at 5 oC for 30 min, after which it 
was warmed to room temperature. The reaction mixture was then diluted with DCM (6 mL), washed 
with saturated NH4Claq (3 x 2 mL), H2O (1 x 2 mL), and brine (1 x 2 mL). The organic phase was dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified by silica gel chromatography, 
eluting with 1:1 EtOAc:hexane to provide 1-[(cyanocarbothioyl)amino]-4-iodobenzene as an orange 
solid (0.100 g, 70 %). Mp: 85-86 oC. 1H-NMR (400 MHz, CDCl3) δ 9.92 (1H, br s, -NH-), , 7.84 (2H, m, 
H-5), 7.72 (2H, d, J = 8.1 Hz, H-4) ppm. 13C-NMR (100.6 MHz, CDCl3) δ 162.0 (C-2), 138.7 (C-3), 138.3 
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Synthesis of D-luciferin analogues 
General procedure for the preparation of D-luciferin C-6 analogues  
D-Cysteine hydrochloride monohydrate (1.05 eq) and the appropriate 2-cyanobenzothiazole (1 eq) 
were dissolved in either MeOH:H2O or CH3CN:H2O. The solution was allowed to stir at room 
temperature for 5 min under a nitrogen atmosphere, after which potassium carbonate (1.05 eq) was 
added. The resulting solution was allowed to stir for an additional 30 min, while maintaining the inert 
atmosphere. Upon consumption of the 2-cyanobenzothiazole, as evidenced by TLC analysis, the 
reaction mixture was concentrated under reduced pressure and the remaining aqueous solution 
cooled to 0 oC and acidified to pH 3 with 3 M HCl. The aqueous was then extracted with EtOAc and the 
combined organics were dried over Na2SO4, filtered, concentrated in vacuo and subjected to column 







Following the above outlined procedure, D-cysteine hydrochloride monohydrate (29.0 mg, 
0.166 mmol, 1.05 eq) and 2-cyano-6-methoxybenzothiazole (30.0 mg, 0.158 mmol, 1 eq) were reacted 
in the presence of potassium carbonate (22.0 mg, 0.166 mmol, 1.05 eq) in 3:1 MeOH:H2O (1 mL) to 
afford D-methoxyluciferin as a pale yellow solid (46.0 mg, 99 %). [α]𝟐𝟎
𝑫 obs
: -26° (DMF, c = 1). Mp: 197-
198 oC. 1H-NMR (400 MHz, DMSO) δ 8.03 (1H, d, J = 8.9, H-7), 7.76 (1H, d, J = 2.3, H-10), 7.22 (1H, dd, 
J = 8.9, 2.3 Hz, H-8), 5.45 (1H, dd, J = 9.7, 8.3 Hz, H-2), 3.79 (3H, s, H-12), 3.72 (2H, m, H-3) ppm. 13C-
NMR (100.6 MHz, DMSO) δ 171.59 (C-1), 164.88 (C-4), 159.29 (C-5), 147.57 (C-9), 137.66 (C-6), 125.19 
(C-11), 123.15 (C-8), 117.55 (C-7), 105.22 (C-10), 78.59 (C-2), 56.34 (C-12), 35.20 (C-3). MS (ESI+): m/z 

















Following the above outlined procedure, D-cysteine hydrochloride monohydrate (18.0 mg, 
0.105 mmol, 1 eq) and 2-cyano-6-iodobenzothiazole (30.0 g, 0.105 mmol, 1 eq) were reacted in the 
presence of potassium carbonate (15.0 mg, 0.105 mmol, 1 eq) to afford D-iodoluciferin as an orange 
solid (41.0 mg, 99 %). [α]𝟐𝟎
𝑫 obs
: -11° (DMSO, c = 1). Mp: 176-179 oC. 1H-NMR (400 MHz, DMSO) δ 8.51 
(1H, d, J = 8.0, H-7), 7.93 (1H, d, J = 2.3, H-10), 7.45 (1H, dd, J = 8.0, 2.0 Hz, H-8), 5.45 (1H, app t, J = 9.0 
Hz, H-2), 3.70 (2H, m, H-3) ppm. 13C-NMR (100.6 MHz, DMSO) δ 177.59 (C-1), 163.78 (C-4), 159.09 (C-








Following the above outlined procedure, D-cysteine hydrochloride monohydrate (27.0 mg, 
0.154 mmol, 1.05 eq) and 2-cyano-6-nitrobenzothiazole (30.0 mg, 0.146 mmol, 1 eq) were reacted in 
the presence of potassium carbonate (21.0 mg, 0.154 mmol, 1.05 eq) to afford D-nitroluciferin as a 
pale yellow solid (45.0 mg, 99 %). [α]𝟐𝟎
𝑫 obs
: -19° (DMSO, c = 1). Mp: 176-179 oC. 1H-NMR (400 MHz, 
DMSO) δ 8.64 (1H, d, J = 8.5, H-7), 8.30 (1H, d, J = 2.0, H-10), 8.07 (1H, dd, J = 8.5, 2.0 Hz, H-8), 5.47 
(1H, app t, J = 9.0, H-2), 3.72 (2H, m, H-3) ppm. 13C-NMR (100.6 MHz, DMSO) δ 177.59 (C-1), 163.78 
(C-4), 159.09 (C-5), 152.51 (C-6), 136.66 (C-11), 131.90 (8), 131.19 (C-10), 123.15 (C-7), 91.29 (C-9), 
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Aldrithiol (0.150 g, 0.680 mmol, 2 eq) was dissolved in solution of MeOH (0.75 mL) and glacial acetic 
acid (0.01 mL). The solution was allowed to stir at room temperature under a nitrogen atmosphere 
for 5 min after which, mercaptoethanol (0.024 mL, 0.340 mmol, 1 eq) dissolved in MeOH (0.25 mL) 
was added dropwise over a 30 min period. The solvent was then evaporated under reduced pressure 
and the crude material purified using silica column chromatography eluting with 1:10 EtOAc:Hexane 
to afford the title compound as a viscous yellow oil (0.0370 g, 58 %). 1H-NMR (300 MHz, CDCl3) δ 8.45 
(1H, m, H-7), 7.82 (2H, m, H-5,6), 7.24 (1H, m, H-4), 4.99 (1H, t, J = 8.3 Hz, -OH), 3.63 (2H, m, H-1), 2.93 
(2H, t, J = 6.3 Hz, H-2) ppm. 13C-NMR (100.6 MHz, CDCl3) 159.9 (C-3), 149.6 (C-7), 138.6 (C-6), 122.2 





GSH (0.120 g, 0.103 mmol, 1 eq) dissolved in water (1.5 mL) was added to a stirring solution of 
aldrithiol (0.360 g, 0.410 mmol, 4 eq) dissolved in glacial acetic acid (0.01 mL) and MeOH (4 mL). The 
solution was then left to further stir overnight at room temperature, after which the solvent was 
evaporated and the crude material re-dissolved in distilled water, washed with copious amounts of 
DCM and then lyophilised to afford the title compound as a white solid (0.0410 g, 96 %). 1H-NMR (300 
MHz, DMSO) δ 8.42 (1H, d, J = 4.9 Hz, H-12), 7.87 (2H, m, H-13/14), 7.36 (1H, m, H-15), 4.58 (1H, dd, J 
= 9.5, 4.4 Hz, H-6), 3.88 (2H, s, H-9), 3.75 (1H, m, H-2), 3.22 (2H, m, H-9), 2.25 (4H, m, H-3/4). 13C-NMR 
(100.6 MHz, DMSO) δ 178.9 (C-1), 174.6 (C-10), 173.7 (C-5), 172.2 (C-7), 157.7 (C-11), 148.3 (C-12), 
139.7 (C-15), 122.6 (C-13), 122.5 (C-14), 53.8 (C-2), 57.2 (C-6), 41.8 (C-8), 39.4 (C-9), 31.3 (C-4), 26.0 
(C-3) ppm. HRMS (ESI+): m/z Calculated for C15H20N4O6S2 [M+H] 417.0902, found 417.0892. 
6.10a 
6.11 
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Method A: GSH (50.0 mg, 0.0429 mmol, 1 eq) and NaBO3 (10.2 mg, 0.0661 mmol, 1.54 eq) were 
suspended and stirred in a solution of water (1 mL) and acetic acid (0.01 mL) at room temperature for 
72 h. The reaction mixture was then concentrated in vacuo and purified using reverse phase 
chromatography eluting with 9:1 H2O:MeOH to afford the disulfide as a white powder (26.0 mg, 99 %).  
Method B: N5-(1-((carboxymethyl)amino)-1-oxo-3-(pyridin-2-yldisulfanyl)propan-2-yl)glutamine 6.11 
(10.0 mg, 0.0249 mmol, 1 eq) and GSH (7.74 mg, 0.0252 mmol, 1.05 eq) were dissolved in water and 
allowed to stir for 15 min. The resulting yellow solution was washed with DCM (8 x 2 mL) until clear. 
Thereafter the aqueous was frozen and lyophilised to afford GSSG as a white powder (15.0 mg, 99 %). 
Mp: 30-42 oC (Lit. 54 oC). 1H-NMR (300 MHz, DMSO) δ 4.58 (1H, dd, J = 9.5, 4.4 Hz, H-6), 3.88 (2H, s, 
H-9), 3.75 (1H, m, H-2), 3.22 (2H, m, H-9), 2.25 (4H, m, H-3,4). MS (ESI+): m/z Calculated for 
C15H20N4O6S2 [M+2H] 614.6460, found 614.6460. 
 




D-Thioluciferin (10.0 mg, 0.0337 mmol, 1 eq) and I2 (1.7 mg, 0.0661 mmol, 0.2 eq) were suspended 
and stirred in a 1:1 solution of chloroform and DMSO (0.4 mL) at room temperature for 10 min. The 
reaction mixture was then diluted with EtOAc, (5 mL) and washed with saturated Na2S2O3 (2 x 2 mL) 
and water (1 x 2 mL). The organic layer was then dried over MgSO4 and concentrated in vacuo to afford 
the disulfide as a pale yellow solid (9.7 mg, 99 %). 1H-NMR (400 MHz, DMSO) δ 8.49 (1H, s, H-10), 8.18 
6.11b 
6.11c 
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(1H, dd, J = 8.7, 0.5 Hz, H-7), 7.78 (1H, dd, J = 8.7, 2.0 Hz, H-8), 5.45 (1H, dd, J = 9.8, 8.3 Hz, H-2), 3.75 
(2H, m, H-3) ppm. MS (ESI+): m/z Calculated for C22H14N4O4S6 [M+H] 591.7472, found 591.7472. 
 




N5-(1-((carboxymethyl)amino)-1-oxo-3-(pyridin-2-yldisulfanyl)propan-2-yl)glutamine 6.11 (5.0 mg, 
0.0125 mmol, 1 eq) and D-thioluciferin (3.7 mg, 0.0125 mmol, 1 eq) were dissolved in a 8:2 solution 
of water:acetonitrile (1 mL) and allowed to stir for 10 min under a nitrogen atmosphere. The resulting 
yellow solution was further diluted with additional water (3 mL) and washed with DCM (10 x 2 mL) 
until clear. Thereafter the remaining aqueous layer was frozen and lyophilised to afford the disulfide 
as a white powder (4.5 mg, 62 %). 1H-NMR (400 MHz, DMSO) δ 8.61 (1H, s, H-10’), 8.18 (1H, dd, J = 8.7, 
0.5 Hz, H-7’), 7.84 (1H, dd, J = 8.7, 2.0 Hz, H-8’), 5.50 (1H, dd, J = 9.8, 8.3 Hz, H-2’), 4.58 (1H, dd, J = 9.5, 
4.4 Hz, H-6), 3.88 (2H, s, H-9), 3.60-3.55 (2H, m, H-2/2’), 3.32-3.22 (2H, m, H-9), 2.25 (4H, m, H-3,4) 
ppm. 13C-NMR (100.6 MHz, DMSO δ 177.8 (C-1’), 175.1 (C-1), 174.9 (C-10), 174.2 (C=O), 174.0 (C=O), 
1664 (Ar-q), 166.3 (Ar-q), 155.9 (Ar-q), 151.7 (C-5’), 150.1 (Ar-q), 125.3 (Ar-H), 123.3 (Ar-H), 82.5 (C-
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Live imaging of luciferase expression  
Luciferase expressing N. Tabacum plants were received from Dr. Suhail Rafudeen of the Plant Stress 
Research Unit at the University of Cape Town. The plants were transfected with a previously prepared 
luciferase coupled stress inducible promotor, XvSap1, isolated from X. viscosa. Luciferase expression 
was then induced by subjecting mature N. Tabacum plants were subjected to a two week dehydration 
period, after which leaves were taken from plants for bioluminescence imaging.  leaves were 
individually sprayed and painted with equal amounts of 5 mM D-Luciferin (VivoGlo, Promega 
Corporation, USA). Luciferase activity was imaged with a 3D-luminometer consisting of a 0.5 square 
inch CCD camera and a field of view of 12.5 cm (Xenogen IVIS Lumina, Caliper, USA) at an exposure 
time of 300 s per leaf. Photon or count emission by luciferase expressing leaves was quantified using 
the Living Image software (Caliper, USA). The GFP assay was selected to negate any luminescence from 
chloroplasts.  
Purified protein luminescence assays 
Luminescence assays were initiated by adding 30 μL of purified luciferase in enzyme buffer (20 mM 
Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 mg/mL BSA) to 30 μL 2x substrate in substrate buffer 
(20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 
3915). Imaging was performed one minute after enzyme addition using a Xenogen IVIS-100 at a final 
enzyme concentration of 10 nM and final substrate concentrations ranging from 0.122 to 250 μM. 
Data acquisition and analysis was performed with Living Image® software. Data are reported as total 
flux (p/s) for each ROI corresponding to each well of the 96-well plate. 
Bioluminescence emission scans 
Purified luciferase in enzyme buffer was rapidly injected into a cuvette containing substrate in 
substrate buffer to a final enzyme concentration of 100 nM and a final substrate concentration of 10 
μM. The emission from 400 to 800 nm was recorded in a SPEX FluoroMax-3 fluorimeter with closed 
excitation slits 10 s after injection. 
Burst kinetics assays 
Using a Turner Biosystems 20/20n luminometer, 40 μL of purified luciferase in enzyme injection buffer 
(20 mM Tris [pH 7.4], 0.1 mM EDTA, 0.625 mM TCEP, and 0.5 mg/mL BSA) was rapidly injected into a 
clear Eppendorf tube containing 10 μL of substrate in substrate injection buffer (20 mM Tris [pH 7.4], 
0.1 mM EDTA, 20 mM MgSO4, and 10 mM ATP) to a final enzyme concentration of 0.2 nM and a final 
luciferin substrate concentration of 250 μM. Measurements were taken every 0.2 s for 1 s pre-
injection and 120 s post-injection. Data acquisition was performed with SIS for 2020n v1.9.0 software. 
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Data are reported as Relative Light Units (RLU). To correct for the wavelength sensitivity of the PMT 
in the 20/20n, total flux was also measured using the IVIS-100 as described above with a final enzyme 
concentration of 10 nM and a final substrate concentration of 250 μM. Data from the IVIS and from 
the 20/20n at the 60 s time point were normalised to the WT + D-luciferin value. The correction factor 
of each enzyme/substrate pair was calculated by dividing the normalized IVIS data by the normalised 
20/20n data. All 20/20n data were then multiplied by their respective correction factors. 
UV-vis Experiments (absorption sectra) 
Absorption spectra for D-Luciferin, luciferin-analogues and all precursor 2-cyanobenzothiazoles were 
recorded with a Cary 60 spectrophotometer, instrument version 2.00. Samples were prepared as a 
0.01 mM DMSO solution unless otherwise stated and were scanned from 200 nm to 650 nm at a UV-
Vis scan rate of 24000.00 nm/min. Data were analysed using Scan Software Version 5.0.0.999.  
Fluorescence Spectrophotometry (excitation emission spectra) 
Excitation and emission spectra were recorded on a Varian Cary Eclipse fluorometer equipped with a 
regulated temperature cell holder and Hellma, Suprasil® quartz fluorescence cuvettes of 10 mm 
pathlength and 1.5 mL volume capacity. Emission spectra were recorded at an excitation wavelength 
corresponding to previously recorded absorption maxima. Samples were prepared as a 0.1 mM DMSO 
solution, unless otherwise stated, and were scanned from 200 nm to 800 nm (Ex. Slit/ Em. Slit 5 nm) 
at a scan rate of 600.00 nm/mn. Data were analysed using Scan Software Version 1.1.  
Purified protein luminescence assays 
Luciferase was prepared as a 10 nM solution in enzyme buffer. Luciferase lyophilized powder 
(luciferase from Photinus Pyralis, Sigma-Aldrich) was dissolved in previously prepared luciferase 
enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 0.8 mg/mL BSA).  D-Luciferin,  
D-aminoluciferin and D-thioluciferin were prepared as 0.1 µM, 3.56 µM, 10 µM, 100 µM and 1 M 
solutions in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP). 
Luminescence assays were initiated by adding 30 μL of luciferase in luciferase enzyme buffer to 60 μL 
substrate in substrate buffer in a white 96-well plate (Costar 3915). Imaging was performed one 
minute after enzyme addition using a Luminoskan Ascent (detector 270 - 670 nm) and data acquisition 
and analyses were performed with Ascent Software version 2.6. Data are reported as RLU for each 
ROI corresponding to each well of the 96-well plate. 
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Purified luciferase inhibition assays 
Luciferase was prepared as a 10 nM solution in enzyme buffer. Luciferase lyophilized powder 
(luciferase from Photinus Pyralis, Sigma-Aldrich) was dissolved in previously prepared luciferase 
enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 0.8 mg/mL BSA).  D-thioluciferin,  
was prepared as a 10 µM solution in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM 
MgSO4, and 4 mM ATP) and D-thioluciferin thioacrylate was prepared as a 0.1 µM 1 µM and 10 µM 
solution in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP). Starting 
solutions of 10 µM D-thioluciferin and increasing concentrations of D-thioluciferin thioacrylate were 
then prepared.  60 µL of a 1:1 solutions of 10 µM D-thioluciferin and 0.1 µM 1 µM and 10 µM 
D-thioluciferin thioacrylate were prepared. Inhibition assays were initiated by adding 30 μL of 
luciferase in luciferase enzyme buffer to 60 μL of a mixture of D-thioluciferin and D-thioluciferin 
thioacrylate in substrate buffer in a white 96-well plate (Costar 3915). Imaging was performed one 
minute after enzyme addition using a Luminoskan Ascent (detector 270 - 670 nm) and data acquisition 
and analyses were performed with Ascent Software version 2.6. Data are reported as RLU for each 
ROI corresponding to each well of the 96-well plate.  
Live imaging of luciferase expression in N. Tabacum plants 
Live imaging of luciferase expression: Luciferase expressing N. Tabacum plants were received from Dr. 
Suhail Rafudeen of the Plant Stress Research Unit at the University of Cape Town. The plants were 
transfected with a previously prepared luciferase coupled stress inducible promotor, XvSap1, isolated 
from X. viscosa. Luciferase expression was then induced by subjecting mature N. Tabacum plants were 
subjected to a 6 day dehydration period, after which leaves were taken from plants for 
bioluminescence imaging.  leaves were individually sprayed and painted with equal amounts of 5 mM 
D-Luciferin (VivoGlo, Promega Corporation, USA). Luciferase activity was imaged with a 3D-
luminometer consisting of a 0.5 square inch CCD camera and a field of view of 12.5 cm (Xenogen IVIS 
Lumina, Caliper, USA) at an exposure time of 300 s per leaf. Photon or count emission by luciferase 
expressing leaves was quantified using the Living Image software (Caliper, USA). The GFP assay was 
selected to negate any luminescence from chloroplasts.  
Agrobacterium infection of leaf disks: Leaf disks were infected for 30 min in the dark with the 
Agrobacterium inoculum containing the promoter cassettes in sterile petri dishes. The petri dish was 
agitated once every 10 min. Thereafter, infected leaf disks were blot dried on sterile filter paper. Each 
infected explant was transferred to co-cultivation medium and incubated for 3 days at 23 oC (18 h 
light, 6 h dark; light intensity of 140 μmol/m2/s). The co-cultivation media comprised 28 hormone free 
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MS basal salts (Highveld Biological, South Africa) supplemented with B5 vitamins, 30 g/L sucrose, 0.1 
mg/L α-naphthaleneacetic acid, 1 mg/L 6-benzylamino purine and 100 μM/l acetosyringone. The pH 
was adjusted to 5.4 with 1M KOH. Following the 3 day co-cultivation period, leaf discs were selected 
on shooting medium comprising hormone free MS basal salts supplemented with B5 vitamins, 30 g/L 
sucrose, 0.1 mg/L α-naphthaleneacetic acid, 1 mg/L 6-benzylamino purine, 10 μg/L nyastatin, 250 
mg/L carbenicillin, and 3 mg/L BASTA (Bayer, South Africa). Leaf explants were placed under an 18 h 
light regime with light intensity of 140 μmol/m2/s at 28ºC. Putative transformants were subcultured 
fortnightly onto fresh media until sizable shoots were formed. BASTA resistant shoots were selected, 
excised and transferred to rooting media. The rooting media comprised half strength hormone free 
MS basal salts (Highveld Biological, South Africa) supplemented with 10 mg/L sucrose, 10 μg/L 
nyastatin, 250 mg/L carbenicillin and 3 mg/L BASTA (Bayer, South Africa). Putative transformants with 
well-established root systems were transferred to pots containing sterile potting soil and cultured with 
set conditions. The plants were covered with saran wrap for 8 days to assist acclimatisation and 
minimise dehydration. Once acclimatised, the putative transformants were transferred to 6 inch pots 
containing potting soil under normal growth conditions.  
 Dehydration of luciferase expressing transgenic tobacco plants: The dehydration treatments were 
carried out as described by Audran et al with the following modification: plants were dehydrated in 
soil instead of hydroponically. Prior to dehydration, plants were transferred to pots containing 800 g 
of soil and 200 ml water to allow for even drying rates. Plants were moved to Percival chambers 
(Percival Scientific Inc, USA) and incubated under set conditions (26 oC; 16 h day, 8 h night; 60% 
humidity; light intensity of 100 μmol/m2/s) for 1 week. Dehydration stress was carried out on whole 
plants and achieved by withholding water for 6 days. Day 0 of the dehydration treatment represents 
the first day after watering ceased. Stressed tobacco leaves were sampled every 24 hours. The 
sampled leaves were used to assay for luciferase activity. 
Glutathione reductase assay using a GSH-Aldrithiol mixed disulfide substrate23  
Glutathione reductase (GSR) activity was measured via the increase in absorbance at 340 nm over 
time as a result of 2-thiopyridine release upon GSR mediated GSH-Aldrithiol reduction. The assay was 
done in triplicate and kinetic data recorded on a Cary 60 eclipse UV-VIS spectrophotometer that had 
been blanked with distilled water. Absorbance was read at 340 nm over 30 min at 30 s intervals.    
Sample preparation: Test samples were prepared by mixing 0.25 mL of  6 mM GSH-Aldrithiol disulfide 
in deionised water with 1 mL of previously prepared phosphate buffer (75 mM potassium phosphate 
monobasic with 0.15 % (w/v) Bovine Serum Albumin (BSA), pH 5.5), 0.15 mL deionised water, 0.05 mL 
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of 4.5 mM NADPH (b-Nicotanamide Adenine Dinucleotide Phosphate, reduced form, tetrasodium salt) 
in deionised water, to a final volume of 1.45 mL. The solution was incubated at 25 oC for 5 min, after 
which the absorbance was recorded at 340 nm on a UV-VIS spectrophotometer until a steady reading 
was observed. After a constant absorbance reading was achieved, 0.05 mL of GSR (0.5 unit/mL in 
deionised water) was then rapidly injected into the solution and it was immediately inverted to mix 
and then the change in absorbance at 340 nm was measured over a 30 min period.  
Final assay concentrations: In a 1.5 mL reaction mixture, the final concentrations are 50 mM potassium 
phosphate, 1.0 mM GSH-Aldrithiol disulfide, 0.15 mM NADPH, 0.01 % (w/v) BSA, and 0.05 unit GSR. 
The assay was repeated at varying GSH-Aldrithiol concentrations (1.7 mM, 1.0 mM, 0.5 mM, 0.35 mM, 
0.25 mM and 0.1 mM) adjusted accordingly with deionized water. 
Rate determination and enzyme kinetics: The rates of disulfide reduction at each concentration 
(1.7 mM, 1.0 mM, 0.5 mM, 0.35 mM, 0.25 mM and 0.1 mM) were obtained from the gradient of the 
absorbance curves. The relative rates were then plotted against their corresponding substrate 
concentrations to generate a Michealis-Menton plot. Graph Pad Prism software version 5.0 was used 
to calculate the apparent Km and Vmax values through its non-linear regression Michealis-kinetics 
option. Km and Vmax are reported as ranges with a 95 % confidence interval.    
Glutathione reductase assay using GSSG24  
Glutathione reductase (GSR) activity was measured via the decrease in absorbance at 340 nm over 
time as a result of NADPH consumption upon GSR mediated GSSG reduction. The assay was done in 
triplicate and kinetic data recorded on a Cary 60 eclipse UV-VIS spectrophotometer that had been 
blanked with distilled water. Absorbance was read at 340 nm over 30 min at 30 s intervals.   
 Sample preparation: Test samples were prepared by mixing 0.25 mL of  6 mM GSSG in deionised water 
with 1 mL of previously prepared phosphate buffer (75 mM potassium phosphate monobasic with 
0.15 % (w/v) Bovine Serum Albumin (BSA), pH 5.5), 0.15 mL deionised water, 0.05 mL of 4.5 mM 
NADPH (b-Nicotanamide Adenine Dinucleotide Phosphate, reduced form, tetrasodium salt) in 
deionised water, to a final volume of 1.45 mL. The solution was incubated at 25 oC for 5 min, after 
which the absorbance was recorded at 340 nm on a UV-VIS spectrophotometer until a steady reading 
was observed. After a constant absorbance reading was achieved, 0.05 mL of GSR (0.5 unit/mL in 
deionised water) was then rapidly injected into the solution and it was immediately inverted to mix 
and then the change in absorbance at 340 nm was measured over a 30 min period.  
Final assay concentrations: In a 1.5 mL reaction mixture, the final concentrations are 50 mM potassium 
phosphate, 1.0 mM GSSG, 0.15 mM NADPH, 0.01 % (w/v) BSA, and 0.05 unit GSR. The assay was 
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repeated at varying GSSG concentrations (1.0 mM, 0.5 mM, 0.25 mM and 0.1 mM) adjusted 
accordingly with deionized water. 
Rate determination and enzyme kinetics: The rates of disulfide reduction at each concentration 
(1.0 mM, 0.5 mM, 0.25 mM and 0.1 mM) were obtained from the gradient of the absorbance curves. 
The relative rates were then plotted against their corresponding substrate concentrations to generate 
a Michealis-Menton plot. Graph Pad Prism software version 5.0 was used to calculate the apparent 
Km and Vmax values through its non-linear regression Michealis-kinetics option. Km and Vmax are 
reported as ranges with a 95 % confidence interval.    
Thiolate release assay 
Potassium thiolates were reacted with vinyl sulfides to determine relative rates and to evaluate the 
effect of the potassium thiolate on the reaction rate. The vinylssulfide was measured at 340 and 380 
nm using a Cary 60 eclipse UV-VIS spectrophotometer, that had been blanked with distilled water. The 
change in absorbance over time as a result of the addition of either potassium thioacetate or L-
Cys/potassium carbonate was then measured. 
Sample preparation: The vinyl sulfides, benzyl (E)-3-((4-aminophenyl)thio)acrylate and benzyl (E)-3-
((4-(((Z)-4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino)phenyl)thio)acrylate, were prepared as a 5 mM 
solution in 1:3 (v/v) H2O:CH3CN. Potassium thioacetate and 1:1 L-Cys:potassium carbonate were 
prepared as 5 mM solutions in deionized water. 
Rate determinations: 0.05 mL of vinyl sulfide was added to 1.45 mL of 1:3 (v/v) H2O:CH3CN, and the 
absorbance was recorded until a constant reading was observed. 0.05 mL of the thiolate was then 
injected and the solution rapidly inverted to mix before reading the change in absorbance for 500 s at 
10 second intervals.  Benzyl (E)-3-((4-aminophenyl)thio)acrylate absorbance was read at 320 nm and 
benzyl (E)-3-((4-(((Z)-4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino)phenyl)thio)acrylate was read at 
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